Aims and Scope: Thorax enjoys an enviable and longstanding reputation for publishing clinical and experimental research articles covering many disciplines, including pathology, immunology and surgery.

International Advisory Board

N Ambrosino (Italy)
J N Barnuni (USA)
P J Barnes (UK)
C R W Beasley (New Zealand)
J R Britton (UK)
A S Buist (USA)
E R Chilvers (UK)
S-H Cho (Korea)
S-E Dahlen (Sweden)
G C Donaldson (UK)
M W Elliott (UK)
Y Fukuchi (Japan)
D M Geddes (UK)
P Goldstraw (USA)
R Goldstein (Canada)
C Griffiths (UK)
J C Hogg (Canada)
S T Holgate (UK)
P Hopewell (USA)
M Ichinose (Japan)
A Kendrick (UK)
T King (USA)
A J Knox (UK)
C K W Lai (China)
G J Laurent (UK)
P LeSouef (Australia)
W MacNee (UK)
C Mayaud (France)

J Moore-Gillon (UK)
A Morice (UK)
R Panettieri (USA)
A Papci (Italy)
G G Papadopoulos (Greece)
M R Partridge (UK)
I D Pavord (UK)
M G Pearson (UK)
T A E Platts Mills (USA)
L Restrick (UK)
D S Robinson (UK)
R M Rudd (UK)
T A R Seemungal (Trinidad & Tobago)
S Sethi (USA)
T Sethi (UK)
A K Simonds (UK)
P Slivinski (Poland)
R A Stockley (UK)
J K Stoller (USA)
M J Tobin (USA)
A Torres (Spain)
J Vestbo (Denmark)
E H Walters (Australia)
S T Weiss (USA)
A Wells (UK)
JW Wilson (Australia)
A A Woodcock (UK)
M Woodhead (UK)
R Zawallack (USA)

Contact Details

Editorial Office
BMJ Publishing Group Ltd, BMJ House, Tavistock Square, London WC1H 9JR, UK
T: +44 (0)20 7383 6147
F: +44 (0)20 7383 6668
E: thorax@bmjgroup.com

Permissions
See http://journals.bmj.com/misc/permissions.dtl

Supplement Enquiries
T: +44 (0)20 7383 6057
F: +44 (0)20 7554 6795
E: journals@bmjgroup.com

Subscriptions (except USA)
Subscription Manager, BMJ Journals, BMJ Publishing Group Ltd, PO Box 299, London WC1H 9TD, UK
T: +44 (0)20 7383 6270
F: +44 (0)20 7383 6402
E: subscriptions@bmjgroup.com

http://group.bmj.com/group/subs-sales/subscriptions

US Subscriptions
PPS6 PO Box 361, Birmingham, AL 35201-0361
T: +1 800 348 6473 (toll free in the USA)
F: +1 205 995 1558
E: bmj-clinicaledvidence@ebsco.com

Advertising
T: +44 (0)20 7383 6181
F: +44 (0)20 7383 6556
E: currencer@bmjgroup.com

http://group.bmj.com/group/advertising

Author Reprints
Reprints Administrator
T: +44 (0)1150 251 5161
F: +44 (0)207 554 6185
E: admin.reprints@bmjgroup.com

Commercial Reprints (except USA & Canada)
Nadia Gurney-Randall
T: +44 (0)20 8445 5825
M: +44 (0)7866 262344
F: +44 (0)20 8445 5870
E: ngurneyrandall@bmjgroup.com

Commercial Reprints (USA & Canada)
Maraha Fogler
T: +1 800 482 1450 (toll free in the USA)
F: +1 856 489 4446 (outside the USA)
F: +1 856 489 4449
E: mfogler@medicalreprints.com

British Thoracic Society
17 Doughty Street
London WC1N 2PL, UK
T: 44 (0)20 7831 8778
F: 44 (0)20 7831 8766
E: bts@brit-thoracic.org.uk
http://www.brit-thoracic.org.uk/index.html

Subscription Information

Thorax is published monthly (subscribers receive all supplements)

Institutional Rates 2008

Print
£437; US$830; €647

Online
Site licences are priced on FTE basis and allow access by the whole institution. Print is available at deeply discounted rates for online subscribers; details available online at http://group.bmj.com/group/subs-sales/subscriptions or contact the Subscription Manager in the UK (see above right).

Personal Rates 2008

Print (includes online access at no additional cost)
£185; US$352; €274

Online only
£99; US$188; €147

ISSN 0040-6376 (print)
ISSN 1468-3296 (online)

Aims and Scope: Thorax enjoys an enviable and longstanding reputation for publishing clinical and experimental research articles covering many disciplines, including pathology, immunology and surgery.

International Advisory Board

N Ambrosino (Italy)
J N Barnuni (USA)
P J Barnes (UK)
C R W Beasley (New Zealand)
J R Britton (UK)
A S Buist (USA)
E R Chilvers (UK)
S-H Cho (Korea)
S-E Dahlen (Sweden)
G C Donaldson (UK)
M W Elliott (UK)
Y Fukuchi (Japan)
D M Geddes (UK)
P Goldstraw (USA)
R Goldstein (Canada)
C Griffiths (UK)
J C Hogg (Canada)
S T Holgate (UK)
P Hopewell (USA)
M Ichinose (Japan)
A Kendrick (UK)
T King (USA)
A J Knox (UK)
C K W Lai (China)
G J Laurent (UK)
P LeSouef (Australia)
W MacNee (UK)
C Mayaud (France)

J Moore-Gillon (UK)
A Morice (UK)
R Panettieri (USA)
A Papci (Italy)
G G Papadopoulos (Greece)
M R Partridge (UK)
I D Pavord (UK)
M G Pearson (UK)
T A E Platts Mills (USA)
L Restrick (UK)
D S Robinson (UK)
R M Rudd (UK)
T A R Seemungal (Trinidad & Tobago)
S Sethi (USA)
T Sethi (UK)
A K Simonds (UK)
P Slivinski (Poland)
R A Stockley (UK)
J K Stoller (USA)
M J Tobin (USA)
A Torres (Spain)
J Vestbo (Denmark)
E H Walters (Australia)
S T Weiss (USA)
A Wells (UK)
JW Wilson (Australia)
A A Woodcock (UK)
M Woodhead (UK)
R Zawallack (USA)

Editor, BMJ

Contact Details

Editorial Office
BMJ Publishing Group Ltd, BMJ House, Tavistock Square, London WC1H 9JR, UK
T: +44 (0)20 7383 6147
F: +44 (0)20 7383 6668
E: thorax@bmjgroup.com

Permissions
See http://journals.bmj.com/misc/permissions.dtl

Supplement Enquiries
T: +44 (0)20 7383 6057
F: +44 (0)20 7554 6795
E: journals@bmjgroup.com

Subscriptions (except USA)
Subscription Manager, BMJ Journals, BMJ Publishing Group Ltd, PO Box 299, London WC1H 9TD, UK
T: +44 (0)20 7383 6270
F: +44 (0)20 7383 6402
E: subscriptions@bmjgroup.com

http://group.bmj.com/group/subs-sales/subscriptions

US Subscriptions
PPS6 PO Box 361, Birmingham, AL 35201-0361
T: +1 800 348 6473 (toll free in the USA)
F: +1 205 995 1558
E: bmj-clinicaledvidence@ebsco.com

Advertising
T: +44 (0)20 7383 6181
F: +44 (0)20 7383 6556
E: currencer@bmjgroup.com

http://group.bmj.com/group/advertising

Author Reprints
Reprints Administrator
T: +44 (0)1150 251 5161
F: +44 (0)207 554 6185
E: admin.reprints@bmjgroup.com

Commercial Reprints (except USA & Canada)
Nadia Gurney-Randall
T: +44 (0)20 8445 5825
M: +44 (0)7866 262344
F: +44 (0)20 8445 5870
E: ngurneyrandall@bmjgroup.com

Commercial Reprints (USA & Canada)
Maraha Fogler
T: +1 800 482 1450 (toll free in the USA)
F: +1 856 489 4446 (outside the USA)
F: +1 856 489 4449
E: mfogler@medicalreprints.com

British Thoracic Society
17 Doughty Street
London WC1N 2PL, UK
T: 44 (0)20 7831 8778
F: 44 (0)20 7831 8766
E: bts@brit-thoracic.org.uk
http://www.brit-thoracic.org.uk/index.html

Subscription Information

Thorax is published monthly (subscribers receive all supplements)

Institutional Rates 2008

Print
£437; US$830; €647

Online
Site licences are priced on FTE basis and allow access by the whole institution. Print is available at deeply discounted rates for online subscribers; details available online at http://group.bmj.com/group/subs-sales/subscriptions or contact the Subscription Manager in the UK (see above right).

Personal Rates 2008

Print (includes online access at no additional cost)
£185; US$352; €274

Online only
£99; US$188; €147

ISSN 0040-6376 (print)
ISSN 1468-3296 (online)
Guideline for emergency oxygen use in adult patients

B R O’Driscoll, L S Howard, A G Davison
on behalf of the British Thoracic Society Emergency Oxygen Guideline Development Group,
a subgroup of the British Thoracic Society Standards of Care Committee
The BTS Guidelines for emergency oxygen use in adult patients is endorsed by: Association of Respiratory Nurse Specialists, Association for Respiratory Technology and Physiology, College of Emergency Medicine, British Cardiovascular Society, British Geriatrics Society, British Paramedic Association, Chartered Society of Physiotherapy, General Practice Airways Group (GPIAG), Intensive Care Society, Joint Royal Colleges Ambulance Liaison Committee, Resuscitation Council (UK), Royal College of Anaesthetists, Royal College of General Practitioners, Royal College of Midwives, Royal College of Nursing, Royal College of Physicians (Edinburgh), Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians (London), Royal Pharmaceutical Society of Great Britain, Society for Acute Medicine.

Also supported by the Royal College of Obstetricians and Gynaecologists.
Guideline for emergency oxygen use in adult patients

i Endorsements

Summary
vi1 Executive summary of the guideline
vi1 Summary of key recommendations for emergency oxygen use
vi10 Hierarchy of evidence and grading of recommendations

Introduction
vi1o 1.1 Clinical context
vi1o 1.2 Prescription of oxygen
vi1o 1.3 Need for a guideline for emergency oxygen therapy and purpose of the guideline
vi1o 1.4 Intended users of guideline and scope of the guideline

vi1 1.5 Areas covered by this guideline
vi1 1.6 Areas not covered by this guideline
vi1 1.7 Limitations of the guideline

Methodology of guideline production
vi11 2.1 Establishment of guideline team
vi11 2.2 Summary of key questions
vi12 2.3 How the evidence was assimilated into the guideline
vi12 2.4 Pilot testing the guideline
vi12 2.5 Planned review and updating of the guideline

Normal values and definitions
vi12 3.1 Blood levels of oxygen and carbon dioxide in health and disease
vi14 3.2 Definitions of hypoxemia, hypoxia, type 1 respiratory failure and hyperoxia
vi15 3.3 Definition of hypercapnia and type 2 respiratory failure
vi15 3.4 Definition of acidosis (respiratory acidosis and metabolic acidosis)

General blood gas physiology
vi15 4.1 Oxygen physiology
vi16 4.2 Carbon dioxide physiology
vi16 4.3 Concept of target oxygen saturation (SaO2) ranges

Advanced blood gas physiology and pathophysiology and physiology of oxygen therapy
vi17 5.1 Regulation of blood oxygen content (CaO2)
vi18 5.2 Pathophysiology of hypoxia and hyperoxia
vi19 5.3 Physiology of carbon dioxide
8.6 Should oxygen be prescribed at a fixed “dose” or to achieve a target saturation?

8.7 What should be the target oxygen saturation range for patients receiving supplementary oxygen?

8.8 Importance of blood gas measurements in guiding oxygen therapy

8.9 What should be the initial choice of oxygen delivery system in hospital settings?

8.10 Recommended oxygen therapy for major medical emergencies and critical illness

8.11 Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic

8.12 Recommended oxygen therapy for patients who may be vulnerable to medium or high doses of oxygen

8.13 Common medical emergencies for which oxygen therapy is indicated only if hypoxaemia is present

Prescription, administration and monitoring of oxygen therapy

11.1 Safe prescription and administration of oxygen therapy

11.2 Starting oxygen therapy

11.3 Monitoring oxygen therapy

Weaning and discontinuation of oxygen therapy

12.1 How to discontinue oxygen therapy for stable patients

Outcomes and audit

13.1 Audit

13.2 Audit of compliance with guidelines

Dissemination and implementation of the guideline

14.1 Dissemination

14.2 Local guidelines

14.3 Local oxygen policy

14.4 New prescription chart

14.5 Staff education

14.6 Local champions

14.7 Benefits of nationwide implementation

Areas requiring further research

16.1 Membership of Working Party

16.2 Authorship of sections of the guideline

Appendices and Abbreviations

List of appendices available on the BTS website

Abbreviations and symbols used in this guideline

Index
BTS guideline for emergency oxygen use in adult patients

B R O’Driscoll,1 L S Howard,2 A G Davison3 on behalf of the British Thoracic Society

EXECUTIVE SUMMARY OF THE GUIDELINE

Philosophy of the guideline

► Oxygen is a treatment for hypoxaemia, not breathlessness. (Oxygen has not been shown to have any effect on the sensation of breathlessness in non-hypoxaemic patients.)

► The essence of this guideline can be summarised simply as a requirement for oxygen to be prescribed according to a target saturation range and for those who administer oxygen therapy to monitor the patient and keep within the target saturation range.

► The guideline suggests aiming to achieve normal or near-normal oxygen saturation for all acutely ill patients apart from those at risk of hypercapnic respiratory failure or those receiving terminal palliative care.

Assessing patients

► For critically ill patients, high concentration oxygen should be administered immediately (table 1 and fig 1) and this should be recorded afterwards in the patient’s health record.

► Oxygen saturation, “the fifth vital sign”, should be checked by pulse oximetry in all breathless and acutely ill patients (supplemented by blood gases when necessary) and the inspired oxygen concentration should be recorded on the observation chart with the oximetry result. (The other vital signs are pulse, blood pressure, temperature and respiratory rate).

► Pulse oximetry must be available in all locations where emergency oxygen is used.

► All critically ill patients should be assessed and monitored using a recognised physiological track and trigger system.

Oxygen prescription

► Oxygen should be prescribed to achieve a target saturation of 94–98% for most acutely ill patients or 88–92% for those at risk of hypercapnic respiratory failure (tables 1–3).

► The target saturation should be written (or ringed) on the drug chart (guidance in fig 1).

Oxygen administration

► Oxygen should be administered by staff who are trained in oxygen administration.

► These staff should use appropriate devices and flow rates in order to achieve the target saturation range (fig 2).

Monitoring and maintenance of target saturation

► Oxygen saturation and delivery system should be recorded on the patient’s monitoring chart alongside the oximetry result.

► Oxygen delivery devices and flow rates should be adjusted to keep the oxygen saturation in the target range.

► Oxygen should be signed for on the drug chart on each drug round.

Weaning and discontinuation of oxygen therapy

► Oxygen should be reduced in stable patients with satisfactory oxygen saturation.

► Oxygen should be crossed off the drug chart once oxygen is discontinued.

Oxygen is one of the most widely used drugs and is used across the whole range of specialities. The Guideline Group recognises that many clinicians will initially wish to read an abbreviated version of this guideline which is available to download from the BTS website (www.brit-thoracic.org.uk).

SUMMARY OF KEY RECOMMENDATIONS FOR EMERGENCY OXYGEN USE

Achieving desirable oxygen saturation ranges in acute illness (sections 6.7 and 6.8)

1. This guideline recommends aiming to achieve a normal or near-normal oxygen saturation for all acutely ill patients apart from those at risk of hypercapnic respiratory failure. [Grade D]

2. The recommended target saturation range for acutely ill patients not at risk of hypercapnic respiratory failure is 94–98%. Some normal subjects, especially people aged >70 years, may have oxygen saturation measurements below 94% and do not require oxygen therapy when clinically stable. [Grade D]

3. Most non-hypoxaemic breathless patients do not benefit from oxygen therapy, but a sudden reduction of more than 3% in a patient’s oxygen saturation within the target saturation range should prompt fuller assessment of the patient (and the oximeter signal) because this may be the first evidence of an acute illness. [Grade D]

4. For most patients with known chronic obstructive pulmonary disease (COPD) or other known risk factors for hypercapnic respiratory failure (eg, morbid obesity, chest wall deformities or neuromuscular disorders), a target saturation range of 88–92% is suggested pending the availability of blood gas results. [Grade C]
5. Some patients with COPD and other conditions are vulnerable to repeated episodes of hypercapnic respiratory failure. In these cases it is recommended that treatment should be based on the results of previous blood gas estimations during acute exacerbations because hypercapnic respiratory failure can occur even if the saturation is below 88%. For patients with prior hypercapnic failure (requiring non-invasive ventilation or intermittent positive pressure ventilation) who do not have an alert card, it is recommended that treatment should be commenced using a 28% Venturi mask at 4 l/min in prehospital care or a 24% Venturi mask at 2–4 l/min in hospital settings with an initial target saturation of 88–92% pending urgent blood gas results. These patients should be treated as a high priority by emergency services and the oxygen dose should be reduced if the saturation exceeds 92%. [Grade D]

6. Because oxygenation is reduced in the supine position, fully conscious hypoxaemic patients should ideally be allowed to maintain the most upright posture possible (or the most comfortable posture for the patient) unless there are good reasons to immobilise the patient (eg, skeletal or spinal trauma). [Grade C]

Clinical and laboratory assessment of hypoxaemia and hypercapnia (section 7.1)

7. Fully trained clinicians should assess all acutely ill patients by measuring pulse, blood pressure, respiratory rate and assessing circulating blood volume and anaemia. Expert assistance from specialists in intensive care or from other disciplines should be sought at an early stage if patients are thought to have major life-threatening illnesses and clinicians should be prepared to call for assistance when necessary, including a call for a 999 ambulance in prehospital care or a call for the resuscitation team or ICU outreach team in hospital care. [Grade C–D]

8. Initial clinical assessment and subsequent monitoring of acutely unwell patients should include the use of a recognised physiological “track and trigger” system, such as the Modified Early Warning Scoring System (mEWS), and a change in this score should require medical review even if there is no change in oxygen saturation. [Grade C]

9. Oxygen saturation, “the fifth vital sign”, should be checked by trained staff using pulse oximetry in all breathless and acutely ill patients (supplemented by blood gases when necessary) and the inspired oxygen concentration should be recorded on the observation chart with the oximetry result. [Grade D]

10. The presence of a normal oxygen saturation (arterial oxygen saturation measured by pulse oximetry [SpO2]) does not always negate the need for blood gas measurements because pulse oximetry will be normal in a patient with normal oxygen tension but abnormal blood pH or carbon dioxide tension (PCO2) or with a low blood oxygen content due to anaemia. Blood gas measurements and full blood counts are therefore required as early as possible in all situations where these measurements may affect patient outcomes. [Grade D]

Arterial and arteriolised blood gases (sections 7.1.3 and 8.4)

11. For critically ill patients or those with shock or hypotension (systolic blood pressure <90 mm Hg), the initial blood gas measurement should be obtained from an arterial specimen. However, for most patients who require blood gas sampling, either arterial blood gases or arteriolised earlobe blood gases may be used to obtain an accurate measure of pH and PCO2. However, the arterial oxygen tension (PaO2) is less accurate in earlobe blood gas samples (it underestimates the oxygen tension by 0.5–1 kPa), so oximetry should be monitored carefully if earlobe blood gas specimens are used. [Grade B]

12. Local anaesthesia should be used for all arterial blood gas specimens except in emergencies or if the patient is unconscious or anaesthetised. [Grade B]

13. Blood gases should be checked in the following situations:
- All critically ill patients.
- Unexpected or inappropriate hypoxaemia (SpO2 <94%) or any patient requiring oxygen to achieve this target range. (Allowance should be made for transient dips in saturation to 90% or less in normal subjects during sleep). [Grade D]
- Deteriorating oxygen saturation or increasing breathlessness in a patient with previously stable hypoxaemia (eg, severe COPD). [Grade D]
- Any previously stable patient who deteriorates and requires a significantly increased fraction of inspired oxygen (FiO2) to maintain a constant oxygen saturation. [Grade D]
- Any patient with risk factors for hypercapnic respiratory failure who develops acute breathlessness, deteriorating oxygen saturation or drowsiness or other symptoms of CO2 retention. [Grade D]
- Breathless patients who are thought to be at risk of metabolic conditions such as diabetic ketoacidosis or metabolic acidosis due to renal failure. [Grade D]
- Acutely breathless or critically ill patients with poor peripheral circulation in whom a reliable oximetry signal cannot be obtained. [Grade D]
- Any other evidence from the patient’s medical condition that would indicate that blood gas results would be useful in the patient’s management (eg, an unexpected change in “track and trigger” systems such as a sudden rise of several units in the mEWS or an unexpected fall in oxygen saturation of 5% or more, even if within the target range). [Grade D]

Oxygen use in specific illnesses

- See tables 1–4 and figs 1 and 2 (and section 8 in main text)
- Critical illness requiring high levels of supplemental oxygen: see table 1 and section 8
- Serious illness requiring moderate levels of supplemental oxygen if a patient is hypoxaemic: see table 2 and section 8.
- COPD and other conditions requiring controlled or low-dose oxygen therapy: see table 3 and section 8.
- Conditions for which patients should be monitored closely but oxygen therapy is not required unless the patient is hypoxaemic: see table 4 and section 8.

Oxygen therapy in pregnancy (section 8.13.3)

14. Women who suffer from major trauma, sepsis or acute illness during pregnancy should receive the same oxygen therapy as any other seriously ill patients, with a target oxygen saturation of 94–98%. The same target range should be applied to women with hypoxaemia due to acute complications of pregnancy (eg, collapse related to amniotic fluid embolus, eclampsia or antepartum or postpartum haemorrhage). [Grade D]
15. Women with underlying hypoxaemic conditions (eg, heart failure) should be given supplemental oxygen during labour to achieve an oxygen saturation of 94–98%. [Grade D]

16. All women with evidence of hypoxaemia who are more than 20 weeks pregnant should be managed with left lateral tilt to improve cardiac output. [Grade B]

17. The use of oxygen during labour is widespread but there is evidence that this may be harmful to the fetus. The use of oxygen during labour is therefore not currently recommended in situations where the mother is not hypoxaemic (except as part of a controlled trial). [Grade A]

Emergency use of oxygen in prehospital and hospital care (sections 8 and 9)

18. Pulse oximetry must be available in all locations where emergency oxygen is being used (see also the limitations of using pulse oximetry, section 7.1.2). [Grade D]

19. Emergency oxygen should be available in primary care medical centres, preferably using oxygen cylinders with integral high-flow regulators. Alternatively, oxygen cylinders fitted with high-flow regulators (delivering over 6 l/min) must be used. [Grade D]

20. All documents which record oximetry measurements should state whether the patient is breathing air or a specified dose of supplemental oxygen. [Grade C]

21. The oxygen saturation should be monitored continuously until the patient is stable or arrives at hospital for a full assessment. The oxygen concentration should be adjusted upwards or downwards to maintain the target saturation range. [Grade D]

22. In most emergency situations, oxygen is given to patients immediately without a formal prescription or drug order. The lack of a prescription should never preclude oxygen being given when needed in an emergency situation. However, a subsequent written record must be made of what oxygen therapy has been given to every patient (in a similar manner to the recording of all other emergency treatment). [Grade D]

23. Patients with COPD (and other at-risk conditions) who have had an episode of hypercapnic respiratory failure should be issued with an oxygen alert card and with a 24% or 28% Venturi mask. They should be instructed to show the card to the ambulance crew and emergency department staff in the event of an exacerbation. [Grade C]

24. The content of the alert card should be specified by the physician in charge of the patient’s care, based on previous blood gas results. [Grade D]

25. The primary care team and ambulance service should also be informed by the responsible clinician that the patient has had an episode of hypercapnic respiratory failure and carries an oxygen alert card. The home address and ideal oxygen dose or target saturation ranges of these patients can be flagged in the ambulance control systems and disseminated to ambulance crews when required. [Grade D]

26. Out-of-hours services providing emergency primary care services should be informed by a responsible clinician that the patient has had an episode of hypercapnic respiratory failure and carries an oxygen alert card. Use of oxygen in these patients will be guided by the instructions on the alert card. [Grade D]

27. During ambulance journeys oxygen-driven nebulisers should be used for patients with asthma and may be used for patients with COPD in the absence of an air-driven compressor system. If oxygen is used for patients with known COPD, its use should be limited to 6 min. This will deliver most of the nebulised drug dose but limit the risk of hypercapnic respiratory failure (section 10.8.2). [Grade D]

28. If a patient is suspected to have hypercapnia or respiratory acidosis due to excessive oxygen therapy, the oxygen therapy should not be discontinued but should be stepped down to 28% or 24% oxygen from a Venturi mask depending on oxygen saturation and subsequent blood gas results. [Grade C]

Equipment used to deliver emergency oxygen therapy (see section 10)

29. (a) It is recommended that the following delivery devices should be available in prehospital settings where oxygen is administered: [Grade D]

- high concentration reservoir mask (non-rebreathe mask) for high-dose oxygen therapy;
- nasal cannulae (preferably) or a simple face mask for medium-dose oxygen therapy;
- 28% Venturi mask for patients with definite or likely COPD (patients who have an oxygen alert card may have their own 24% or 28% Venturi mask);
- tracheostomy masks for patients with tracheostomy or previous laryngectomy.

(b) Most hospital patients can be managed with the same delivery device as in 29a, but 24% Venturi masks should also be available. [Grade D]

30. For many patients Venturi masks can be substituted with nasal cannulae at low flow rates (1–2 l/min) to achieve the same target range once patients have stabilised. [Grade D]

31. The flow rate from simple face masks should be adjusted between 5 and 10 l/min to achieve the desired target saturation. Flow rates below 5 l/min may cause carbon dioxide rebreathing and increased resistance to inspiration. [Grade C]

32. Patients with COPD with a respiratory rate of >50 breaths/min should have the flow rate set to 50% above the minimum flow rate specified for the Venturi mask and/or packaging (increasing the oxygen flow rate into a Venturi mask increases the total gas flow from the mask but does not increase the concentration of oxygen which is delivered). [Grade C]

33. Trusts should take measures to eliminate the risk of oxygen tubing being connected to the incorrect wall oxygen outlet or to outlets that deliver compressed air or other gases instead of oxygen. Air flow meters should be removed from the wall sockets or covered with a designated air outlet cover when not in use. Special care should be taken if twin oxygen outlets are in use. [Grade D]

34. Humidification is not required for the delivery of low-flow oxygen or for the short-term use of high-flow oxygen. It is not therefore required in prehospital care. Pending the results of clinical trials, it is reasonable to use humidified oxygen for patients who require high-flow oxygen systems for more than 24 h or who report upper airway discomfort due to dryness. [Grade B]

35. In the emergency situation humidified oxygen use can be confined to patients with tracheostomy or an artificial airway, although these patients can be managed without humidification for short periods of time (eg, ambulance journeys). [Grade D]
36. Humidification may also be of benefit to patients with viscous secretions causing difficulty with expectoration. This benefit can be achieved using nebulised normal saline. [Grade C]

37. Bubble bottles should not be used because there is no evidence of clinically significant benefit but there is a risk of infection. [Grade C]

38. When oxygen is required by patients with prior tracheostomy or laryngectomy, a tracheostomy mask (varying the flow as necessary) should achieve the desired oxygen saturation (tables 1–4). An alternative delivery device, usually a two-piece device fitted directly to the tracheostomy tube, may be necessary if the patient deteriorates. [Grade D]

Oxygen therapy during nebulised treatments (see section 10)

39. For patients with asthma, nebulisers should be driven by piped oxygen or from an oxygen cylinder fitted with a high-flow regulator capable of delivering a flow rate of >6 l/min. The patient should be changed back to his/her usual mask when nebuliser therapy is complete. If the cylinder does not produce this flow rate, an air-driven nebuliser (with electrical compressor) should be used with supplemental oxygen by nasal cannulae at 2–6 l/min to maintain an appropriate oxygen saturation level. [Grade D]

40. When nebulised bronchodilators are given to patients with hypercapnic acidosis, they should be driven by compressed air and, if necessary, supplementary oxygen should be given concurrently by nasal cannulae at 2–4 l/min to maintain an oxygen saturation of 88–92%. The same precautions should be applied to patients who are at risk of hypercapnic respiratory failure prior to the availability of blood gas results. Once the nebulised treatment is completed for patients at risk of hypercapnia, controlled oxygen therapy with a fixed concentration (Venturi) device should be instituted. [Grade D]

Prescription, administration, monitoring and discontinuation of oxygen therapy (see sections 11 and 12)

Oxygen should always be prescribed or ordered on a designated document. In emergencies, oxygen should be given first and documented later. See recommendations 41–76 in section 11 of the main guideline for prescription, administration and monitoring of oxygen therapy and recommendations 77–84 in section 12 for guidance on meaning and discontinuation of oxygen therapy.

All primary care trusts, ambulance trusts and hospital trusts should take specific measures to institute safe and effective administration and documentation of oxygen as described in recommendations 41–84 in sections 11 and 12 of this guideline.

Table 1  Critical illnesses requiring high levels of supplemental oxygen (see section 8.10)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Additional comments</th>
<th>Grade of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac arrest or resuscitation</td>
<td>Use bag-valve mask during active resuscitation</td>
<td>Grade D</td>
</tr>
<tr>
<td>Shock, sepsis, major trauma, near-drowning, anaphylaxis, major pulmonary haemorrhage</td>
<td>Aim for maximum possible oxygen saturation until the patient is stable</td>
<td>Grade D</td>
</tr>
<tr>
<td>Major head injury</td>
<td>Also give specific treatment for the underlying condition</td>
<td>Grade D</td>
</tr>
<tr>
<td>Carbon monoxide poisoning</td>
<td>Early intubation and ventilation if comatose</td>
<td>Grade D</td>
</tr>
<tr>
<td></td>
<td>Give as much oxygen as possible using a bag-valve mask or reservoir mask. Check carboxyhaemoglobin levels</td>
<td>Grade C</td>
</tr>
<tr>
<td></td>
<td>A normal or high oximetry reading should be disregarded because saturation monitors cannot differentiate between carboxyhaemoglobin and oxyhaemoglobin owing to their similar absorbances. The blood gas PaO2 will also be normal in these cases (despite the presence of tissue hypoxia)</td>
<td>Grade D</td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease; PaO2, arterial oxygen tension.

BTS guideline
Table 2  Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic (section 8.11)

- The initial oxygen therapy is nasal cannulae at 2–6 l/min (preferably) or simple face mask at 5–10 l/min unless stated otherwise.
- For patients not at risk of hypercapnic respiratory failure who have saturation <85%, treatment should be commenced with a reservoir mask at 10–15 l/min.
- The recommended initial oxygen saturation target range is 94–98%.
- If oximetry is not available, give oxygen as above until oximetry or blood gas results are available.
- Change to reservoir mask if the desired saturation range cannot be maintained with nasal cannulae or simple face mask (and ensure that the patient is assessed by senior medical staff).
- If these patients have co-existing COPD or other risk factors for hypercapnic respiratory failure, aim at a saturation of 88–92% pending blood gas results but adjust to 94–98% if the PaCO₂ is normal (unless there is a history of previous hypercapnic respiratory failure requiring NIV or IPPV) and recheck blood gases after 30–60 min.

<table>
<thead>
<tr>
<th>Illness</th>
<th>Additional comments</th>
<th>Grade of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute hypoxaemia (cause not yet diagnosed)</td>
<td>Reservoir mask at 10–15 l/min if initial SpO₂ &lt;85%, otherwise nasal cannulae or simple face mask. Patients requiring reservoir mask therapy need urgent clinical assessment by senior staff.</td>
<td>Grade D</td>
</tr>
<tr>
<td>Acute asthma</td>
<td></td>
<td>Grade C</td>
</tr>
<tr>
<td>Pneumonia</td>
<td></td>
<td>Grade C</td>
</tr>
<tr>
<td>Lung cancer</td>
<td></td>
<td>Grade C</td>
</tr>
<tr>
<td>Postoperative breathlessness</td>
<td>Management depends on underlying cause</td>
<td>Grade D</td>
</tr>
<tr>
<td>Acute heart failure</td>
<td>Consider CPAP or NIV in cases of pulmonary oedema</td>
<td>Grade D</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>Most patients with minor pulmonary embolism are not hypoxaemic and do not require oxygen therapy.</td>
<td>Grade D</td>
</tr>
<tr>
<td>Pleural effusions</td>
<td>Most patients with pleural effusions are not hypoxaemic. If hypoxaemic, treat by draining the effusion as well as giving oxygen therapy.</td>
<td>Grade D</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>Needs aspiration or drainage if the patient is hypoxaemic. Most patients with pneumothorax are not hypoxaemic and do not require oxygen therapy. Use a reservoir mask at 10–15 l/min if admitted for observation. Aim at 100% saturation (oxygen accelerates clearance of pneumothorax if drainage is not required).</td>
<td>Grades C and D</td>
</tr>
<tr>
<td>Deterioration of lung fibrosis or other interstitial lung disease</td>
<td>Reservoir mask at 10–15 l/min if initial SpO₂ &lt;85%, otherwise nasal cannulae or simple face mask.</td>
<td>Grade D</td>
</tr>
<tr>
<td>Severe anaemia</td>
<td>The main issue is to correct the anaemia. Most anaemic patients do not require oxygen therapy.</td>
<td>Grades B and D</td>
</tr>
<tr>
<td>Sickle cell crisis</td>
<td>Requires oxygen only if hypoxaemic (below the above target ranges or below what is known to be normal for the individual patient). Low oxygen tension will aggravate sickling.</td>
<td>Grade B</td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; IPPV, intermittent positive pressure ventilation; NIV, non-invasive ventilation; PaCO₂, arterial carbon dioxide tension; SpO₂, arterial oxygen saturation measured by pulse oximetry.
Table 3  COPD and other conditions requiring controlled or low-dose oxygen therapy (section 8.12)

- Prior to availability of blood gases, use a 28% Venturi mask at 4 l/min and aim for an oxygen saturation of 88–92% for patients with risk factors for hypercapnia but no prior history of respiratory acidosis. [Grade D]

- Adjust target range to 94–98% if the PaCO₂ is normal (unless there is a history of previous NIV or IPPV) and recheck blood gases after 30–60 min [Grade D]

- Aim at a prespecified saturation range (from alert card) in patients with a history of previous respiratory acidosis. These patients may have their own Venturi mask. In the absence of an oxygen alert card but with a history of previous respiratory failure (use of NIV or IPPV), treatment should be commenced using a 28% oxygen mask at 4 l/min in prehospital care or a 24% Venturi mask at 2–4 l/min in hospital settings with an initial target saturation of 88–92% pending urgent blood gas results. [Grade D]

- If the saturation remains below 88% in prehospital care despite a 28% Venturi mask, change to nasal cannulae at 2–6 l/min or a simple mask at 5 l/min with target saturation of 88–92%. All at-risk patients with alert cards, previous NIV or IPPV or with saturation <88% in the ambulance should be treated as a high priority. Alert the A&E department that the patient requires immediate senior assessment on arrival at the hospital. [Grade D]

- If the diagnosis is unknown, patients aged >50 years who are long-term smokers with a history of chronic breathlessness on minor exertion such as walking on level ground and no other known cause of breathlessness should be treated as if having COPD for the purposes of this guideline. Patients with COPD may also use terms such as chronic bronchitis and emphysema to describe their condition but may sometimes mistakenly use “asthma”. FEV₁ should be measured on arrival in hospital if possible and should be measured at least once before discharge from hospital in all cases of suspected COPD. [Grade C]

- Patients with a significant likelihood of severe COPD or other illness that may cause hypercapnic respiratory failure should be triaged as very urgent and blood gases should be measured on arrival in hospital. [Grade D]

- Blood gases should be rechecked after 30–60 min (or if there is clinical deterioration) even if the initial PaCO₂ measurement was normal. [Grade D]

- If the PaCO₂ is raised but pH is ≥7.35 ([H⁺] < 45 nmol/l), the patient has probably got long-standing hypercapnia; maintain target range of 88–92% for these patients. Blood gases should be repeated at 30–60 min to check for rising PaCO₂ or falling pH. [Grade D]

- If the patient is hypercapnic (PaCO₂ >6 kPa or 45 mm Hg) and acidotic (pH <7.35 or [H⁺] >45 nmol/l) consider non-invasive ventilation, especially if acidosis has persisted for more than 30 min despite appropriate therapy. [Grade A]

<table>
<thead>
<tr>
<th>Condition</th>
<th>Additional comments</th>
<th>Grade of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>May need lower range if acidic or if known to be very sensitive to oxygen therapy. Ideally use alert cards to guide treatment based on previous blood gas results. Increase flow by 50% if respiratory rate is &gt;30 (see recommendation 32).</td>
<td>Grade C</td>
</tr>
<tr>
<td>Exacerbation of CF</td>
<td>Admit to regional CF centre if possible; if not, discuss with regional centre or manage according to protocol agreed with regional CF centre. Ideally use alert cards to guide therapy. Increase flow by 50% if respiratory rate is &gt;30 (see recommendation 32).</td>
<td>Grade D</td>
</tr>
<tr>
<td>Chronic neuromuscular disorders</td>
<td>May require ventilatory support. Risk of hypercapnic respiratory failure</td>
<td>Grade D</td>
</tr>
<tr>
<td>Chest wall disorders</td>
<td>For acute neuromuscular disorders and subacute conditions such as Guillain-Barré syndrome (see table 4)</td>
<td>Grade D</td>
</tr>
<tr>
<td>Morbid obesity</td>
<td></td>
<td>Grade D</td>
</tr>
</tbody>
</table>

CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; IPPV, intermittent positive pressure ventilation; NIV, non-invasive ventilation; PaCO₂, arterial carbon dioxide tension; SpO₂, arterial oxygen saturation measured by pulse oximetry.
> If hypoxaemic, the initial oxygen therapy is nasal cannulae at 2–6 l/min or simple face mask at 5–10 l/min unless saturation is <85% (use reservoir mask) or if at risk from hypercapnia (see below).
> The recommended initial target saturation range, unless stated otherwise, is 94–98%
> If oximetry is not available, give oxygen as above until oximetry or blood gas results are available
> If patients have COPD or other risk factors for hypercapnic respiratory failure, aim at a saturation of 88–92% pending blood gas results but adjust to 94–98% if the PaCO₂ is normal (unless there is a history of respiratory failure requiring NIV or IPPV) and recheck blood gases after 30–60 min

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Additional comments</th>
<th>Grade of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarction and acute coronary syndromes</td>
<td>Most patients with acute coronary artery syndromes are not hypoxaemic and the benefits/harms of oxygen therapy are unknown in such cases</td>
<td>Grade D</td>
</tr>
<tr>
<td>Stroke</td>
<td>Most stroke patients are not hypoxaemic. Oxygen therapy may be harmful for non-hypoxaemic patients with mild to moderate strokes.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Pregnancy and obstetric emergencies</td>
<td>Oxygen therapy may be harmful to the fetus if the mother is not hypoxaemic (see recommendations 14–17)</td>
<td>Grades A–D</td>
</tr>
<tr>
<td>Hyperventilation or dysfunctional breathing</td>
<td>Exclude organic illness. Patients with pure hyperventilation due to anxiety or panic attacks are unlikely to require oxygen therapy. Rebreathing from a paper bag may cause hypoxaemia and is not recommended</td>
<td>Grade C</td>
</tr>
<tr>
<td>Most poisonings and drug overdoses (see table 1 for carbon monoxide poisoning)</td>
<td>Hypoxaemia is more likely with respiratory depressant drugs, give antidote if available (eg, naloxone for opiate poisoning). Check blood gases to exclude hypercapnia if a respiratory depressant drug has been taken. Avoid high blood oxygen levels in cases of acid aspiration as there is theoretical evidence that oxygen may be harmful in this condition. Monitor all potentially serious cases of poisoning in a level 2 or level 3 environment (high dependency unit or ICU)</td>
<td>Grade D</td>
</tr>
<tr>
<td>Poisoning with paraquat or bleomycin</td>
<td>Patients with paraquat poisoning or bleomycin lung injury may be harmed by supplemental oxygen. Avoid oxygen unless the patient is hypoxaemic. Target saturation is 88–92%.</td>
<td>Grade C</td>
</tr>
<tr>
<td>Metabolic and renal disorders</td>
<td>Most do not need oxygen (tachypnoea may be due to acidosis in these patients)</td>
<td>Grade D</td>
</tr>
<tr>
<td>Acute and subacute neurological and muscular conditions producing muscle weakness</td>
<td>These patients may require ventilatory support and they need careful monitoring which includes spirometry. If the patient’s oxygen level falls below the target saturation, they need urgent blood gas measurements and are likely to need ventilatory support</td>
<td>Grade C</td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IPPV, intermittent positive pressure ventilation; NIV, non-invasive ventilation; PaCO₂, arterial carbon dioxide tension; SpO₂, arterial oxygen saturation measured by pulse oximetry.
Is the patient critically ill or in a peri-arrest condition?

Yes

Commence treatment with reservoir mask or bag-valve mask and manage as advised in table 1

No

Is this patient at risk of hypercapnic respiratory failure (type 2 respiratory failure)?

The main risk factor is severe or moderate COPD (especially with previous respiratory failure or on long-term oxygen)

Other patients at risk include people with severe chest wall or spinal disease (e.g. kyphoscoliosis), neuromuscular disease, severe obesity, cystic fibrosis, bronchiectasis or previously unrecognized COPD

Narcotic/sedative overdose not covered by this algorithm (see table 4 and section 8.13.5)

Yes

Target saturation is 88–92% or level on alert card whilst awaiting blood gas results

Start 28% or 24% O2 and obtain ABGs (reduce FiO2 if SpO2 > 92% or above range stated on alert card)

pH < 7.35* or [H+] > 45 nmol/l* and P CO2 > 6.0 kPa (Respiratory acidosis or patient tiring)

Seek immediate senior review
Consider NIV or invasive ventilation

pH ≥ 7.35 or [H+] < 45 nmol/l and P CO2 > 6.0 kPa (Hypercapnia)

Treat with the lowest dose Venturi mask that will keep SpO2 between 88–92%

Seek immediate senior review
Consider NIV or ICU admission

Repeat ABGs at 30–60 min:
If respiratory acidosis (pH < 7.35 or [H+] > 45 nmol/l and P CO2 > 6.0)
Seek immediate senior review, consider NIV/ICU.
Consider reducing FiO2 if P CO2 > 8.0 kPa

Treat properly aiming to keep SpO2 between 94% and 98%**
Repeat ABG in 30–60 min for all patients at risk of type 2 respiratory failure

No

Aim for SpO2 94–98%

SpO2 ≤ 94% on air or oxygen or if requiring oxygen to achieve above targets

PCO2 ≤ 6.0 kPa
(normal or low)

持って państw

P CO2 > 6.0 kPa
or respiratory deterioration (see box in chart 2)

Seek immediate senior review
Consider invasive ventilation

Monitor SpO2. Oxygen not required unless saturation falls below target range

Any increase in FiO2 must be followed by repeat ABGs in 1 h (or sooner if conscious level deteriorates)

*If pH is < 7.35 ([H+] > 45 nmol/l) with normal or low P CO2, investigate and treat for metabolic acidosis and keep SpO2 94–98%

**Patients previously requiring NIV or IPPV should have a target range of 88–92%, even if the initial P CO2 is normal.

Figure 1  Chart 1: Oxygen prescription for acutely hypoxaemic patients in hospital. ABG, arterial blood gas; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; ICU, intensive care unit; NIV, non-invasive ventilation; P CO2, carbon dioxide tension; SpO2, arterial oxygen saturation measured by pulse oximetry.
See patient's drug chart and chart 1 and tables 1–4 for starting dose and target saturation

Choose the most suitable delivery system and flow rate

Titrate oxygen up or down to maintain the target oxygen saturation.

The table below shows available options for stepping dosage up or down. The chart does not imply any equivalence of dose between Venturi masks and nasal cannulae.

Allow at least 5 minutes at each dose before adjusting further upwards or downwards (except with major and sudden fall in saturation).

Once your patient has adequate and stable saturation on minimal oxygen dose, consider discontinuation of oxygen therapy.

**Figure 2** Chart 2: Flow chart for oxygen administration on general wards in hospitals. ABG, arterial blood gas; EPR, electronic patient record; EWS, Early Warning Score; SpO₂, arterial oxygen saturation measured by pulse oximetry.
HIERARCHY OF EVIDENCE AND GRADING OF RECOMMENDATIONS

Levels of evidence and grades of recommendation are based on the levels of evidence used in the NICE COPD guideline25 (see tables 5 and 6). For most of the topics covered by the guideline there were either no randomised trials or just a handful of observational studies. Members of the group reviewed the evidence for each topic and assigned the most appropriate grading which was usually grade C evidence (case-control or cohort studies) or grade D evidence (expert opinion or case reports).

Each recommendation has been allocated a grading which directly reflects the hierarchy of evidence upon which it is based.

Please note that the hierarchy of evidence and the recommendation gradings relate to the strength of the literature, not to clinical importance. This is especially important in the field of oxygen therapy where there are very few controlled trials.

### Table 5 Hierarchy of evidence

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia</td>
<td>Evidence from systematic reviews or meta-analysis of randomised controlled trials</td>
</tr>
<tr>
<td>Ib</td>
<td>Evidence from at least one randomised controlled trial</td>
</tr>
<tr>
<td>IIa</td>
<td>Evidence from at least one controlled study without randomisation</td>
</tr>
<tr>
<td>IIb</td>
<td>Evidence from at least one other type of quasi-experimental study</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from non-experimental descriptive studies such as comparative studies, correlation studies and case-control studies</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence from expert committee reports or opinions and/or clinical experience of respected authorities</td>
</tr>
</tbody>
</table>

### Table 6 Grading of recommendations

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Based on hierarchy I evidence</td>
</tr>
<tr>
<td>B</td>
<td>Based on hierarchy II evidence or extrapolated from hierarchy I evidence</td>
</tr>
<tr>
<td>C</td>
<td>Based on hierarchy III evidence or extrapolated from hierarchy I or II evidence</td>
</tr>
<tr>
<td>D</td>
<td>Directly based on hierarchy IV evidence or extrapolated from hierarchy I, II or III evidence</td>
</tr>
</tbody>
</table>

SECTION 1: INTRODUCTION

1.1 Clinical context

Oxygen is probably the commonest drug to be used in the care of patients who present with medical emergencies. Currently, ambulance teams and emergency department teams are likely to give oxygen to virtually all breathless patients and to a large number of patients with other conditions such as ischaemic heart disease, sepsis or trauma. The North West Ambulance Service serves a population of about 7.25 million people and transports about 700,000 people to hospital emergency departments each year. About 54% of these journeys involve oxygen use at some stage.7 This translates to about two million instances of emergency oxygen use per annum by all UK ambulance services, with further use in patients’ homes, GP surgeries and in hospitals.

At present, oxygen is administered for three main indications of which only one is evidence-based. First, oxygen is given to correct hypoxaemia as there is good evidence that severe hypoxaemia is harmful. Second, oxygen is administered to ill patients in case they might become hypoxaemic. Recent evidence suggests that this practice may actually place patients at increased risk if severe hypoxaemia does actually develop (see section 6.3.4). Third, a very high proportion of medical oxygen is administered because most clinicians believe that oxygen can alleviate breathlessness. However, there is no evidence that oxygen relieves breathlessness in non-hypoxaemic patients and there is evidence of lack of effectiveness in non-hypoxaemic breathless patients with chronic obstructive pulmonary disease (COPD) and advanced cancer (see sections 6.6 and 8.11.4).

1.2 Prescription of oxygen

Most clinicians who deal with medical emergencies will encounter adverse incidents and occasional deaths due to underuse and overuse of oxygen. Audits of oxygen use and oxygen prescription have shown consistently poor performance in many countries.7–8 One major problem is that healthcare professionals receive conflicting advice about oxygen use from different “experts” during their training and during their clinical careers, and many are confused about the entire area of oxygen prescription and use.

1.3 Need for a guideline for emergency oxygen therapy and purpose of the guideline

There is considerable controversy concerning the benefits and risks of oxygen treatment in virtually all situations where oxygen is used. Unfortunately, this is an area of medicine where there are many strongly-held beliefs but very few randomised controlled trials. The only published UK guideline for emergency oxygen therapy is the North West Oxygen Guideline published in 2001, based on a systematic literature review by the same authors.9 10 Against this background, the Standards of Care Committee of the British Thoracic Society (BTS) established a working party in association with 21 other societies and colleges listed at the front of this document. The objective was to produce an evidence-based and up-to-date guideline for emergency oxygen use in the UK.

1.4 Intended users of the guideline and scope of the guideline

This guideline is intended for use by all healthcare professionals who may be involved in emergency oxygen use. This will include ambulance staff, paramedics, doctors, nurses, midwives, physiotherapists, pharmacists and all other healthcare professionals who may deal with ill or breathless patients.
Specific versions of this guideline will be available on the BTS website for use in the following situations:

- Hospital use
- Primary care use
- Ambulance use
- Version for use by nursing staff

These abbreviated versions of the guideline will contain the key recommendations and tables and charts that are relevant to the particular situation. The “mini-guidelines” can be downloaded by health care trusts for use on trust intranets and to produce paper versions of the guideline for key staff.

1.5 Areas covered by this guideline
The guideline will address the use of oxygen in three main categories of adult patients in the prehospital and hospital setting:

- Critically ill or hypoxaemic patients.
- Patients at risk of hypoxaemia.
- Non-hypoxaemic patients who might benefit from oxygen (eg, carbon monoxide poisoning).

1.6 Areas not covered by this guideline
- Oxygen use in paediatrics: the present guideline applies only to subjects aged ≥16 years.
- Oxygen use for high-altitude activities.
- Oxygen use during air travel.
- Use of heliox mixtures.
- Use of nitrous oxide/oxygen mixtures (eg, Entonox).
- Respiratory support techniques including intubation, invasive ventilation, non-invasive ventilation (NIV) and continuous positive airway pressure (CPAP).
- Self-initiated use of oxygen by patients who have home oxygen for any reason (this is covered by the guidelines for home oxygen use).
- Ongoing care of hypoxaemic patients at home.

1.7 Limitations of the guideline
This guideline is based on the best available evidence concerning oxygen therapy. However, a guideline can never be a substitute for clinical judgement in individual cases. There may be cases where it is appropriate for clinicians to act outwith the advice contained in this guideline because of the needs of individual patients. Furthermore, the responsibility for the care of individual patients rests with the clinician in charge of the patient’s care and the advice offered in this guideline must, of necessity, be of a general nature and should not be relied upon as the only source of advice in the treatment of individual patients. In particular, this guideline gives very little advice about the management of the many medical conditions that may cause hypoxaemia (apart from the specific issue of managing the patients’ hypoxaemia). Readers are referred to other guidelines for advice on the management of specific conditions such as COPD, pneumonia, heart failure, etc. Some of these disease-specific guidelines suggest slightly different approaches to emergency oxygen therapy whereas the present guideline aims to provide simple all-embracing advice. All differences involving oxygen therapy for common medical emergencies are discussed in detail in section 10 of this guideline.

SECTION 2: METHODOLOGY OF GUIDELINE PRODUCTION

2.1 Establishment of guideline team
The need for a national guideline for emergency oxygen use was recognised by the BTS Standards of Care Committee in 2003. A working party was established with representatives from a wide range of professions involved in oxygen therapy and a lay representative (see full list of guideline group members in section 16). The original group was expanded in 2006 because it became clear that the development and implementation of a national guideline would require input from a very wide range of professional groups. Most development and editing of the guideline took place subsequent to this expansion of the group. The group agreed the remit of this guideline and a series of key questions as shown below. The group devised a search strategy for relevant studies. A Medline search for “oxygen” yielded over a quarter of a million “hits”, most of which were not relevant to this guideline. For this reason, the BTS commissioned the Centre for Reviews and Dissemination and Centre for Health Economics at the University of York to undertake bespoke literature searches using the search strategies shown in detail in Appendix 14 on the BTS website (www.brit-thoracic.org.uk).

2.2 Summary of key questions

Key question 1: Physiology and pathophysiology of oxygen

- What are the dangers of hypoxia/hypoxaemia (ie, what happens to the human body)?
- What level of hypoxaemia is dangerous to all patients (even healthy adults)?
- What level of hypoxaemia is dangerous to vulnerable groups (eg, ischaemic heart disease, stroke, elderly)?
  - Repeat the above searches with additional key words: elderly, stroke, myocardial infarction, heart failure, chronic obstructive pulmonary disease (COPD), trauma, renal failure.
- Same questions for hypercarbia/hypercapnia:
  - Search for “hypercapnia” combined with terms implying a harmful outcome (death/tissue injury/brain damage/coma).
- What level of hypercapnia is dangerous to all patients?
- What level of hypercapnia is dangerous to vulnerable groups (as above)?
- Same questions for respiratory acidosis:
  - Search for “respiratory acidosis” combined with terms implying a harmful outcome (death/tissue injury/brain damage/coma).
- What level of respiratory acidosis is dangerous to all patients?
- What level of respiratory acidosis is dangerous to vulnerable groups (as above)?

Key question 2: Clinical aspects of hypoxaemia and oxygen therapy for common medical emergencies

- How to assess hypoxaemia (clinical, early warning score systems, oximetry, arterial and capillary blood gases).
- How to assess hypercarbia/hypercapnia.
BTS guideline

- Use of oxygen to relieve symptomatic breathlessness.
- Use of oxygen in acute COPD.
- Use of oxygen in acute asthma.
- Use of oxygen in pneumonia.
- Use of oxygen for pulmonary embolus.
- Use of oxygen in trauma.
- Use of oxygen in heart failure.
- Use of oxygen in myocardial infarction.
- Use of oxygen in angina.
- Use of oxygen for other patients with less common conditions were searched individually (eg, cystic fibrosis, muscular dystrophy, motor neurone disease, severe kyphoscoliosis, anaphylaxis, hyperventilation).

Key question 3: Oxygen prescription, oxygen delivery systems and oxygen transport

- Oxygen carriage in transport (practical issues; safety issues).
- Oxygen delivery systems in ambulances.
- Prescription of oxygen.
- Local hospital guidelines for oxygen use.
- Oxygen delivery systems in hospitals.
- Advantages/disadvantages of each delivery system (Venturi masks, simple face masks, nasal cannulae, high-flow masks such as non-rebreathing reservoir masks).
- Use of oxygen-driven nebulisers.
- Use of “alert cards”, alert bracelets or similar hazard warning systems for patients who are known to be at risk of hypercapnia.

2.3 How the evidence was assimilated into the guideline

The initial search strategy was devised at two meetings of the group in 2004 and 2005. The searches in October 2005 yielded 3306 papers, the abstracts of which were checked for relevance by group members. One hundred and eighty-four of these abstracts were considered to be relevant to the present guideline. Full reprints of all relevant papers were obtained. Further references were obtained from the group’s personal literature collections and from the references contained within the papers which the search yielded and by focused literature searches by members of the guideline group. The group continued to monitor the literature up to the end of 2007 for important new publications or very high quality abstracts from international meetings that were thought to be relevant to this guideline.

The group was divided into three subgroups to work on specific areas of oxygen use: (1) emergency care; (2) hospital care; (3) oxygen physiology and devices. Evidence from the literature searches was graded according to the levels of evidence used in the NICE COPD guideline (see tables 5 and 6).

The Guideline Development Group corresponded by email on a regular basis (usually at least once weekly) for most of 2006 to discuss the evidence and to produce an initial outline of the guideline and its key recommendations. The guideline was consolidated over the course of 2006 and early 2007 with each section being led by nominated group members but taking into account feedback from the complete group. Meetings of the full group were held in February 2006, September 2006 and February 2007. Between November 2006 and February 2007 the group had an intensive review and email discussion of one guideline section per week with the objective of achieving a consensus on all of the key points before the final meeting of the group in February 2007. The draft guideline was first submitted to the BTS Standards of Care Committee in March 2007. The guideline was further refined by email discussion following comments by this committee. The resulting draft was sent to 17 peer reviewers (see section 17) and was posted on the BTS website for 4 weeks in August 2007 and comments were invited. The document was then sent back to the Standards of Care Committee and the 21 other Societies and Colleges for endorsement.

2.4 Piloting the guideline

The principles of the guideline (target saturation ranges, etc) have been piloted since 2004 at Salford Royal University Hospital and Southend University Hospital. The pilot projects have included the following elements:

- Discussion with senior colleagues and management to agree the need for an oxygen guideline (and the content).
- Trust-wide introduction of the agreed hospital policy.
- Educational programme for doctors, nurses and other users of oxygen.
- Designing prescription charts and patient observation charts to facilitate the standardisation of oxygen therapy (charts 3 and 4 in figs 17 and 18 in the guideline).
- Production of a detailed implementation document which has become hospital policy in both hospitals (web appendix 3).
- The charts which are necessary to guide the prescription and administration of oxygen (charts 1 and 2 in figs 1 and 2) have been piloted successfully at both hospitals.
- The educational materials and lecture presentations in web appendix 9 have been piloted in both hospitals.

There was a lot of discussion with colleagues about the ideal target saturation range and about how to implement safe oxygen prescribing. These issues should not arise with implementation of this national guideline as the key issues are already agreed by all of the relevant specialties and are as evidence-based as is possible. Implementation proceeded smoothly at both hospitals and audit showed improved practice. However, a lot of effort is required to maintain good quality prescribing of oxygen and the role of “oxygen champions” has been piloted successfully in both hospitals (see section 14.6).

2.5 Planned review and updating of the guideline

The guideline will be reviewed by the BTS and by the endorsing organisations within 5 years from publication (2013).

SECTION 3: NORMAL VALUES AND DEFINITIONS

- Normal blood levels of oxygen and carbon dioxide.
- Normal oxygen saturation (SaO₂) and normal blood pH.
- Definitions of hypoxaemia, hypoxia, hypercapnia, acidosis, respiratory failure.

Oxygen is essential for mammalian life; severe hypoxaemia such as that seen during cardiac arrest, suffocation or drowning will cause loss of consciousness, rapid organ failure and death. Oxygen is carried in the bloodstream bound to the haemoglobin molecule and delivered to the tissues. Oxygen demand and oxygen delivery increase during exercise and reduce during rest and sleep.

3.1 Blood levels of oxygen and carbon dioxide in health and disease

The human lung delivers oxygen to the blood and removes carbon dioxide. Several mechanisms exist to regulate breathing in such a way that both gases are maintained within quite a narrow range.
3.1.1 Normal ranges for oxygen saturation (SaO₂) and oxygen tension (PaO₂) in the blood at sea level

For adults aged <70 years, the two standard deviation (2SD) range for SaO₂ is approximately 94–98% at sea level but this may decline gradually within this age range. The normal range for PaO₂ in the blood in seated adults at sea level is shown in table 7. However, the PaO₂ is 0.8 kPa (6 mm Hg) lower in the supine position than in the upright position and most emergency measurements are made in the supine position.

3.1.2 Oxygen saturation in elderly patients

The mean SaO₂ may be lower in older people than in young adults. However, it is difficult to dissociate the effects of advancing age from the effects of the diseases that become commoner in old age. Some papers have reported a fall in the blood PaO₂ in elderly subjects but others have failed to confirm this observation. The mean SaO₂ in seated adults aged >64 years in one published study was 95.5% compared with 96.9% in adults aged 18–24 years, and the standard deviation was wider in the older age group with a 2SD range of 92.7–98.3% (table 7). The mean (SD) SaO₂ for recumbent healthy men aged >70 years in another study was 95.3 (1.4)% giving a 2SD range of 92.5–98.1% for men of this age. The mean (SD) SaO₂ was 94.8 (1.7)% for recumbent healthy women aged >70 years with a 2SD range of 91.5–98.2%. The authors of this study did not observe any age-related decline in SaO₂ beyond the age of 70 years. The mean SaO₂ in this study of approximately 95.0% for recumbent healthy men and women aged >70 years was below the normal range for seated healthy young adults. The mean PaO₂ in elderly subjects in this study was 10.3 kPa for men and 9.8 kPa for women, which is lower than two other studies which reported mean PaO₂ values of 11.2 kPa and 11.1 kPa in healthy elderly subjects. Some of these differences are probably due to different selection of subjects, but there are also variations in the results obtained by different blood gas analysers. Unfortunately there are no published data which can provide a normal range for the SaO₂ in the elderly population in the UK. However, an as yet unpublished audit of 320 stable hospital patients in Salford and Southend with no history of lung disease found a mean (SD) SaO₂ of 96.7 (1.77)% (2SD range 95.2–100%) in patients aged >71 years (R O’Driscoll, A Davison, L Ward, personal communication). These values were measured by pulse oximetry in UK hospitals in 2008 and are more likely to represent the expected normal range of pulse oximetry measurements in the elderly UK population than previous North American studies based on blood gas estimations. The variation with age, sex and posture makes it difficult to give a precise target range that will apply to all adults who might require oxygen therapy, but the guideline development committee believe that a target range of 94–98% will achieve normal or near-normal SaO₂ for most adults in the UK.

Normal daytime haemoglobin SaO₂ is 96–98% in young adults in the seated position at sea level but the lower limit falls slightly with age and is about 95% in adults aged >70 years. [Evidence III]

3.1.3 Oxygen saturation at altitude

The partial pressure of oxygen in the atmosphere is substantially lower at high altitude, even at altitudes where large populations live. The SaO₂ at a given altitude varies with age, sex, ethnic group and degree of acclimatisation to altitude. For example, a sample of 3812 people of all ages living in Tibet at an altitude of about 4000 m had a mean SaO₂ of only 88.2%, but people native to the Andes had an SaO₂ about 2.6% higher than Tibetans living at the same altitude. Millions of people live at these altitudes with SaO₂ values that would cause serious concern at sea level. The city of La Paz in Bolivia has a mean altitude of 3600 m and a population of approximately 1.5 million people. The SaO₂ of climbers on Mount Everest (8848 m) can fall below 70%. Sudden exposure to altitudes above about 4000 m can cause mountain sickness, high altitude pulmonary oedema and high altitude cerebral oedema in unacclimatised individuals. Long-term exposure to high altitude (or to hypoxaemia for any other reason) can lead to pulmonary hypertension.

3.1.4 Oxygen saturation in acute and chronic disease

If the blood oxygen level falls to extremely low levels for even a few minutes (eg, during cardiac arrest), tissue hypoxia and cell death will occur, especially in the brain. The brain appears to be the most vulnerable organ during profound hypoxaemia; brain malfunction is the first symptom of hypoxia and brain injury is the most common long-term complication in survivors of cardiac arrest and other episodes of profound hypoxaemia. Sudden exposure to low arterial oxygen saturations below about 80% can cause altered consciousness even in healthy subjects. It is likely that other organs in patients with critical illness or chronic organ damage are vulnerable to the risk of hypoxic tissue injury at oxygen levels above 80%.

Most experts emphasise the importance of keeping the SaO₂ above 90% for most acutely ill patients. However, the degree of hypoxia that will cause cellular damage is not well established and probably is not an absolute value. Healthy older adults, for instance, have lower SaO₂ values at rest than younger adults. Patients with chronic lung diseases may tolerate low levels of SaO₂ chronically. However, although chronically hypoxaemic patients may tolerate an abnormally low SaO₂ at rest when in a clinically stable condition, these resting oxygen levels may not be adequate for tissue oxygenation during acute illness when the tissue oxygen demand may increase (eg, sepsis, trauma, pneumonia, head injury; see section 8). Acute hypoxaemia with SaO₂ <90% and sometimes <80% is seen in many acute illnesses such as pneumonia and heart failure and it is likely that the clinical manifestations of hypoxaemia in illness would be similar to those of experimental hypoxaemia in hypobaric chambers (impaired mental function followed by loss of consciousness). However, the clinical manifestations of the illness itself make it difficult to identify

### Table 7

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean (SD) PaO₂</th>
<th>Range ± 2SD PaO₂</th>
<th>Mean (SD) SaO₂</th>
<th>SaO₂ ± 2SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>18–24</td>
<td>13.4 (0.7)</td>
<td>11.98–14.82</td>
<td>96.9 (0.4)</td>
<td>96.1–97.7</td>
</tr>
<tr>
<td>25–34</td>
<td>13.4 (0.66)</td>
<td>12.08–14.72</td>
<td>96.7 (0.7)</td>
<td>95.3–98.1</td>
</tr>
<tr>
<td>35–44</td>
<td>13.18 (1.02)</td>
<td>11.14–15.22</td>
<td>96.7 (0.6)</td>
<td>95.5–97.9</td>
</tr>
<tr>
<td>45–54</td>
<td>13.0 (1.07)</td>
<td>10.86–15.14</td>
<td>96.5 (1)</td>
<td>94.4–98.5</td>
</tr>
<tr>
<td>55–64</td>
<td>12.09 (0.60)</td>
<td>10.89–13.29</td>
<td>95.1 (0.7)</td>
<td>94.7–97.3</td>
</tr>
<tr>
<td>&gt;64</td>
<td>11.89 (1.43)</td>
<td>9.02–14.76</td>
<td>95.5 (1.4)</td>
<td>92.7–98.3</td>
</tr>
</tbody>
</table>

PaO₂, arterial oxygen tension; SaO₂, arterial oxygen saturation.

Values shown for seated healthy men and women non-smoking volunteers at sea level (adapted from Crapo et al 

---

**BTS guideline**

which symptoms and signs are due to hypoxaemia. Pure hypoxaemia, as seen in hypobaric chambers and at altitude, does not seem to cause breathlessness in resting subjects.

Patients with chronic diseases such as COPD, lung fibrosis, neuromuscular disorders or congenital heart disease may routinely attend outpatient clinics with SaO2 levels well below 90% even at a time when their disease is stable. In an emergency a clinician who was not familiar with such a patient (when stable) might interpret the low saturation as having occurred acutely and aim to achieve an oxygen saturation that was well above the patient’s usual oxygen saturation level. Many such patients would qualify for long-term oxygen therapy. The UK COPD guideline recommends a threshold of 7.3 kPa (55 mm Hg) below which most patients with COPD will benefit from long-term oxygen therapy (equivalent to a SaO2 of about 88–99%) and an arterial oxygen tension (PaO2) threshold below 8.0 kPa (60 mm Hg) for patients with established cor pulmonale and some other subgroups.

- Many patients with chronic lung disease, congenital cyanotic heart disease or chronic neuromuscular conditions have oxygen saturations substantially below the normal range, even when clinically stable. [Evidence III]

3.1.5 Variation in oxygen saturation during sleep

Healthy subjects in all age groups have greater variation in SaO2 when sleeping than while awake. A study of 330 people referred to a sleep laboratory with normal results of overnight polysomnography (patients with cranial facial or neurological abnormalities or previously diagnosed pulmonary disease were excluded) showed that desaturation routinely occurred with a mean (SD) minimum SaO2 or “ nadir” of 90.4 (3.1)% during the night (2SD range 84.2–96.6%). The mean (SD) overnight SaO2 “ nadir” was 89.3 (2.8)% for subjects aged >60 years. In this study subjects aged 20–30 years spent 10% of the night with SaO2 levels below 94.8% and half the night below 96.5%, and those aged >60 years spent 10% of the night below 92.8% and half the night below 95.1%. Furthermore, the authors of this study excluded obese patients with any features of sleep apnoea or hypopnoea because these patients are known to desaturate to very low levels during sleep (often below 70%). The variation in SaO2 during sleep is exaggerated by alcohol and by sedative drugs. This makes it difficult to evaluate a “spot reading” of SaO2 on a sleeping subject. It is suggested that SaO2 measurements of sleeping subjects should be interpreted with caution and ideally observed for a few minutes to see if the subject has got sustained hypoxaemia or just a transient normal “nocturnal dip”.

- All subjects have transient dips in oxygen saturation at night with a mean nadir of 90.4% (2SD range 84.2–96.6%) in healthy subjects in all age groups. [Evidence III]

3.1.6 Normal range for carbon dioxide tension (PaCO2) in the blood

The reference range for arterial carbon dioxide tension (PaCO2) is approximately 4.6–6.1 kPa (34–46 mm Hg) for healthy adult men aged 15–38 years. Although this study was undertaken in 1948, it is consistent with the clinical experience of the guideline group members and with most modern reference values for PaCO2. Although different laboratories and textbooks give slightly different reference values, all are within 0.2 kPa of the above reference range. Any value of PaCO2 of >6.1 kPa (45 mm Hg) should be considered abnormal, but values up to 6.7 kPa (50 mm Hg) may be obtained by breath-holding.

3.2 Definitions of hypoxaemia, hypoxia, type 1 respiratory failure and hyperoxia

**Hypoxaemia**

Hypoxaemia refers to low oxygen tension or partial pressure of oxygen (PaO2) in the blood. For practical reasons, hypoxaemia can also be measured in relation to oxyhaemoglobin saturation. In adults the normal range is influenced by age and co-morbidity and the normal ranges for healthy adults are given in section 3.1.1. The precise level at which a patient becomes hypoxaemic is debatable. One could argue that any saturation below the lower limit of normal constitutes hypoxaemia. Various authors have defined hypoxaemia as SaO2 of (1) <94%; (2) <92%; (3) <90%; or (4) PaO2 <60 mm Hg or 8 kPa. Most authors who have studied this area have defined hypoxaemia as PaO2 <60 mm Hg (8 kPa) or SaO2 <90%. There is no known risk of hypoxic tissue injury above this level and many guidelines on critical care set 90% as the minimum below which SaO2 should not be allowed to fall.

**Type 1 respiratory failure**

Type 1 respiratory failure is most widely defined as PaO2 <8 kPa or 60 mm Hg (equivalent to SaO2 of approximately 90%) with a normal or low PaCO2 level.

**Hypoxia**

The term hypoxia is less specific and refers to lack of oxygen in a particular compartment (eg, alveolar or tissue hypoxia). Tissue hypoxia may result from four main causes (see below). It should be noted that the first two causes—hypoxaemia and anaemia—do not always result in tissue hypoxia as oxygen delivery to tissues can be augmented in other ways such as increasing cardiac output.

**Hypoxic hypoxia**

Hypoxic hypoxia (sometimes also referred to as hypoxic hypoxia) is present when the oxygen content in the blood is low due to reduced partial pressure of oxygen. This occurs naturally at altitude and in many diseases such as emphysema which impair the efficiency of gas exchange in the lungs.

**Anaemic hypoxia**

Anaemic hypoxia results from a reduced level of haemoglobin available for oxygen transport. Although the patient may not be hypoxic (with a normal PaO2 and oxygen saturation measured by oximetry (SpO2)), the reduced oxygen content of the blood may lead to tissue hypoxia. Carbon monoxide poisoning may also produce a form of anaemic hypoxia by impairing the ability of haemoglobin to bind oxygen, thereby reducing oxygen-carrying capacity.

**Stagnant hypoxia**

Stagnant hypoxia is a low level of oxygen in the tissues due to inadequate blood flow (either globally or regionally). This condition may occur in the extremities if a person is exposed to cold temperatures for prolonged periods of time and it is the cause of gangrene in tissue that is deprived of blood in severe peripheral vascular disease. Stagnant hypoxia may occur in low cardiac output states.

**Histotoxic hypoxia**

Histotoxic hypoxia is an inability of the tissues to use oxygen due to interruption of normal cellular metabolism. The best known example of this occurs during cyanide poisoning which...
impairs cytochrome function. It is increasingly thought that mitochondrial dysfunction may lead to decreased oxygen utilisation in sepsis despite adequate oxygen delivery. This has also been termed "cytopathic dysoxia".35

**Hyperoxia and hyperoxaemia**

Hyperoxia and hyperoxaemia are the counterparts to the above terms and in this guideline refer to high oxygen content in the blood and high oxygen tension in the blood, respectively. As stated above, for practical purposes the oxygen tension in the blood is often measured as oxyhaemoglobin saturation. Furthermore, this guideline is centred on providing target saturations for various conditions, but it should be noted that above a PaO2 of approximately 16 kPa (120 mm Hg) the oxyhaemoglobin saturation will obviously not change from 100%, yet the effects of further increases in PaO2 may be important in certain conditions such as COPD. This is discussed in further detail in sections 5 and 6.

**3.3 Definition of hypercapnia and type 2 respiratory failure**

Hypercapnia is present when the PaCO2 is above the normal range of 4.6–6.1 kPa (34–46 mm Hg) and patients with hypercapnia are said to have type 2 respiratory failure even if the oxygen saturation is in the normal range.32

**3.4 Definition of acidosis (respiratory acidosis and metabolic acidosis)**

**Acidosis**

Acidity in any fluid is determined by the concentration of hydrogen ions [H+] and is normally regulated between 35 and 45 nmol/l. Acidity is more often expressed in terms of pH where pH = −log10[H+]. The normal pH range of the blood in humans is between 7.35 and 7.45 units. Acidosis is defined as a pH <7.35 ([H+] >45 nmol/l) and alkalosis is defined as a pH >7.45 ([H+] <35 nmol/l). Acidosis can be caused by respiratory or metabolic disorders.

**Respiratory acidosis**

Carbon dioxide (CO2) can combine with water (H2O) to form carbonic acid (H2CO3) in the blood which, in turn, dissociates to bicarbonate (HCO3-) and a hydrogen ion (H+). Acute respiratory acidosis occurs if the pH of the blood falls below 7.35 ([H+] >45 nmol/l) in the presence of a raised CO2 level.

If respiratory acidosis has been present for more than a few hours the kidney retains bicarbonate to buffer the acidity of the blood and, over hours to days, this may be sufficient to produce a normal pH. This situation (high PaCO2 with high bicarbonate and normal pH) is known as “compensated respiratory acidosis”. This situation is common in patients with chronic severe but stable COPD, but they may have an additional acute rise in PaCO2 during an acute exacerbation giving rise to “acute on chronic” respiratory acidosis despite their high bicarbonate level. This happens because the bicarbonate level was equilibrated with the previous CO2 level and is insufficient to buffer the sudden further increase in CO2 level that may occur during an exacerbation of COPD. Respiratory acidosis is common in clinical practice. Plant and colleagues showed that about 20% of patients with acute exacerbations of COPD requiring hospital admission have respiratory acidosis.34

**Metabolic acidosis**

This can be caused by failure to excrete acid produced by the body’s normal metabolic processes (eg, during renal failure) or by increased production of acid from abnormal metabolic conditions such as diabetic ketoacidosis. Alternatively, it may result from direct loss of bicarbonate from the kidney or gut (eg, during chronic diarrhoea). In all forms of metabolic acidosis there is a low blood bicarbonate level, either due to loss of bicarbonate or due to buffering of excess acid by bicarbonate which is excreted as CO2. A common cause of metabolic acidosis is lactic acidosis caused by tissue hypoxia. This may result from decreased oxygen delivery such as occurs in hypoxaemia, or low cardiac output states or conditions such as sepsis where oxygen consumption is impaired in the face of adequate oxygen delivery. In health, metabolic acidosis will occur at peak exercise where oxygen delivery is insufficient to meet demand.

**SECTION 4: GENERAL BLOOD GAS PHYSIOLOGY**

A full understanding of blood gas physiology in the body requires a detailed understanding of the anatomy, physiology and biochemistry of respiration and gas exchange. It is recognised that most readers of this guideline may not have had full training in all of these specialties, so this physiology section contains a brief overview of basic principles for the non-specialist reader (section 4) followed by a more detailed overview of the pathophysiology of oxygen for the expert reader (section 5). The rationale for targeted oxygen therapy is discussed in detail in section 6.

**4.1 Oxygen physiology**

Oxygen is the main “fuel” of the cells in mammalian bodies and it is essential for humans to maintain a safe level of oxygen in the bloodstream. Most of the oxygen carried in the blood is bound to an oxygen-carrying protein in red blood cells called haemoglobin. Oxygen itself does not dissolve easily in blood so only a small amount is carried dissolved in the bloodstream. As there is a fixed amount of haemoglobin circulating in the blood, the amount of oxygen carried in the blood is often expressed in terms of how saturated with oxygen the circulating haemoglobin is. This is what is meant by “oxygen saturation level”. If this is measured directly from an arterial blood sample, it is called the SaO2. If the measurement is calculated from a pulse oximeter it is called the SpO2. Alternatively, one can measure the oxygen tension of the blood (PaO2), known as the “partial pressure of oxygen” in the blood. This measurement can be expressed in kilopascals (kPa) (normal range 12.0–14.6 kPa) or in millimetres of mercury (normal range 90–110 mm Hg for young adults).31

The normal SaO2 in healthy adults at sea level is maintained within a narrow range of about 95–98% as discussed in section 3.1 above. This means that almost all of the oxygen-carrying capacity of haemoglobin in the blood is used when the SaO2 is in the normal range. Therefore, giving supplementary oxygen to a healthy young person will increase the saturation level only slightly from about 97% to 99% or a maximum of 100%, thus producing only a very small increase in amount of oxygen made available to the tissues.

Sudden exposure to low SaO2 levels (below about 80%) can cause impaired mental functioning even in healthy subjects. The brain is the most sensitive organ to the adverse effects of hypoxia, but it is possible that other organs in patients with critical illness may be vulnerable to the risk of hypoxic tissue injury at oxygen levels above this range. Most experts emphasise the importance of keeping the SaO2 above 90% for the majority of acutely ill patients.31–24 The present guideline suggests a desirable target saturation range of 94–98%. This
range mirrors the normal range for UK adults with a wide margin of safety above the 90% threshold which is mentioned above. Oxygen passes from inspired air in the lungs into the bloodstream and is delivered to the tissues. If oxygen levels fall in the blood, this is sensed by receptors in the carotid body (connected to the carotid artery in the neck) and ventilation is stimulated to increase the amount of oxygen coming into the lung and therefore the blood. The lung has the ability to divert blood flow away from areas which are poorly ventilated, so that blood returning from the body can be replenished with oxygen and can also clear carbon dioxide. This occurs through a process called “hypoxic vasoconstriction” whereby localised low oxygen levels in the lung airspaces cause constriction of feeding blood vessels, therefore diverting blood to areas of the lung with more normal oxygen levels.

If the oxygen-carrying capacity of the blood is low as, for example, in anaemia, this is detected by the kidneys which produce a hormone, erythropoietin, to stimulate red blood cell production. As one of the goals of the circulation is to deliver oxygen to the tissues of the body, the heart also responds to low oxygen levels by increasing its output, so increasing “oxygen delivery”.

Hypoxaemia, low PaO2, can be caused by a number of mechanisms. The most common form of hypoxaemia occurs when there is sufficient oxygen-carrying capacity (in patients with a normal level of haemoglobin) but insufficient oxygen taken up in the lungs. This can be the result of poor aeration of areas of lung or due to abnormalities of gas exchange within the lung during serious illnesses such as pneumonia. This form of hypoxaemia is the easiest to treat with oxygen therapy. Oxygen therapy is less effective in other causes of hypoxaemia including anaemia where there is a low carrying capacity or where the carrying capacity of haemoglobin has been reduced by a toxic substance because oxygen availability is not the limiting feature in these conditions. For example, carbon monoxide blocks oxygen binding to haemoglobin despite having a normal level of oxygen in the lungs and in the blood.

4.2 Carbon dioxide physiology
Carbon dioxide is a product of the body’s metabolism. It is cleared from the body by being transferred from the bloodstream into the alveoli in the lungs and then exhaled from the lungs. In a similar way to oxygen, carbon dioxide levels in the blood are controlled by chemical sensors (both in the carotid body and brainstem).

Carbon dioxide is highly soluble in the blood and is carried in three forms: bicarbonate (70%), dissolved carbon dioxide (10%) and bound to haemoglobin (20%). As carbon dioxide carriage is not limited by a carrier molecule such as haemoglobin, it is not expressed as a saturation. Because its carriage is approximately proportional to the partial pressure (gas tension) of carbon dioxide in the blood within the physiological range, carbon dioxide carriage is usually expressed in terms of its partial pressure. The normal range is 4.6–6.1 kPa or 34–46 mm Hg.

Increased levels of carbon dioxide will stimulate ventilation, thus increasing clearance from the lungs and therefore from the bloodstream. However, this mechanism is less effective in some respiratory diseases such as COPD where increased airway resistance and respiratory muscle weakness can restrict this response. Hypercapnia will occur when there is decreased ventilation for any reason. Safe elimination of carbon dioxide is as important to the body as the intake of oxygen.

Too little oxygen can give rise to organ failure but too much oxygen can also be harmful in some situations, especially to some vulnerable patients with COPD, chest wall deformities or muscle weakness. About a quarter of patients with acute flare-ups of COPD are at risk of carbon dioxide retention if they are given an excessively high dose of oxygen. If high concentrations of oxygen are given to these patients, the oxygen level in the blood will rise but the level of carbon dioxide will also rise and this can cause acidosis with subsequent organ dysfunction and, when severe, coma. In the past it was thought that the main problem was that these patients were dependent on the stimulus of a low blood oxygen level—called “hypoxic drive”—to stimulate breathing. It was thought that giving oxygen would cause a rise in the carbon dioxide level by simply reducing the stimulus to breathe due to “lack of hypoxic drive”. It is now known that the mechanisms for carbon dioxide retention in some patients are much more complex than this simple model suggested. Much of the rise in carbon dioxide which occurs during high-dose oxygen therapy is due to deterioration in the matching of blood flow and gas flow in the lungs. This can be avoided by giving controlled lower concentration oxygen therapy to vulnerable patients (see table 3).

4.3 Concept of target oxygen saturation (SaO2) ranges
One might ask why one should not aim for an SaO2 of 100% (hyperoxaemia) in all acutely ill patients (and some clinicians took this view in the past). This policy would clearly be risky for vulnerable patients with COPD and chest wall problems, but it could also harm other patients in a variety of ways. The more controversial risks of hyperoxaemia include coronary and cerebral vasconstriction and decreased cardiac output. Although these physiological effects are well documented, their significance in clinical practice is almost unknown owing to a lack of clinical trials of oxygen therapy.

High oxygen concentrations lead to an increase in reactive oxygen species which may cause tissue damage and may be responsible for some of the detrimental effects observed with high-flow oxygen in myocardial infarction and stroke. It is recognised that very high inhaled oxygen levels can give rise to partial collapse of some lung units, a condition known as “absorption atelectasis”. There is also the potential concern that a high oxygen saturation produced by high concentration oxygen therapy could mask a major deterioration in the patient’s clinical condition causing dangerous delays in treatment. An example of this is a patient who has taken an opiate overdose which has produced respiratory depression and the patient is underbreathing. If the patient is given excessive oxygen therapy, high or normal oxygen saturations may be recorded at a time when the carbon dioxide levels are dangerously high. The high oxygen saturation could mask the real situation and give the health professionals a false sense of confidence.

As alluded to above, acutely raised carbon dioxide levels can be dangerous. In acute circumstances where carbon dioxide levels have risen rapidly, the kidneys are unable to compensate for the consequent increased acid load. There are good data to show that the lower the pH of the blood, the higher the risk of intubation or death in patients with exacerbations of COPD. The purpose of oxygen therapy is to increase oxygen delivery to tissues, not just to increase oxygen carried by the blood. It must therefore be remembered that there may be other physiological disturbances that need correcting to increase oxygen delivery such as low cardiac output and severe anaemia. For example, improving these factors will improve oxygen delivery.
delivery much more than administering oxygen to a patient with a saturation of 90% which, at most, will produce a 10% rise in delivery. In addition to optimising oxygen delivery from the lungs to the tissues, it is important also to treat problems that might impair delivery of oxygen to the lungs themselves such as upper airway obstruction, bronchoconstriction and pulmonary oedema (remember the “ABC” of resuscitation – airway, breathing, circulation).

There is uncertainty about defining the ideal target saturation and this is one of the core debates in oxygen therapy. This uncertainty is largely due to a lack of evidence from clinical trials. In some specific disease areas such as COPD there are good data to inform the ideal target saturation and these will be covered in sections 8 and 9. In the general population without a specific indication for running high or low saturations, historically there has been a tendency to apply oxygen therapy specifically indicated (eg, carbon monoxide poisoning). The consensus among the members of the guideline group is that one should aim for a normal or near-normal SaO2 range of 94–98% for acutely ill patients except those at risk of hypercapnic respiratory failure (see recommendations 1–5 in section 6 of this guideline).

SECTION 5: ADVANCED BLOOD GAS PHYSIOLOGY AND PATHOPHYSIOLOGY AND PHYSIOLOGY OF OXYGEN THERAPY

Many of the issues discussed in this section are of a technical nature and may not be easily comprehensible to the general reader. However, recommendations 1–5 in section 6 of the guideline will follow logically from this section and from the brief overview of oxygen physiology in section 4.

The neurocardiopulmonary axis is designed to optimise global oxygen delivery and carbon dioxide clearance and the local tissue vascular beds are responsible for the distribution of blood flow.

Oxygen delivery (DO2) is expressed by the equation:

$$DO_2 = CaO_2 \times Q$$

where $CaO_2$ is the oxygen content of the arterial blood and $Q$ is the cardiac output. $CaO_2$ is the sum of oxygen dissolved in the blood and the amount of oxygen carried by haemoglobin. The solubility of oxygen in the blood is very low and therefore $CaO_2$ is largely determined by the total amount of haemoglobin and the proportion which is bound by oxygen, namely saturation. The relationship between haemoglobin $SaO_2$ and $PaO_2$ is shown in fig 3 and table 8. In health and disease, haemoglobin saturation is also influenced by other factors such as pH, PCO2, temperature and 2,3 diphosphoglycerate (Bohr effect; fig 3 and section 5.1.3). Consequently, there is not an exact relationship between $SaO_2$ and $PaO_2$ but table 8 gives approximate equivalents.

5.1 Regulation of blood oxygen content ($CaO_2$)

Figure 4 shows the level of oxygen and carbon dioxide in the pulmonary artery, in the alveolus and room air and in the pulmonary venous circulation which leads directly to the arterial circulation. The $PaO_2$ of mixed systemic venous blood rises markedly from a low level in the pulmonary artery (about 6 kPa or 45 mm Hg) to about 16 kPa (120 mm Hg) by the end of the pulmonary capillary. However, because the lung is not homogeneously made up of alveolar capillary units that are matched for perfusion and ventilation, the $PaO_2$ in the larger pulmonary veins is lower (13 kPa, 100 mm Hg). This is explained in more detail below. The gradient of carbon dioxide is much more gradual, falling from about 7 kPa (52 mm Hg) in the venous system and pulmonary artery to about 5 kPa (37 mm Hg) in the pulmonary vein and in the arterial system.

5.1.1 Arterial oxygen tension ($PaO_2$)

The pulmonary vasculature maximises $PaO_2$ by ensuring that the well ventilated areas of the lung receive most of the pulmonary blood flow, a process called ventilation/perfusion (V/Q) matching. This is largely achieved through a process called hypoxic pulmonary vasoconstriction (HPV).

The pulmonary circulation is unique in this regard compared with all the other vascular beds in the body which dilate in response to hypoxia. In poorly ventilated areas of lung the precapillary pulmonary arterioles constrict in response to sensing low alveolar PO2 ($PaO_2$). This is a compensating process and, despite it, some deoxygenated blood may still leave poorly ventilated alveolar capillary units. Deoxygenated blood leaving poorly ventilated alveolar capillary units cannot be compensated for by
mixing with blood from well ventilated units as the relationship between PaO2 and CaO2 is not linear. This physiological phenomenon is often not fully appreciated and therefore is worth a theoretical worked example (see box).

A much less studied phenomenon that regulates V/Q matching is hypoxic bronchodilation. This effect increases ventilation to poorly ventilated areas of the lung.36 If PaO2 falls, the peripheral chemoreceptors in the carotid body drive an increase in ventilation to increase PaO2.37 This will not increase PaO2 leaving already well ventilated units, but will increase PaO2 leaving less well ventilated alveolar units by increasing PaO2 in these units. Although the ventilatory response to SaO2, and therefore CaO2, is linear (fig 5), the carotid body senses PaO2 and not CaO2. This prevents excessive ventilation in response to anaemia which would be ineffective in increasing CaO2. The peripheral chemoreceptors are able to do this because the very high ratio of DO2 to oxygen consumption of the carotid body means that the tissue PO2 in the carotid body continues to reflect PaO2 and will not fall even in the presence of anaemic hypoxia.38

Figure 5 Ventilatory response to hypoxaemia. The relationship is inversely linear when plotted against oxyhaemoglobin (solid line) saturation but inversely exponential when plotted against arterial oxygen tension (PaO2) (dashed line).

5.1.2 Haematocrit
Erythropoiesis is controlled by a negative feedback system involving erythropoietin. By contrast with the carotid bodies, the peritubular cells in the kidney are well suited to sensing oxygen delivery as oxygen extraction is relatively high compared with oxygen delivery.40 41 Although oxygen delivery to the kidneys as a whole organ is high due to high renal blood flow, DO2 is reduced to the renal medulla as oxygen can pass from arterioles to the post-capillary venous system by shunt diffusion due to the parallel organisation of arterial and venous systems.42 Consequently, the peritubular cellular PO2 is low. It falls to even lower levels following reductions in DO2 either as a result of hypoxaemia or low haematocrit.

5.1.3 The Bohr effect
The oxygen-carrying capacity of haemoglobin is regulated in response to other metabolic factors to increase the efficiency of oxygen pick-up and delivery.43 Acidosis and hypercapnia shift the oxygen dissociation curve to the right (fig 3), thus favouring the dissociation of oxygen from haemoglobin in metabolically active tissues. The converse would hold true for the lungs where lower carbon dioxide levels favour oxygen loading of haemoglobin. Chronic hypoxaemia increases 2,3-diphosphoglycerate (2,3-DPG) in erythrocytes, shifting the dissociation curve to the right and therefore increasing oxygen delivery to the tissues.

5.1.4 Regulation of DO2 (oxygen delivery from the lungs to the tissues)
Acutely, the cardiovascular effects of hypoxaemia will tend to counter the impact of lower CaO2 on DO2 by increasing cardiac output through increased heart rate and myocardial contractility and by decreasing afterload by reducing systemic vascular resistance.44 45 Anaemic hypoxia is sensed in the aortic body, presumably owing to lower perfusion relative to oxygen consumption. Consequently, the aortic body can act as a sensor of reduced oxygen delivery as a result of either low oxygen tension or low haematocrit (unlike the carotid body).38

At local tissue level, oxygen delivery can be adjusted to changes in local oxygen consumption. For example, exercising skeletal muscle receives a greater proportion of total cardiac output than resting skeletal muscle. This relates in part to hypoxaemia recruiting a larger proportion of the capillary bed by the relaxation of pericytes, and also through arteriolar vasodilatation.46

5.2 Pathophysiology of hypoxia and hyperoxia
Hypoxia may result from a number of different diseases discussed in section 8 of this guideline. In each case one or more of the following pathophysiological mechanisms may apply:
▶ Hypoxaemic hypoxia
▶ Other mechanisms of hypoxia
▶ Hyperoxia

5.2.1 Hypoxaemic hypoxia (see definition in section 3.1.2)
Hypoxaemic hypoxia in blood leaving an alveolar capillary unit in the lung may be induced by alveolar hypoxia or incomplete gas exchange. The alveolar gas equation calculates the oxygen level in the alveolus using the following formula:

$$\text{PAO}_2 = \text{PIO}_2 - \frac{\text{PACO}_2}{\text{RER}}$$

where PAO2 and PACO2 represent alveolar levels of oxygen and carbon dioxide, RER is the respiratory exchange ratio or the ratio of carbon dioxide production to oxygen consumption and
inspired \( P_O_2 \) \( (P_I_0_2) = F_I_0_2 \times (\text{barometric pressure} \ [100 \text{ kPa}, 750 \text{ mm Hg}] – \text{water vapour pressure} \ [-6 \text{ kPa}, 45 \text{ mm Hg}]) \).

Considering this equation, alveolar hypoxia can be induced by decreased \( P_O_2 \) or increased \( P_A_0_2 \). If an alveolar capillary unit is relatively underventilated for its degree of perfusion (low V/Q ratio), \( P_A_0_2 \) will rise due to inadequately clear ance and thus \( P_A_0_2 \) will fall. This may happen for a number of reasons such as increased dead space ventilation during the non-fatiguing pattern of shallow respiration in respiratory failure or abnormal lung mechanics in advanced COPD. In diseases that cause global hypoventilation such as respiratory muscle weakness, effectively all areas of lung have low V/Q ratios and this explains the hypercapnia and hypoaxaemia associated with these conditions.

An extreme form of low V/Q pathology occurs in intrapulmonary and extrapulmonary shunt where no gas exchange occurs at all. An example of intrapulmonary shunt is when the airway to a lung segment is obstructed by mucus creating an area of lung tissue that is perfused but not ventilated, thus acting as a right-to-left shunt. An example of extrapulmonary shunt is a ventricul septal defect with right-to-left shunting in Eisenmenger’s syndrome.

In health and at rest, oxygen has equilibrated across the alveolar capillary membrane one-third of the way along the length of the capillary. With increased thickness of this membrane, as in fibrotic lung disease, equilibration may take longer and an oxygen gradient may persist between the alveolus and blood at the end of the capillary. The overall effect of this when multiple alveolar capillary units are affected will lead to an increased alveolar-to-arterial \( (A–a) \) gradient. This exacerbates during exercise, when capillary transit time decreases.

5.2.2 Other mechanisms of hypoxia (see definitions in section 3.1.2) Anaemia and carbon monoxide poisoning may result in “anaemic hypoxia” by reducing oxygen-carrying capacity. A low cardiac output state will reduce oxygen delivery even in the absence of hypoxaemia. Tissue hypoxia may develop in these circumstances and this is often termed “stagnant hypoxia”.

5.2.3 Hyperoxia Hyperoxia can be caused by hyperoxaemia and polycythaemia. Considering again the alveolar gas equation in the previous section, hyperoxaemia can only exist in the presence of high inspired \( P_O_2 \) or low \( P_A_0_2 \) (resulting from hyperventilation). The term “hyperoxia” could technically be used to describe a patient with polycythaemia without hyperoxaemia, but most clinicians use the term only to describe situations in which the \( P_A_0_2 \) is raised.

5.3 Physiology of carbon dioxide

5.3.1 Normal carbon dioxide homeostasis Carbon dioxide is principally carried in the blood in three forms: carbon dioxide, bicarbonate and as a carbamino compound. In the normal physiological range of 4.5–6.0 kPa (34–45 mm Hg) the relationship between \( P_A_0_2 \) and \( C_A_0_2 \) (carbon dioxide content) can be considered linear (fig 6).

5.3.2 Regulation of carbon dioxide \( P_A_0_2 \) is sensed at the peripheral and central chemoreceptors (in the medulla oblongata) by its effect on intracellular pH. Consequently, the regulation of \( P_A_0_2 \) is intimately related to pH homeostasis (fig 7).

It is often not appreciated how V/Q matching relates to \( P_A_0_2 \). As discussed in section 5.2.1, alveolar capillary units with a low V/Q ratio have increased \( P_A_0_2 \). Because of the high solubility and diffusibility of carbon dioxide, there is little A–a gradient for carbon dioxide at the end of the capillary, so blood leaving low V/Q alveolar capillary units has a high \( P_A_0_2 \).

As described above, areas of low V/Q are usually minimised through hypoxic pulmonary vasoconstriction. It is also thought that a high \( P_A_0_2 \) can cause pulmonary vasoconstriction, adding to the homeostatic mechanisms of the lung, matching perfusion to ventilation. As the relationship between \( P_A_0_2 \) and carbon dioxide dissolved in the blood is approximately linear over the physiological range (unlike oxygen), blood does not become saturated with carbon dioxide and therefore a high pulmonary venous \( P_A_0_2 \) from low V/Q areas can be partially balanced by a low pulmonary venous \( P_A_0_2 \) from high V/Q areas. Consequently, by increasing overall alveolar ventilation, the cardiopulmonary system is able to prevent hypercapnia despite significant V/Q mismatch or shunt, unless respiratory mechanics are limiting.

As with the carriage of oxygen (Bohr effect), there is a reciprocal relationship between \( P_O_2 \) and carbon dioxide carriage. This is known as the Haldane effect. Deoxygenated haemoglobin has a higher carbon dioxide buffering capacity than oxygenated haemoglobin. This favours carbon dioxide pick-up in the systemic venous circulation and carbon dioxide offloading in the lungs.

Acutely, carbon dioxide acts as a sympathomimetic on the heart: it increases heart rate and stroke volume, increasing cardiac output. Peripherally it causes vasoconstriction, reducing systemic vascular resistance. Locally, carbon dioxide acts as a...
vasodilator, thus diverting blood flow to tissues with high metabolic demand. The resulting physical signs of hypercapnia are described in section 7.2.

5.4 Pathophysiology of hypercapnia and hypocapnia

5.4.1 Mechanisms of hypercapnia and hypocapnia

The mechanisms of hypercapnia are simpler than hypoxaemia and there are four possible causes:51

1. Increased concentration of carbon dioxide in the inspired gas.
2. Increased carbon dioxide production.
3. Hypoventilation or ineffective ventilation.
4. Increased dead space.

The mechanisms of hypercapnia in COPD (and other conditions predisposing to hypercapnic respiratory failure) are discussed in 6.3.1.

Increased concentration of carbon dioxide in the inspired gas

This iatrogenic cause of hypercapnia is uncommon but should be excluded at the outset in any patient unexpectedly found to be hypercapnic when breathing from, or being ventilated by, external equipment. The severity of hypercapnia due to rebreathing is limited by the rate at which the P\textsubscript{CO\textsubscript{2}} can increase (no more than 0.4–0.8 kPa/min, 3–6 mm Hg/min).

Increased carbon dioxide production

This is likely only to cause hypercapnia if the minute ventilation is fixed by artificial means and if carbon dioxide production is increased (e.g., due to sepsis or increased work of breathing).

Hypoventilation or ineffective ventilation

Low alveolar minute ventilation is by far the most common cause of hypercapnia. In clinical practice, COPD is the most common disease to cause hypercapnia; the problem is secondary to alveolar hypoventilation rather than a reduced minute ventilation per se. Patients adopt a rapid shallow pattern of breathing during an acute exacerbation of COPD with the result that the ratio of dead space to tidal volume is increased with more ventilation therefore being “wasted”. A rapid shallow pattern of breathing results in a bigger proportion of each breath being wasted because of the need to ventilate the anatomical dead space. Furthermore, during acute COPD exacerbations, V/Q mismatch may lead to an increase in physiological dead space, exacerbating the problem further. It is important to note that this commonly occurs in the context of an apparent overall increase in minute ventilation. Alveolar hypoventilation due to a reduction in minute ventilation is seen following medullary respiratory centre depression by drugs, obstruction of a major airway or restriction of the lungs or chest wall or by respiratory muscle weakness, head injury, intracerebral haemorrhage or opioid narcosis.

Increased dead space

This would be most common in patients breathing through an artificial apparatus which has been incorrectly configured. It can also be due to any cause of V/Q mismatch in which the normal response to hypoxaemia (i.e., to increase ventilation) is compromised because of lung disease. It is important to note therefore that hypercapnia sometimes may be seen in conditions more usually associated with hypoxaemia (e.g., pulmonary embolus, pneumonia) when it occurs in patients with lung disease and an increased physiological dead space. Although alveolar hypoventilation is the most common cause of hypercapnia, it is important to consider the other potential causes, particularly when patients are receiving assisted ventilation and an artificial breathing circuit is used.

5.4.2 Hypoventilation and hyperventilation

Hyperventilation may be physiological—for example, in the face of a metabolic alkalosis. Pathological hyperventilation will occur either when the respiratory muscles are unable to ventilate the lungs sufficiently because they are pathologically weak or they are unable to overcome abnormal lung mechanics such as during an exacerbation of COPD. Reduced respiratory drive caused by drugs with sedative properties or by neurological injury will also produce hyperventilation.

Using the same physiological principles but in reverse, hyperventilation for any reason will produce hypocapnia. This may occur during pure hyperventilation during an anxiety attack or during physiological hyperventilation.

5.5 Physiology of oxygen therapy

Oxygen therapy increases P\textsubscript{AO\textsubscript{2}} and is therefore only effective when alveolar capillary units have some functional ventilation. Oxygen therapy is ineffective if there is a pure shunt (such as pulmonary arteriovenous malformations) where mixed venous blood does not pass through an alveolar capillary unit. There will only be a small overall increase in P\textsubscript{AO\textsubscript{2}} due to an increase in dissolved oxygen in the pulmonary venous blood from ventilated alveolar capillary units, which is small compared with the content of oxygen carried by haemoglobin. Despite this, there is good evidence that breath-hold times can be increased by breathing oxygen.52–54 One study found that the breath-hold time of 15 healthy subjects increased from 56 s after breathing air to 92 s after breathing 4 litres of nasal oxygen for 2 min, and another study found that 31 healthy volunteers had an increase in breath-hold time from 32 s breathing air to 61 s after breathing oxygen whereas the breath-hold time of 29 patients with chronic pulmonary disease was 9 s compared with 22 s for a group of 29 similar patients after breathing oxygen. The same principles are used to preoxygenate patients before intubation during anaesthesia. It is thought that the additional breath-hold time is produced not by the marginal increase in blood oxygen levels but by the increased reservoir of oxygen in the lungs after breathing oxygen-enriched air.

In poorly ventilated units (i.e., low V/Q ratio), P\textsubscript{AO\textsubscript{2}} will be low. Increasing F\textsubscript{IO\textsubscript{2}} will increase P\textsubscript{AO\textsubscript{2}} and therefore P\textsubscript{O\textsubscript{2}}. Hypoventilation disorders can be considered as lungs made up entirely of low V/Q units.

When there is diffusion limitation due to increased alveolar capillary membrane thickness such as in fibrotic lung disease, increasing P\textsubscript{AO\textsubscript{2}} will augment the rate of diffusion across the alveolar capillary membrane by increasing the concentration gradient.

Increasing dissolved oxygen in plasma by oxygen therapy may also be used to offset the effects of hypoperfusion to some extent (stagnant hypoxia) and may well be important in certain situations (cardiogenic shock), although the effect is only marginal. Increased inspired oxygen will only marginally mitigate the effects of anaemic hypoxia but, because the Ca\textsubscript{O\textsubscript{2}} in patients with anaemia is less than that in patients with normal haemoglobin, the effect of additional oxygen carried in solution may become more important in these situations.

5.6 Strategies for improving oxygenation and delivery

Tissue oxygenation is dependent upon optimal or adequate oxygen delivery to the tissue (DO\textsubscript{2}). This physiological process is composed of various components that independently and interdependently influence and determine DO\textsubscript{2} and therefore
tissue oxygenation. These components can be considered sequentially.

5.6.1 Optimising PaO2
The physiology of oxygen therapy has already been discussed in the previous section. However, increasing FiO2 is only one component in increasing oxygen uptake in the lungs. Other key manoeuvres to ensure oxygen delivery to the alveolar capillary bed include:
- Maintaining a satisfactory airway.
- Ensuring adequate alveolar ventilation.
- Reversing any respiratory depressants such as narcotics.
- Invasive or non-invasive ventilation where necessary.
- Treating airflow obstruction by bronchodilation or sputum clearance techniques.
- Optimising transfer factor (diffusion capacity).
- Treatment of pulmonary oedema.

5.6.2 Optimising oxygen carriage
Oxygen is carried in blood mainly by haemoglobin with only a very small amount of oxygen dissolved in the blood itself. Adequate haemoglobin is therefore essential for optimal oxygen content (CaO2) of blood. The ideal haemoglobin level for optimal CaO2 and therefore for optimal DO2 has long been a subject of debate. Previous practices have favoured haemoglobin levels close to 100 g/l (10 g/dl), providing adequate CaO2 as well as reducing viscosity of blood for better perfusion in critically ill patients. However, studies by Canadian researchers in the late 1990s have shown that haemoglobin levels of 70 g/l (7 g/dl) were as safe as higher levels and may produce fewer complications in the critically ill. However, this study was conducted using non-leucocyte depleted blood and it is possible that some of the infective complications in the group who were given more transfusions might have been avoided by the use of leucocyte-depleted blood. The optimal transfusion target for critically ill patients therefore remains the subject of ongoing discussion among experts in critical care medicine. Although the issue of optimal haemoglobin in patients with unstable or symptomatic coronary artery disease is not settled, haemoglobin levels of 100 g/l (10 g/dl) are recommended for adequate DO2 (see box).

5.6.3 Optimising delivery
Besides adequate CaO2 and PaO2, delivery of oxygen depends upon adequate flow of oxygenated blood. Cardiac output in turn depends upon adequate blood (circulating) volume, adequate venous return and adequate and optimal myocardial function. To avoid tissue hypoxia, attention must therefore be paid to the volume status of the patient and the adequacy of cardiac function, as well as initiating oxygen therapy. In severely shocked patients (eg, cardiogenic shock, septic shock), invasive monitoring and inotropic/vasopressor therapy will usually be indicated in appropriate higher dependency environments. It has been shown that deliberately increasing oxygen delivery in critically ill patients as well as high-risk surgical patients reduces organ failure, reduces length of ICU stay and, most importantly, improves mortality.

Increased oxygen delivery partly involves oxygen therapy, but these studies did not show any benefit from aiming at supra-physiological oxygen delivery.

The following worked example illustrates how minor abnormalities in each of the parameters discussed above, when occurring together, can result in a dramatic fall in oxygen delivery.

Oxygen delivery in health can be calculated as follows where CO is cardiac output and Hb is haemoglobin (normal values: CO = 5 l/min; SaO2 = 94–98%, Hb = 15 g/l):

\[
DO2 = CO \times CaO2 \\
DO2 = CO \times \{\frac{SaO2}{100} \times Hb \times 1.3\} + \{PaO2 \times 0.003 \text{ mm Hg} \times 10\}
\]

Therefore:

\[
DO2 = 5 \times \{[0.98 \times 150 \times 1.3] + [100 \times 0.003 \times 10]\}
\]

\[
DO2 = 970 \text{ ml/min or } 1000 \text{ ml/min}
\]

This is well above the normal oxygen consumption (V\text{O}2) of about 250 ml/min.

Now consider an anaemic patient with a haemoglobin level of 10 g/dl, cardiac output 3.5 l/min and SaO2 of 90%; the oxygen delivery becomes approximately 410 ml/min:

\[
DO2 = 3.5 \times \{[0.9 \times 100 \times 1.3] + [60 \times 0.003 \times 10]\}
\]

Although this value is still above the V\text{O}2 at resting physiology, in practice the V\text{O}2 would most likely have risen owing to a number of factors such as increased work of breathing and increased catabolic state of sepsis. This example is not rare and occurs daily in clinical practice. It is therefore important not to consider oxygen therapy in isolation. As many patients may not have adequate haemoglobin, cardiac output or blood volume, they may suffer from tissue hypoxia when they become acutely ill. All such patients should have supplemental oxygen therapy until they are evaluated by a responsible healthcare professional.

**SECTION 6: HYPOXIA, HYPEROXIA, HYPERCAPNIA AND THE RATIONALE OF TARGETED OXYGEN THERAPY**

6.1 Effects and risks of hypoxia and rationale for target oxygen saturation range
As this guideline is addressing emergency oxygen therapy, this section will only focus on the effects and risks of acute hypoxia. Section 8 will discuss the emergency treatment of acute hypoxia in patients with long-term diseases associated with chronic hypoxia. The approximate relationship between PaO2 and SaO2 is shown in table 8 and fig 3 (oxygen dissociation curve).

The effects and risks of hypoxia are summarised in table 9. Severe hypoxia may lead to brain damage and death. In general,

Table 8 Approximate relationship between arterial blood saturation (SaO2) and arterial oxygen tension (PaO2)

<table>
<thead>
<tr>
<th>PaO2 (kPa)</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>&gt;17</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO2 (mm Hg)</td>
<td>30</td>
<td>37.5</td>
<td>45</td>
<td>52.5</td>
<td>60</td>
<td>67.5</td>
<td>75</td>
<td>82.5</td>
<td>90</td>
<td>97.5</td>
<td>104</td>
<td>112.5</td>
<td>120</td>
<td>&gt;127.5</td>
</tr>
<tr>
<td>SaO2 (%)</td>
<td>57.4</td>
<td>71.4</td>
<td>80.7</td>
<td>86.8</td>
<td>90.7</td>
<td>93.2</td>
<td>94.9</td>
<td>96.2</td>
<td>97.0</td>
<td>97.8</td>
<td>98.2</td>
<td>98.6</td>
<td>98.8</td>
<td>&gt;99.0</td>
</tr>
</tbody>
</table>

* Thorax 2008;63(Suppl VI):vi1–vi68. doi:10.1136/thx.2008.102947 vi21
many of the physiological effects of hypoxia are mediated by low PaO₂, irrespective of oxygen content. For example, even when the total blood oxygen content is normal in the presence of polycythaemia, hypoxaemia will still exert a physiological effect such as stimulation of ventilation. The risks of hypoxia, however, are usually mediated by low tissue Po₂ which may occur as a consequence of a low PaO₂ and other mechanisms such as severe anaemia and low cardiac output states.

These problems can be illustrated in the pathophysiology of myocardial ischaemia which will develop when there is an imbalance between myocardial D O₂ and oxygen consumption (vO₂). D O₂ is not only dependent on PaO₂, but also coronary flow and haematocrit. vO₂ will also depend on the stroke work of the heart. Defining a lower limit of PaO₂ which is considered safe is therefore impossible given the other variables.

Hypoxaemia refers to an abnormally low oxygen tension in the blood (see section 3.1). However, it is not possible to define a single level of hypoxaemia that is dangerous to all patients. Some patients with chronic lung disease may be accustomed to living with SaO₂ as low as 80% (PaO₂ about 6 kPa or 45 mm Hg) while other patients with acute organ failure may be harmed by short-term desaturation <90% (PaO₂ <6 kPa or 45 mm Hg).

It has been shown that medical patients with sustained desaturation <90% have impaired medium-term survival compared with medical patients with saturations which stay >90%. However, much of this survival disadvantage may be due to the underlying disease which has caused the low oxygen level (eg, severe COPD or pneumonia) and the degree of hypoxaemia may be a marker of disease severity, therefore the contribution of modest hypoxaemia to mortality rates is not known.

Mental functioning becomes impaired if the PaO₂ falls rapidly to <6 kPa (45 mm Hg, SaO₂ <80%) and consciousness is lost at <4 kPa (30 mm Hg, SaO₂ <56%) in normal subjects. Young subjects tolerate acute hypoxaemia for longer than older subjects in terms of “time of useful consciousness”. Safe levels of hypoxaemia in COPD have been discussed in detail in a review by Murphy and colleagues. Many patients with COPD have a PaO₂ of <5 kPa (37.5 mm Hg) corresponding to a SaO₂ of <70% during an acute exacerbation. Furthermore, sudden hypoxaemia is more dangerous than hypoxaemia of gradual onset both in health and in disease. For example, millions of people live at altitudes above 3000 m despite an average PaO₂ of about 7.3 kPa (55 mm Hg, saturation about 88%) and acclimatised climbers on Mount Everest can tolerate short-term exposure to an oxygen saturation of 70% or less with an estimated PaO₂ of about 3.7 kPa (28 mm Hg). Campbell summarised this issue eloquently in 1967 when he said “Better a year at a PaO₂ of 50 mm Hg (6.7 kPa) than an hour at a PaO₂ of 20 mm Hg (2.7 kPa)”.

Hypoxic hepatitis has been reported in patients with respiratory failure associated with oxygen levels below 4.5 kPa or 34 mm Hg, whereas hypoxic hepatitis in patients with cardiac disease is mainly due to decreased hepatic blood flow (stagnant hypoxia) and occurs at higher blood oxygen levels.

An in-flight study of patients with COPD with mean SaO₂ of 96% at sea level showed a fall to 90% in-flight in a commercial airliner and a further fall to a mean SaO₂ of 87% while walking in the aircraft aisles. These patients had no symptoms during these hypoxaemic episodes. A study of 84 healthy airline passengers found that the mean SaO₂ fell from 97% at ground level to 95% (15.85–3819) at cruising altitude. A study of healthy airline cabin crew has shown that the SaO₂ of flight attendants falls to a mean nadir of 88.6% without causing breathlessness or any other symptoms. Individual nadirs of SaO₂ ranged from 93% down to 80%. Without any randomised evidence, the guideline production team have suggested that the level of saturation which is tolerated by healthy people without any symptoms (about 85% saturation) should be regarded as the safe lower limit of hypoxaemia. However, other co-morbidities may need to be taken into account and expert opinion recommends that the SaO₂ should be maintained above 90% for seriously ill patients. For this reason, the present guideline recommends a target SaO₂ (and SpO₂) above 94% for most hypoxaemic patients to ensure that the actual oxygen level remains above 90% for most of the time with a 4% margin of safety to allow for oximeter error and artefact such as a weak signal or dark coloured skin. The accuracy of and pitfalls of
oximetry are addressed in section 7.1.2. Specific targets for oxygen therapy in other diseases will be considered theoretically in this section and practically in sections 8 and 9. Some patients—especially older people or those with chronic lung disease—may have an SaO2 below 94% when clinically stable and oxygen should not be given just to maintain the SaO2 above 94% if the patient is clinically stable.

In assessing an ill patient, the SaO2 level is only one of several physiological variables that should be monitored. Many patients with sudden acute illness such as postoperative pulmonary emboli will have a sudden alteration in physiological variables as assessed by “track and trigger” systems such as the modified Early Warning Scoring systems (mEWS). Such patients may have only a small fall in SaO2 owing to physiological compensation mechanisms such as increased ventilation. Healthcare professionals therefore need to be alert for falls in SaO2 even within the recommended target ranges.

Because of the wide normal range for SaO2 and the uncertainty concerning the possible physiological consequences of minor hypoxaemia, there was more debate among the guideline group about desirable target ranges than about any other aspect of the guideline. If the SaO2 should fall slightly below 94%, the key issue is to identify and treat the cause of the hypoxaemia which is not of itself dangerous at this level. However, there is a danger that healthcare workers might fail to respond appropriately to abnormal hypoxaemia. After much debate it was concluded that the guideline would recommend a target range of 94–98% for all adult patients. This reflects the approximate normal range of SaO2 in healthy adults as discussed in section 3.1. However, a sustained fall in SaO2 of >5%, even within the normal range, may be an indicator of acute illness and should require clinical assessment of a patient while a minority or patients (especially those aged >70 years) may have an SaO2 of <94% even when clinically stable.

6.1 Desirable oxygen saturation ranges in acute illness

► Acute hypoxaemia is considered dangerous to healthy subjects below a PaO2 of about 6 kPa (45 mm Hg) or an SaO2 of about 80% due to impaired mentation and risk of tissue hypoxia, but patients with acute illness or chronic organ disease or ischaemia are likely to be at risk at PaO2 >6 kPa. [Evidence level III]

► Changes in physiological “track and trigger” systems such as mEWS may occur in acute illness with either no change or only a small change in SaO2 levels. [Evidence level III]

► Critical illness may present initially with only a small fall in SaO2 level because of compensating mechanisms. [Evidence level IV]

► The upper end of the recommended range in this guideline (98%) is the upper limit of SaO2 in healthy adults. [Evidence level III]

► The lower end of the suggested target saturation range (94%) is about the lower end of the normal range and ensures that the SaO2 remains above 90% most of the time. [Evidence level III]

6.2 Potential benefits of hyperoxaemia and supplemental oxygen therapy in non-hypoxaemic patients

Supplemental oxygen therapy is most commonly given to correct hypoxaemia as discussed throughout this guideline. However, there are some circumstances where supplemental oxygen may be given to non-hypoxaemic patients.

6.2.1 Benefits of hyperoxaemia in carbon monoxide poisoning and pneumothorax

Hyperoxaemia is useful in some clinical situations. The best example of this is carbon monoxide (CO) poisoning. CO combines with haemoglobin and has a higher affinity for the haemoglobin molecule giving rise to carboxyhaemoglobin (COHb). The half-life of COHb is about 4–5 h when breathing air but is reduced to about 40 min when breathing 100% oxygen. Hyperoxaemia may also be used to accelerate the resolution of pneumothorax in patients who do not require a chest drain.

6.2.2 Other potential benefits of oxygen therapy in non-hypoxaemic patients

► Most guidelines for cardiopulmonary resuscitation and the care of patients with critical illness recommend the use of 100% oxygen in the initial stages of resuscitation. Although these recommendations are not evidence-based, it is unlikely that controlled trials would ever be undertaken using different levels of oxygen therapy in these emergencies and it seems intuitive to maximise oxygen delivery for critically ill patients with circulatory collapse. However, randomised trials have been undertaken of resuscitation of neonates breathing room air or oxygen and the unexpected outcome of a Cochrane review was that the outcome was possibly better when room air was used. This surprising finding cannot be extrapolated to adult patients, but it does emphasise the need for clinical trials even in areas where one might intuitively believe that oxygen would be beneficial. Furthermore, there is theoretical evidence that patients who have survived the initial stages of resuscitation may be managed more safely with 30% oxygen compared with 100% oxygen.

► It has been shown that early intervention to increase oxygen delivery to the tissues in critically ill patients as well as high-risk surgical patients reduces organ failure, reduces length of ICU stay and, most importantly, improves survival.

Increased oxygen delivery in part involves oxygen therapy, but these studies did not show any benefit from aiming at supraphysiological oxygen delivery.

► Short-term postoperative oxygen therapy (for 2 h) has been shown to reduce the risk of surgical wound infections in double blind trials of patients having bowel surgery but not in general surgery.

► Oxygen therapy has been reported to improve anastomotic integrity in animal models and to have potential benefit in human anastomotic surgery.

► Reported benefits of oxygen therapy in healing of established wounds and in treatment of wound sepsis are controversial. Hyperbaric oxygen reduced the risk of amputation in patients with chronic diabetic foot ulcer and may improve the chance of healing over 1 year, but the Cochrane reviewers had concerns about the size and quality of existing studies and recommended further trials. It is not known if conventional oxygen therapy has any effect on wound healing.

► Relief from cluster headaches has been reported in about 60% of cases but this observation is based on very small studies from the 1980s. Although this could be considered as a form of emergency oxygen therapy, these patients are not breathless.

► Through relief of breathlessness and work of breathing, oxygen therapy may decrease carbon dioxide production and consequently offset some of the potential increase in PaO2 that might otherwise occur due to the mechanisms...
described in section 6.3.1. However, there are no controlled trials supporting the use of oxygen for this indication.

- Oxygen therapy may reduce nausea and vomiting in postoperative patients and in ambulances. Although some reports have suggested that oxygen may have a specific antiemetic effect during ambulance transfers and in the postoperative state, subsequent studies reported no effect on motion sickness and no antiemetic effect in postoperative patients. 35–92

6.3 Potential adverse effects and risks of supplemental oxygen therapy and hyperoxaemia

These are summarised in table 9 and in the review by Downs 93 and in other sources. 94–97 The following paragraphs will summarise the physiology and pathophysiology of supplemental oxygen therapy and hyperoxaemia.

6.3.1 Respiratory system

The most significant effect of excess oxygen on the respiratory system is hypercapnic respiratory failure in a population of vulnerable patients. This does not occur in the absence of significant pulmonary disease or musculoskeletal disease affecting the thorax, and it occurs while the PaO2 is still within the normal range or slightly below normal. There are at least five mechanisms responsible for this:

- V/Q mismatch.
- Ventilatory drive.
- Haldane effect.
- Absorption atelectasis.
- Higher density of oxygen compared with air.

V/Q mismatch

During air breathing, poorly ventilated alveolar capillary units will be hypoxic and therefore poorly perfused due to hypoxic pulmonary vasoconstriction (HPV). If high concentration oxygen is administered, the PaO2 will rise, thus reversing the HPV and increasing blood flow to that unit. However, although the oxygen in the unit has increased, it remains poorly ventilated with a high PAO2 and therefore a high pulmonary venous PCO2. As more blood is now passing through these units, the PaCO2 will rise. Normally when there is no significant lung disease or thoracic musculoskeletal disease, the respiratory system is able to compensate for these changes by increasing overall ventilation thereby lowering PaCO2. However, where respiratory mechanics are such that increased ventilation is not possible, PaCO2 will rise. Several authors have reported that this mechanism is more important than reduction in ventilatory drive in producing hypercapnia when supplementary oxygen is administered, but this continues to be a controversial area of respiratory physiology. 90–105

Ventilatory drive

Hypoxaemia drives an increase in ventilation so it follows that relief of hypoxaemia will cause a decrease in ventilation. The consequent rise in PaCO2 is inversely proportional to the decrease in ventilation such that a halving of alveolar ventilation will lead to a doubling in PaCO2, assuming constant carbon dioxide production. As shown in fig 5, any increase in PaO2 above 8 kPa (60 mm Hg) will not significantly reduce ventilation and increases above 15 kPa (100 mm Hg) will have no impact on ventilation as the carotid sinus discharge is largely attenuated above 15 kPa. This mechanism is therefore only of importance in explaining increases in PaCO2 when PaO2 rises to 13 kPa, but not increases thereafter. This phenomenon is also seen in normal individuals. Several clinical studies have suggested that “hypoxic drive” makes only a small contribution to the rise in PaCO2 that is seen clinically when high-dose oxygen is given to patients with COPD, but one recent study has supported this mechanism. 90–105

Haldane effect

The third effect of increasing FiO2 is to decrease the carbon dioxide buffering capacity of haemoglobin through the Haldane effect. 45

Absorption atelectasis

The fourth effect, absorption atelectasis, is thought to occur as a result of absorption of oxygen from alveoli with high PaO2 beyond obstructed airways. This can happen at FiO2 as low as 30–50% and will result in a shunt (increased V/Q mismatch). 45

Higher density of oxygen compared with air

Johnson and colleagues 106 have shown a reduction in forced expiratory volume in 1 s (FEV1) in patients who were breathing pure oxygen compared with breathing air. They concluded that the effect was probably related to the slightly increased density and viscosity of oxygen relative to air. This would increase the work of breathing which could contribute to hypercapnia in an exhausted patient.

It has been stated for several decades that “hyperoxaemia causes hypercapnic respiratory failure by producing decreased respiratory drive in patients with intrinsic lung disease, such as COPD”, and many—if not most—medical textbooks from the 1960s to the present time refer to “loss of hypoxic drive” as the main cause of hypercapnia and acidosis when high-dose oxygen is given to patients with an acute exacerbation of COPD. This assertion is usually attributed to Campbell who championed the concept of controlled oxygen therapy in the 1960s. However, Campbell has been widely misquoted. What he actually said in 1967 was as follows: “It is usual to attribute the rise in PaCO2 in these patients to removal of the hypoxic drive to ventilation but I share the doubts of Pain and co-workers 105 that this is the whole story; changes in the pulmonary circulation may also be important”. Most but not all subsequent studies have shown that Campbell was correct in this assumption. 90–105 Another curious feature of hypercapnia in acute exacerbations of COPD is that it is not universal. 66 Some patients with COPD are prone to repeated episodes of hypercapnic respiratory failure and others may not ever suffer from this complication. Even among COPD patients with chronic hypercapnia, not all will develop an increased carbon dioxide level (and acidosis) during acute exacerbations.

The theory of “loss of hypoxic drive” as the cause of hypercapnia is further confounded by the observation that PaO2 continues to rise as PaO2 is increased above 13 kPa (100 mm Hg), which has little impact on decreasing ventilation and most patients with respiratory acidosis during an exacerbation of COPD have PaO2 above 10 kPa, equivalent to saturation above about 98%. Therefore, while a small reduction in ventilation may be a contributing factor to the rise in carbon dioxide levels during oxygen therapy in COPD, the major factor is the worsening of V/Q matching.

Additional effects of increasing FiO2 will relate to atelectasis and perhaps worsening airflow obstruction due to increased viscosity. In diseases where there is little intrinsic lung disease but significant respiratory muscle weakness, loss of hypoxic
respiratory drive will be a greater factor in the development of hypercapnia. However, HPV remains a significant regulator of V/Q matching even in non-diseased lung.

6.3.2 Rebound hypoxaemia following sudden cessation of supplementary oxygen therapy

Patients who have developed worsened hypercapnic respiratory failure following high concentration oxygen therapy face a further significant danger of rebound hypoxaemia if oxygen is suddenly withdrawn in an attempt to correct the effects of excess oxygen therapy. Rebound hypoxaemia can be explained using the alveolar gas equation and, given its importance, is best illustrated with a working example (box).

For the purposes of simplicity, this example makes several assumptions such as a constant respiratory exchange ratio and alveolar–arterial gradient between stages 1 and 3. It also assumes that ventilation remains unchanged. Although when \( P_{aCO_2} \) falls to 3.4 kPa upon removal of oxygen, ventilation will rise, by definition it will not be able to rise sufficiently to meet the need to clear the carbon dioxide stores for the same reason that hypercapnic respiratory failure developed in the first instance.

Rebound hypoxaemia is a major risk and may be more dangerous than the hypercapnic respiratory failure itself. Consequently, this guideline will recommend that oxygen therapy be stepped down gradually through sequential Venturi devices while monitoring saturation continuously.

- Sudden cessation of supplementary oxygen therapy can cause rebound hypoxaemia with a rapid fall in oxygen tension to below the tension that was present prior to the commencement of supplementary oxygen therapy. [Evidence level III]

Example 3: Rebound hypoxaemia

- **Stage 1:** Consider a patient with an exacerbation of COPD whose arterial blood gases are as follows: \( PaO_2 6.5 \text{ kPa} \); \( PaCO_2 7.5 \text{ kPa} \) breathing room air. The \( PaO_2 \) calculated from the alveolar gas equation (5.2.1) will be 11.6 assuming a respiratory exchange ratio of 0.8, giving an alveolar–arterial gradient of 5.1 kPa.
- **Stage 2:** Given maximal oxygen through a reservoir bag mask, his blood gases become: \( PaO_2 32 \text{ kPa} \); \( PaCO_2 10 \text{ kPa} \). Because of the high solubility of carbon dioxide, the total body stores of carbon dioxide will have risen.
- **Stage 3:** If oxygen therapy is suddenly withdrawn, \( PaCO_2 \) and \( PaO_2 \) will remain high initially because of the high carbon dioxide stores and therefore \( PaO_2 \) will fall further than it was initially before oxygen therapy to 8.5 kPa. Assuming the alveolar–arterial gradient for oxygen stays at 5.1 kPa for room air breathing, then calculated \( PaO_2 \) will become 3.4 kPa.

6.3.3 Cardiovascular and cerebrovascular system

The theoretical risks of hyperoxia have been summarised by Thomson and colleagues in an editorial which made a strong case for more trials.86 Hyperoxaemia causes coronary vasoconstriction and, if the haematocrit is sufficiently low, this may theoretically cause paradoxical myocardial hypoxia because of overall reduction in \( D_{O_2} \).

One randomised double blind trial of oxygen in uncomplicated myocardial infarction found higher rates of sinus tachycardia and a significantly greater rise in myocardial enzyme in the oxygen group, suggesting a greater infarct size.107

There was a threefold increase in mortality in patients on oxygen therapy that did not reach statistical significance (3 deaths in 77 patients treated with air versus 9 deaths in 80 patients given oxygen at 6 l/min via simple face mask for 24 h). This trial was published in 1976 and oxygen has been given routinely to millions of normoxaemic patients with myocardial infarction and chest pain for a further 30 years without any evidence to support the practice. Furthermore, a more recent trial showed increased mortality in patients with non-hypoxaemic strokes of mild to moderate severity in those randomised to treatment with oxygen.111 This creates an urgent need for large randomised trials of oxygen therapy for non-hypoxaemic patients with acute cardiac and cerebral ischaemia.

Thompson et al.96 have suggested that oxygen should be “prescribed, administered and monitored with care” in order “to achieve optimal tissue oxygenation”, not maximal oxygenation. This view was proposed by other authors such as Bryan and Jenkinson97 in the 1980s, but standard medical practice has not taken note of this advice. Because there are no published data suggesting benefit from hyperoxaemia for most medical conditions and because of the theoretical risks, optimal management should aim for physiological oxygenation. Targets for oxygen therapy in specific circumstances, with evidence, are discussed in section 8.

6.3.4 Reactive oxygen species

Aside from the potentially detrimental physiological effects of hyperoxaemia, the toxic effects mediated by reactive oxygen species (ROS) have potential risk.108 Excess ROS are generated in the presence of high tissue \( P_{O_2} \) in the form of hydrogen peroxide and superoxide, causing oxidative stress and free radical damage. At physiological levels ROS act as signalling molecules, but at higher levels they are cytotoxic, notably being released by primed neutrophils as a host defence mechanism. It is thought that ROS are responsible for the development of bronchopulmonary dysplasia in ventilated hyperoxygenated premature infants109 and reperfusion injury post-myocardial infarction.111

6.3.5 Delay in recognition of physiological deterioration

It was previously believed that a high \( F_{IO_2} \) is protective and gives patients a margin of safety. However, Downs and Beasley have argued that unstable patients may actually be placed at risk by the precautionary use of high-dose oxygen therapy.95 97 112 During physiological deterioration, a patient given high-dose oxygen therapy would have a normal or high pulse oximeter reading masking a progressive decline in the \( PaCO_2/F_{IO_2} \) ratio and therefore not alerting staff to impending deterioration requiring mechanical support. Furthermore, a patient who deteriorated physiologically while at a low \( F_{IO_2} \) would be detected early by pulse oximetry and could have the \( F_{IO_2} \) increased while being transferred to an intensive care unit, whereas a patient who was already receiving a high \( F_{IO_2} \) would desaturate more slowly but, when the oximeter eventually detected desaturation, there would be fewer treatment options because increasing the \( F_{IO_2} \) further would have little effect.95 97 112

6.3.6 Lung injury in patients with acute paraquat poisoning, bleomycin lung injury and acid aspiration

Oxygen is known to be hazardous to patients with paraquat poisoning113 114 and oxygen potentiates bleomycin lung injury and...
may potentiate lung injury from aspiration of acids. Further details concerning these conditions are given in section 8.13.5.

6.3.7 Summary of risks of hyperoxia and supplemental oxygen therapy

**Physiological risks**

1. Worsened V/Q mismatch.
2. Absorption atelectasis.
3. Coronary and cerebral vasoconstriction.
4. Reduced cardiac output.
5. Damage from oxygen free radicals.
6. Increased systemic vascular resistance.

**Clinical risks**

1. Worsening of hypercapnic respiratory failure.
2. Delay in recognition of clinical deterioration.
3. Worse outcomes in mild to moderate stroke.
4. Specific risk in patients with previous bleomycin lung disease or with paraquat poisoning or acid aspiration.
5. Unknown risk-benefit balance in acute coronary artery disease with normal oxygen saturation.
6. Damage from oxygen free radicals.

- Uncontrolled supplemental oxygen therapy can be harmful to patients who are at risk of hypercapnic respiratory failure, especially if the PaO₂ is raised above 10 kPa. [Evidence level IIa]
- High-dose oxygen therapy to produce hyperoxaemia (above normal oxygen saturation) can cause absorption atelectasis, myocardial ischaemia and unfavourable outcomes in some patient groups (eg, patients with mild and moderate strokes). [Evidence levels Ib–III]

6.4 Risks of hypercapnia (and respiratory acidosis)

Hypercapnia and respiratory acidosis are inextricably linked and are best considered together. If hypercapnia develops slowly (over several days), a patient will have renal compensation (retention of bicarbonate) and acidosis will not occur in most such cases. However, acute elevation of the blood carbon dioxide level produces respiratory acidosis and symptoms of hypercapnia. Some of the consequences of an elevated carbon dioxide tension are a consequence of the resulting acidosis. Sometimes the effect of a raised carbon dioxide tension on a particular organ system is opposed by an opposite effect of acidosis.

Carbon dioxide is a vasodilator and patients with hypercapnia may appear flushed with dilated peripheral veins and a bounding pulse. Cranial vasodilation may cause headache. Carbon dioxide in high concentrations has hypnotic effects and patients with hypercapnia may progress from drowsiness to confusion to coma. A link has been shown between severe respiratory acidosis in acute COPD and an increased risk of death or requirement for mechanical ventilation. However, the problem of respiratory acidosis is not confined to patients with COPD. Depressed respiration for any reason will give rise to hypercapnia. Examples are opiate overdoses, obesity with hypoventilation and neuromuscular disorders affecting the muscles of respiration.

6.4.1 Effects of a raised blood carbon dioxide level

**Nervous system**

Carbon dioxide exerts its effect either directly or as a consequence of acidosis. Hypercapnia increases cerebral blood flow and thereby may influence the cerebrospinal fluid pressure. It is the main factor influencing the intracellular pH which has an important effect on cellular metabolism. It exerts an inert gas narcotic effect similar to that of nitrous oxide. It influences the excitability of neurones particularly relevant in the reticular activating system. Carbon dioxide can induce narcosis when the PaCO₂ rises above 12–16 kPa (90–120 mm Hg).

**Pulmonary circulation**

An elevated PaCO₂ causes vasoconstriction in the pulmonary circulation although the effect is less marked than that of hypoxia. In healthy subjects an end expiratory PaCO₂ of 7 kPa (52 mm Hg) increases pulmonary vascular resistance by 32% which, along with raised cardiac output, increases mean pulmonary artery pressure by 60%. Changes in pH are thought to be the primary factor responsible for carbon dioxide-mediated changes in the pulmonary vasculature. Consequently, as with HPV, changes in PaCO₂ help to match perfusion to ventilation.

**Respiratory system**

As explained in section 6.2.1, a raised carbon dioxide level may worsen hypoxia and its effects because the concentration of carbon dioxide in the alveolar gas reduces that of oxygen if the concentration of nitrogen remains constant. Also an increase in PaCO₂ shifts the oxygen dissociation curve to the right.

**Cardiovascular system**

In general, both hypercapnia and acidosis have direct depressant effects on cardiac myocytes and vascular smooth muscle cells. These effects are normally opposed by the increase in catecholamines caused by the raised PaCO₂. The overall effect of carbon dioxide on the cardiovascular system is therefore unpredictable. In artificially ventilated children a rise in carbon dioxide increases cardiac output and reduces total peripheral resistance and blood pressure tends to rise. Although an increase in carbon dioxide depresses heart rate, tachycardia is more common because of the effects of catecholamine stimulation overriding the depressant effects on the heart. Arrhythmias have been reported but are seldom clinically significant in normal subjects. Carbon dioxide is a systemic vasodilator.

**Kidneys**

Renal blood flow and glomerular filtration rate are reduced in the presence of high levels of PaCO₂. If severe, this can lead to anuria.

**Blood electrolyte levels**

The acidosis that accompanies hypercapnia may cause a rise in potassium if the acidosis is severe and sustained.

**Endocrine system**

Hypercapnia increases plasma levels of both adrenaline and noradrenaline.

6.4.2 Clinical signs

The clinical signs of hypercapnia are produced by the physiological changes described above and are described in detail in section 7.2.1.

6.5 Risks of acidosis

The major effect of acidosis is depression of the central nervous system with severe acidosis (pH <7.0 or [H⁺] >100 nmol/l)
causing disorientation and later coma. However, as described above, the effects of pH are inextricably linked with both hypoxia and hypercapnia. As a consequence of opposing effects of acidosis, hypoxia and hypercapnia on different target organs in individual patients together with the fact that derangements of all three components may occur at the same time, it is very difficult to predict the effects of acidosis per se in an individual patient. Furthermore, tissue hypoxia will exacerbate acidosis. The consequences will depend upon the interplay of the three variables, complicated by the effects of co-morbid disease states. It is well known that, in patients with COPD, a pH of <7.30 or [H+] >50 nmol/l during an acute exacerbation is associated with a much worse prognosis.34

6.6 Rationale of oxygen therapy
Oxygen therapy is usually defined as the administration of oxygen at concentrations greater than those found in ambient air. It is usually undertaken to treat or prevent hypoxaemia, thereby preventing tissue hypoxia which may result in tissue injury or even cell death. In some circumstances such as carbon monoxide poisoning or cluster headache, oxygen therapy is used to achieve hyperoxia. There are no published trials supporting the use of oxygen to relieve breathlessness in non-hypoxaemic patients and there is evidence from randomised studies that oxygen does not relieve breathlessness compared with air in non-hypoxaemic patients with COPD who are breathless following exertion or in non-hypoxaemic patients with advanced cancer.129–132

At the tissue level, mitochondrial activity requires oxygen for aerobic ATP synthesis for cellular activity. PaO2 of dry air at sea level is 21.2 kPa (159 mm Hg), but at the mitochondrion, Po2 is in the range of 0.5–3.0 kPa (4–22 mm Hg) depending on tissue type and local metabolic activity. This gradient from atmosphere to mitochondrion is known as the oxygen cascade. There are many factors in this cascade that affect the final mitochondrial Po2 including alveolar gas exchange, oxygen transport in the blood and tissue perfusion. Under pathological conditions, any change in one step in this cascade may result in hypoxia at the mitochondrial level. Therefore, although not necessarily addressing the underlying cause of tissue hypoxia, increasing FiO2 with oxygen therapy is the simplest and quickest way of avoiding hypoxic tissue damage. Besides oxygen therapy, other steps are usually necessary to improve the delivery of oxygen to the tissue (see section 5.6).

6.7 Target oxygen saturation in acute illness (see also sections 4.3 and 6.1)
Many disease states lead to a reduced oxygen level and it is standard practice for breathless patients to be treated with oxygen. However, there have been few controlled trials comparing different levels of inspired oxygen for patients with any of the common diseases that lead to hypoxaemia. It must also be remembered that oxygen therapy is only one of several strategies that may be used to increase tissue oxygen delivery for critically ill patients (section 5.6).

In many clinical situations oxygen therapy is applied without a specific end point in mind. It has been suggested by many studies that hypoxia can have deleterious physiological and clinical effects (see section 6.3), albeit such effects are not widely reported in conditions other than COPD. However, potential for harm may well exist with hyperoxia and good medical practice should be followed as in all drug prescriptions. As the actual Po2 at the mitochondrial level is so variable and dependent on many variables other than PaO2, it is often difficult to set a minimum level of PaO2 below which definite cell damage will occur or above which the host is safe from the effects of hypoxic cell damage. In addition, it is not possible to monitor mitochondrial Po2 clinically and the only clinically available surrogate of mitochondrial hypoxia is lactate production. Although blood lactate levels are useful and indicate tissue hypoxia, it is a late marker and therefore is an insensitive tool. Thus, targets set for “ideal” blood gas levels are based on arbitrary goals. Owing to the natural decline in normal arterial oxygen levels with age, it has been suggested that the ideal target PaO2 can be determined by the following equation:130

\[
\text{Ideal PaO2} = 13.3 \text{ kPa} - 0.04 \times \text{age (in years)} \quad \text{or 100 mm Hg} - 0.3 \times \text{age (in years)}
\]

In terms of oxygen saturation measured by the bedside, this would translate into an SaO2 of 94–98% in most situations. This strategy avoids tissue hypoxia in almost all patients and also avoids potential deleterious effects of hyperoxia. Thus, the standard practice should be to prescribe oxygen to a specific saturation (or PaO2) rather than in terms of FiO2.

Clearly, consideration will need to be given to patients who have oxygen-sensitive carbon dioxide retention and targets may well have to be set lower for these patients to strike a balance between achieving a desirable and safe SaO2/PaO2 and carbon dioxide retention. Specific disease states will be addressed in section 8.

Patients with moderate to severe hypoxaemia are usually breathless and have an increased respiratory rate. Apart from causing physical tiredness, this also increases work of breathing, therefore increasing both oxygen consumption and carbon dioxide production. In these circumstances, oxygen therapy may reduce the work of breathing and therefore reduce carbon dioxide production. Therefore, oxygen therapy should theoretically improve breathlessness in hypoxaemic patients. However, this effect has not been demonstrated in clinical trials involving patients who were breathless but not hypoxaemic. For example, a recent meta-analysis of all published blinded studies of short burst oxygen therapy for patients with COPD with breathlessness failed to confirm any clinical benefit despite the widespread belief of doctors and patients that oxygen relieves breathlessness in this condition.131 A systematic review of oxygen and airflow on the relief of dyspnoea at rest in patients with advanced disease of any cause found only low-grade scientific evidence that oxygen and airflow improve dyspnoea in some patients with advanced disease at rest, and almost all of these subjects were hypoxaemic and already using oxygen therapy.134

Recommendations
1. This guideline recommends aiming to achieve a normal or near-normal oxygen saturation for all acutely ill patients apart from those at risk of hypercapnic respiratory failure. [Grade D]
2. The recommended target saturation range for acutely ill patients not at risk of hypercapnic respiratory failure is 94–98%. Some normal subjects, especially people aged ≥70 years, may have oxygen saturation measurements below 94% and do not require oxygen therapy when clinically stable. [Grade D]
3. Most non-hypoxaemic breathless patients do not benefit from oxygen therapy, but a sudden reduction of more than 3% in a patient’s oxygen saturation within the target saturation range should prompt
fuller assessment of the patient (and the oximeter signal) because this may be the first evidence of an acute illness. [Grade D]

4. For most patients with known COPD or other known risk factors for hypercapnic respiratory failure (eg, morbid obesity, chest wall deformities or neuromuscular disorders), a target saturation range of 88–92% is suggested pending the availability of blood gas results. [Grade C]

5. Some patients with COPD and other conditions are vulnerable to repeated episodes of hypercapnic respiratory failure. In these cases it is recommended that treatment should be based on the results of previous blood gas estimations during acute exacerbations because hypercapnic respiratory failure can occur even if the saturation is below 88%. For patients with prior hypercapnic failure (requiring non-invasive ventilation or intermittent positive pressure ventilation) who do not have an alert card, it is recommended that treatment should be commenced using a 28% Venturi mask at 4 l/min in prehospital care or a 24% Venturi mask at 2–4 l/min in hospital settings with an initial target saturation of 88–92% pending urgent blood gas results. These patients should be treated as a high priority by emergency services and the oxygen dose should be reduced if the saturation exceeds 92%. [Grade D]

6.8 Effects of body positioning including restraint systems

Appropriate positioning of a patient can maximise V/Q matching. In the healthy self-ventilating adult lung, V/Q matching improves from non-dependent to dependent areas. In lung disease there is a disruption of this pattern and, in these instances, appropriate positioning may be advantageous in optimising V/Q matching, therefore improving gas exchange, oxygenation and carbon dioxide clearance. For these reasons, breathless patients usually prefer to sit upright or near upright provided they are able to do so.

The relationship between dependency and V/Q matching is maintained irrespective of the position of the subject. The physiology is then transferable into alternate side lying positions; for example, in left side lying the dependent lung (left) will have the better V/Q matching. This is important in the presence of asymmetrical lung pathology as the “good lung down” principle will maximise V/Q matching.

Many unwell patients are nursed in the semi-rectumbent and supine positions. These positions do not facilitate V/Q matching as in the upright and full side lying position due to the hindrance to expansion of the dependent lung by the diaphragm and chest wall. Even in healthy subjects the oxygen tension is 0.7 kPa (5 mm Hg) lower in the supine position than in the upright position. Similarly, 10% of patients with right hemiparesis and concomitant chest disease were more hypoxaemic in the left lateral position. Where there is pathological lung disease and hence already significant V/Q mismatch, gas exchange may be further impaired. This is discussed in a review of the effects of position on oxygen saturation in acute stroke.

Patients with acute stroke without respiratory co-morbidities may be permitted to adopt any body position that they find most comfortable, while those with respiratory compromise should be positioned as upright as possible, avoiding slouched or supine positions to optimise oxygenation.

The semi-rectumbent/supine position is commonly adopted in an ambulance. In addition, for safety, the patient is strapped into the stretcher with abdominal and chest restraints with their arms by their side. While there are a lack of specific data regarding this, physiological principles suggest that the use of such positioning and restraints would compromise both respiratory muscle function and gas exchange.

Finally, there are some rare patients with liver disease, cardiac shunts or lung fibrosis who have “platypnoea and orthodeoxia” which means that they are more hypoxic in the upright position. Other patients with scoliosis or with a paralysed hemidiaphragm may feel more comfortable with the “good lung up”. These patients should be allowed to choose the position in which their breathing is most comfortable for them.

Recommendation

6. Because oxygenation is reduced in the supine position, fully conscious hypoxaemic patients should ideally be allowed to maintain the most upright posture possible (or the most comfortable posture for the patient) unless there are good reasons to immobilise the patient (eg, skeletal or spinal trauma). [Grade C]

SECTION 7: CLINICAL AND LABORATORY ASSESSMENT OF HYPOXAEMIA AND HYPERCAPNIA

7.1 Assessment of hypoxaemia

7.1.1 Clinical assessment of breathless patients and assessment of cyanosis

Clinicians examining a critically ill patient should remember the “ABC” of emergency medicine (airway, breathing, circulation). In the case of critically ill patients it may be necessary to secure the airway and resuscitate a patient before a detailed history can be obtained and before a full physical examination can be undertaken.

In assessing an ill patient the SaO2 level is only one of several physiological variables that should be monitored. Many patients with sudden acute illness such as postoperative pulmonary emboli will have a sudden alteration in physiological “track and trigger” variables as assessed by the modified mEWS system. Such patients may have only a small fall in SaO2 due to physiological compensation mechanisms such as increased ventilation. Clinicians therefore need to be alert for falls in SaO2 even within the recommended target ranges.

Recommendations

7. Fully trained clinicians should assess all acutely ill patients by measuring pulse, blood pressure, respiratory rate and assessing circulating blood volume and anaemia. Expert assistance from specialists in intensive care or from other disciplines should be sought at an early stage if patients are thought to have major life-threatening illnesses and clinicians should be prepared to call for assistance when necessary including a call for a 999 ambulance in prehospital care or a call for the resuscitation team or ICU outreach team in hospital care. [Grade C–D]

8. Initial clinical assessment and subsequent monitoring of acutely unwell patients should include the use of a recognised physiological “track and trigger” systems such as the modified Early Warning Scoring system (mEWS), and a change in this score should require medical review even if there is no change in oxygen saturation. [Grade C]
Traditional clinical assessment of hypoxaemia involves clinical inspection of the skin and buccal mucous membranes to decide whether central cyanosis is present or absent. This is a difficult clinical skill, especially in poor lighting conditions. Clinical assessment of hypoxaemia is made even more unreliable by the presence of anaemia or polycythaemia. Some patients may have peripheral cyanosis due to poor peripheral circulation in the presence of normal SaO2. Several studies have shown that hypoxaemia is often not recognised by emergency medical service providers, especially if the patient does not complain of respiratory distress.259–261 A systematic review of the literature in 2005 reported that most hypoxaemic patients had at least one vital sign abnormality but skin colour was a poor indicator of hypoxaemia compared with pulse oximetry.24 For these reasons it is recommended that clinicians should not rely on visual assessments of “cyanosis” but should instead use pulse oximetry to obtain an accurate assessment of a patient’s oxygen saturation.

The nature of a patient’s presenting illness may make hypoxaemia a likely outcome, thus prompting a careful clinical search for evidence of cyanosis complemented by urgent pulse oximetry. This situation applies to many common acute illnesses such as heart failure, COPD exacerbation, pneumonia and pulmonary embolism. A study of 2276 patients with pneumonia showed that hypoxaemia was independently associated with six risk factors: age >50 years (odds ratio (OR) 3.2), COPD (OR 1.9), congestive heart failure (OR 1.5), respiratory rate >24/min (OR 2.3), altered mental status (OR 1.6) and chest radiographic infiltrate involving >1 lobe (OR 2.2).26 Acutely ill patients with significant hypoxaemia are likely to have an increased pulse rate or respiratory rate and, for this reason, usually score at least 3 points on a mEWS.72 73 138 The respiratory rate is the single best predictor of severe illness.73 However, many patients with marked hypoxaemia may present with non-specific findings such as restlessness and confusion rather than breathlessness, and oxygen saturation has been shown to be an independent predictor of mortality in multivariate analysis of the outcome of emergency medical admissions.132 Furthermore, the work of Thrush et al133 on normal volunteers has shown that heart rate, blood pressure and respiratory rate are not reliable indicators of hypoxaemia down to saturation levels as low as 70%. This would suggest that the changes in vital signs which are seen in most hypoxaemic patients are due to the underlying illness rather than hypoxaemia per se.

Hypoxaemia may be associated with increased or decreased ventilation. Although some hypoxaemic patients may have reduced levels of ventilation as a causative factor, the majority of hypoxaemic patients have increased minute ventilation in an attempt to increase the blood oxygen level. For example, a patient with an opiate overdose may have reduced ventilation causing hypoxaemia despite having structurally normal lungs, whereas a patient with pneumonia or major pulmonary embolism may have significant hypoxaemia due to ventilation-perfusion mismatch despite an increased level of ventilation. The first patient in this example may appear peaceful and non-distressed despite significant hypoventilation and hypoxaemia, while the second patient is likely to have increased ventilation and tachycardia. The clinician therefore needs to make separate assessments of a patient’s oxygen saturation and level of ventilation.

Having completed the history and rapid assessment of the patient, more detailed physical examination may reveal signs of an illness such as major pleural effusion, major pneumothorax or unexpected heart failure that may prompt the clinician to anticipate the presence of hypoxaemia.

**Advice and recommendations for clinical assessment of patients with suspected hypoxaemia**

- The medical history should be taken when possible in an acutely breathless patient and may point to the diagnosis of a particular acute illness such as pneumonia or pulmonary embolism or an exacerbation of a chronic condition such as COPD, asthma or heart failure. [Evidence level IV]
- Physical examination may provide evidence of a specific diagnosis such as heart failure or a large pleural effusion, but it is common for the cause of breathlessness to remain undiagnosed until the results of tests such as chest radiographs are available. [Evidence level IV]
- Patients with severe hypoxaemia may present with a non-respiratory manifestation such as confusion or agitation rather than breathlessness and cyanosis is a difficult physical sign to record confidently (especially in poor light or with an anaemic or plethoric patient). [Evidence level IV]
- Tachycardia and tachypnoea are commoner than a physical finding of cyanosis. [Evidence level III]
- Physiological “track and trigger” systems such as the Early Warning Scoring system (EWS or mEWS) are extremely valuable in identifying patients with life-threatening illness even if this is not immediately obvious from the patient’s history. [Evidence level III]

### 7.1.2 Value and limitations of pulse oximetry

Clinical assessment of hypoxaemia has been revolutionised by the advent of pulse oximetry in much the same manner as the clinical assessment of blood pressure was transformed by the invention of the sphygmomanometer. However, it is common to see patients with acute respiratory illness who have had multiple measurements of their blood pressure but no record made of their oxygen saturation, peak expiratory flow or FEVi. In addition to the clinical consequences of underassessment, Howes et al134 and Macnab et al135 have reported that the availability of a pulse oximeter was highly cost-effective because the finding of normal oximetry (>94%) in many patients allowed paramedics to use oxygen less frequently with a potential financial saving of up to $2524 (approximately £1200) per ambulance per annum.

Pulse oximetry measures haemoglobin oxygen saturation by detecting the absorption of light at two specific wavelengths that correspond to the absorption peaks of oxygenated and deoxygenated haemoglobin. Oximeters are less reliable at low saturation such as 80%, but modern oximeters reflect the arterial oxygen saturation accurately at saturation above about 88%.146–148 In almost all clinical circumstances covered by this guideline, patients with a saturation below 88% will be given intensive therapy to bring the saturation up to at least 90%, so the inaccuracy of the instruments at very low saturation levels should not affect patient management.

In one study of 125 adult patients who had simultaneous measurements of pulse oximetry and arterial oxygen saturation measured in arterial blood gases, the 95% confidence interval for the median difference ranged from −0.6 to +0.5%.142 It has been estimated that an oxygen saturation of 92% or above measured by pulse oximetry has a sensitivity of 100% and specificity of 96% for excluding hypoxaemia defined as an arterial oxygen saturation below 60 mm Hg (8 kPa).143
Oximetry may be less accurate in acutely ill patients on intensive care units, but there are no direct comparisons of the accuracy of pulse oximetry in critically ill patients compared with stable patients and healthy individuals. The study of Perkins and colleagues showed a mean SpO2 of 94.6% compared with a mean SaO2 of 95.9% from 1132 simultaneous oximeter and arterial blood gas measurements on an intensive care unit.152 Fortunately, this average difference of 1.3% was lower for pulse oximeter readings, thus allowing a margin of safety in most cases. This study also showed that fluctuations in oxygen saturation measured by oximetry tended to be greater than changes in arterial oxygen saturation measured with samples from an indwelling radial artery catheter.

Although oximetry is widely used, there are few clinical studies examining its utility. The Cochrane meta-analysis of the use of oximetry in perioperative monitoring of more than 20 000 patients failed to show any reduction in complications or deaths where oximetry was used, although oxygen was given more often to patients who were monitored with pulse oximetry.153 The authors suggested that the correction of modest hypoxaemia probably does not have much effect on clinical outcomes.

Pulse oximetry gives no information concerning pH, PCO2 or haemoglobin level. Blood gases and full blood count tests are therefore required as early as possible in all situations where these measurements may affect patient outcomes.

The accuracy of pulse oximetry is diminished in patients with poor peripheral perfusion which may occur chronically in conditions such as systemic sclerosis or acutely in patients with hypotension or hypovolaemia. However, it has been suggested that many types of oximeter may remain accurate at arterial pressures as low as 20 mm Hg so long as the machine is able to obtain a reading despite the low pulse pressure.154 Most oximeters give an indication of the pulse signal strength. It is important to ensure that the oximeter has a good signal if technically possible, and the probe may need to be tried on different fingers or toes or on the earlobe to obtain the best available signal for the individual patient. There are some patients with poor perfusion for whom pulse oximetry measurements cannot be made. This includes patients with cold peripheries, severe hypotension and peripheral “shut down”.

It must be remembered that oximetry gives a normal reading for oxygen saturation in most patients with anaemia because the oxygen saturation of the available haemoglobin is normal although the total amount of haemoglobin available for oxygen transport is reduced. These patients have normal oxygen saturation levels despite having “anaemic hypoxia” which may cause considerable reduction in the total oxygen content of the blood. It is often not recognised that a patient with an SpO2 of 98% but a haemoglobin of 7 g/dl (7×0.98×1.34 = 9.2 ml O2/dl) will have a greatly reduced blood oxygen content compared with a patient with a haemoglobin of 15 g/dl and a saturation of 85% (15×0.85×1.34 = 17 ml O2/dl) (each g/dl haemoglobin when fully saturated carries 1.34 ml oxygen).

The accuracy of oximetry is unreliable in the presence of carbon monoxide or methaemoglobin. Both of these substances have similar light absorption characteristics to oxyhaemoglobin so an apparently normal SpO2 in a patient with carbon monoxide poisoning or methaemoglobinemia may be falsely reassuring. Carboxyhaemoglobin levels above 2% may cause falsely elevated SpO2 measurements.155 Many smokers will have carboxyhaemoglobin levels above this level shortly after smoking a cigarette, and the carboxyhaemoglobin level may be elevated to 15% in some smokers and up to 50% or more in acute carbon monoxide poisoning. It is not known if the reduced blood oxygen content in smokers who develop sudden illness within a few hours of smoking cigarettes has any effect on clinical outcomes, or if heavy smokers might benefit from a slightly higher target saturation range than non-smokers during the first few hours of a serious illness in an effort to maintain a similar blood oxygen content.

Skin pigmentation may also influence the accuracy of pulse oximetry readings (usually overestimation but sometimes underestimation). In particular, the accuracy of pulse oximetry is impaired in dark skinned subjects at saturation levels below 80–85%.156–158 However, this should rarely be a problem in clinical practice if the saturation is maintained in the range suggested in the present guideline (94–98% for most patients), although the work of Jubran and Tobin on ventilated subjects suggested that an oxygen saturation of 92% was useful in predicting a PaO2 above 60 mm Hg (8 kPa) in ventilated white subjects but was less reliable in ventilated black subjects who sometimes had an SpO2 reading that was more than 4% above the directly measured PaO2.25 In the case of sickle cell crisis, pulse oximetry may underestimate the level of oxygenation.159 In these circumstances, under-reading is safer than over-reading because no truly hypoxaemic patient would be denied oxygen therapy. However, another study found that pulse oximeters did not misdiagnose either hypoxaemia or normoxaemia during a sickle cell crisis provided a good wave signal was present.160

Oximeters can be affected by motion of the patient’s hand, but this is less of a problem with modern oximeters than with older devices.161 Motion artefact is more of a problem if the patient also has reduced perfusion of the measuring site.162 A malpositioned oximeter sensor can cause artefact which can overestimate or underestimate the true oxygen saturation; this can be a particular problem during repositioning of ill patients.163

The site of oximetry is also important. Finger and earlobe measurements are more accurate than measurements from a probe applied to the toe, and finger probes may be more accurate than ear probes.164,165 Finally, clinical staff need to remember to remove nail varnish and false nails to avoid artefacts in oximetry measurements.

- Pulse oximeters are accurate to within 1–2% of directly measured arterial oxygen saturation in most subjects but the error (usually overestimation but sometimes underestimation) is greater in dark skinned subjects, especially with very low saturation (below 80–85%). [Evidence level IIa]
- The accuracy of oximeters in shock, sepsis and hypotension is largely unknown, but most errors are likely to result in falsely low readings which would result in additional oxygen being given. Most errors in oximetry are therefore not likely to place patients at risk, but it is important to ensure that the oximeter has a good signal and it is important to avoid artefact due to motion, nail varnish or other potential sources of error. [Evidence level IIa]
- Oximetry is a valuable clinical tool but subject to artefact and errors of interpretation. All clinical staff who use oximeters must therefore be trained in their use and made aware of the limitations of oximetry. [Evidence level IV]
- It is advised that oximetry measurements on sleeping patients should be recorded over several minutes to avoid the possibility of being misled by a normal transient nocturnal dip in oxygen saturation. [Evidence level III]
- Pulse oximetry can be misleadingly normal in smokers because of raised blood carboxyhaemoglobin levels which...
will cause a reduced blood oxygen content despite an apparently normal oxygen saturation and a normal oxygen tension. Patients who have smoked cigarettes in the previous 10 h may therefore be at increased risk from hypoxia. [Evidence level III]

**Recommendations**

9. Oxygen saturation, “the fifth vital sign”, should be checked by trained staff using pulse oximetry in all breathless and acutely ill patients (supplemented by blood gases when necessary) and the inspired oxygen concentration should be recorded on the observation chart with the oximetry result. [Grade D]

10. The presence of a normal SpO2 does not always negate the need for blood gas measurements because pulse oximetry will be normal in a patient with normal oxygen tension but abnormal blood pH or PCO2 or with a low blood oxygen content due to anaemia. Blood gases and full blood count tests are therefore required as early as possible in all situations where these measurements may affect patient outcomes. [Grade D]

### 7.1.3 Arterial and arteriolised blood gases (indications for blood gas sampling are given in section 8.4 and recommendation 13)

Arterial blood gases are the “gold standard test” for assessing respiratory failure. However, recent studies have shown that arterioedilated capillary gases from the earlobe (but not from the finger) can provide an assessment of pH and PaCO2 that is almost identical to that obtained from an arterial sample.166-170 In both acute and stable situations the earlobe specimen gives a PO2 measurement which is 0.5–1 kPa (3.7–7.5 mm Hg) lower than the simultaneous arterial measurement with most of the divergence occurring at oxygen tensions above 8–10 kPa (60–75 mm Hg).167 170 This means that most patients can be managed safely based on the pH and PCO2 levels measured from earlobe blood gases supplemented by oxygen saturation measured by a pulse oximeter.167 170 In critically ill patients the initial specimen should be an arterial specimen to guarantee an accurate initial assessment, but capillary gases are especially valuable for monitoring progress of the blood gases as a patient stabilises.

Patients who have had simultaneous arterial and earlobe samples rated the earlobe puncture procedure as being considerably less painful than arterial puncture.171 However, the administration of local anaesthesia before arterial blood gas sampling produced a significant reduction in pain.172 There is a very small risk of arterial damage from arterial puncture, especially if the radial site is used. Most reports of hand ischaemia have involved indwelling radial artery cannulae, but the vessel could also be injured by needle puncture.173 The guideline therefore recommends that arterioedilated earlobe specimens should be used more widely than at present as a safer and less painful alternative to arterial blood gas sampling and local anaesthetic should be used wherever possible for arterial blood gas sampling, but this is often not practical in medical emergencies and blood gas sampling should not be delayed in these circumstances. However, the accuracy of earlobe samples in shock or hypotension is not known and it is recommended that arterial blood gases should be used in all cases of shock or hypotension (systolic blood pressure <90 mm Hg).

The technique of patient preparation, sample acquisition and sample processing for arterioedilated capillary gases is complex and should only be undertaken by fully trained staff. [Grade IV]

### 7.1.4 Transcutaneous oxygen assessments

Transcutaneous oxygen devices give different information from pulse oximetry. They are more sensitive to reduced perfusion and may be used to monitor tissue oxygenation in trauma patients but their use is beyond the scope of this guideline.174

### 7.2 Assessment of hypercapnia and acidosis

#### 7.2.1 Clinical assessment

In patients with lung disease hypercapnia may be accompanied by visible respiratory distress, but this will be absent when hypercapnia is a consequence of a reduction in minute ventilation. Patients may have a flushed face, a full and bounding pulse and muscle twitching together with the characteristic flap of the outstretched hands. In severe cases consciousness may be depressed and convulsions may occur. Gross hypercapnia usually occurs with profound hypoxaemia and it is therefore difficult to disentangle the direct effect of hypercapnia per se. Coma will usually occur when the PaCO2 is in the range 12–16 kPa (90–120 mm Hg).
Survival has been seen following a PaCO₂ of 67 kPa (500 mm Hg). The presence of hypercapnic respiratory failure can be anticipated in patients with severe exacerbations of COPD or other diseases such as severe neuromuscular disorders. Carbon dioxide is a vasodilator so patients with hypercapnia may develop headache. Carbon dioxide in high concentrations has hypnotic effects and patients with hypercapnia may progress from drowsiness with flapping tremor to confusion to coma. A study of 127 episodes of acute respiratory acidosis showed that the best clinical predictors of respiratory acidosis were drowsiness (OR 7.1), flushing (OR 4.1), the presence of known COPD (OR 5.5) and the presence of intercostal retraction (OR 2.9).

Clinical signs of carbon dioxide retention include:
- Vasodilation producing flushing and warm peripheries with dilated blood vessels (including retinal veins).
- Bounding pulse.
- Drowsiness.
- Flapping tremor.
- Confusion.
- Coma.

7.2.2 Blood arterial and arteriolar gases (see section 7.1.3 for further details)
Arterial or arteriolar earlobe capillary blood gases will give an accurate estimation of pH and PaCO₂. The blood gases will need to be repeated in 30–60 min in patients with significant hypercapnia or acidosis to monitor the response to treatment. Patients with COPD who remain acidic despite 30–60 min of standard treatment (including controlled low-dose oxygen therapy) are likely to need non-invasive ventilation.

7.2.3 Venous PCO₂ sampling
It has been suggested that the venous PCO₂ level can be used to screen for hypercapnia in patients with acute respiratory disease. A study of 196 paired samples of arterial and venous blood from patients with acute respiratory disease showed that the PCO₂ in the venous sample was an average of 0.77 kPa (5.8 mm Hg) higher than the simultaneous arterial sample. A venous PCO₂ below 6 kPa (45 mm Hg) had 100% sensitivity for eliminating the risk of hypercapnia (arterial PCO₂ above 6 kPa or 45 mm Hg), although the specificity was low at 57% and there was more variation in other studies. For patients who are not at risk of metabolic acidosis, the presence of a satisfactory oxygen saturation measured by pulse oximetry and a venous PCO₂ below 6 kPa (45 mm Hg) can exclude the possibility of significant arterial hypoxia or hypercapnia and may obviate the need for arterial blood gas measurements. However, venous PCO₂ sampling is not widely used in clinical practice at present and the guideline committee have therefore made no recommendations on its use.

7.2.4 Carbon dioxide monitors and non-invasive assessments of hypercapnia
End-tidal carbon dioxide monitors are used primarily to confirm tracheal intubation during anaesthesia, intensive care and for any patients requiring endotracheal intubation. They are considered the “gold standard” by the Royal College of Anaesthetists. The absence of any detectable carbon dioxide output indicates a failed intubation. The management of intubated patients is outside the remit of this guideline.

End-tidal carbon dioxide monitors are also useful in the management of cardiac arrest and circulatory collapse. Very low levels of carbon dioxide excretion indicate very low (or absent) cardiac output and a low likelihood of survival. These devices are also useful in the care of intubated patients in the emergency department because, through visualising a typical “box wave form”, they can confirm that the tube is in the airway even in the absence of carbon dioxide production during a cardiac arrest. The appearance of carbon dioxide may be the first sign of spontaneous circulation.

End-tidal carbon dioxide measurements correlate poorly with arterial carbon dioxide levels in patients with COPD, but they may be useful in some research studies of hyperventilation syndromes. However, these devices are inaccurate in patients with airways disease and those with a high respiratory rate, so they should not be used in the management of patients with respiratory failure and they will not be discussed further in this guideline.

An exciting new possibility is the development of probes that can assess PaCO₂ as well as SPO₂ from a single probe. Early studies indicate that such devices can be accurate in normal volunteers and there have been some encouraging preliminary studies in patients with respiratory disease. Transcutaneous carbon dioxide monitors are also being developed in association with transcutaneous oxygen monitors for use in patients with shock and critical illness.

SECTION 8: EMERGENCY OXYGEN USE IN HOSPITAL SETTINGS
The hospital management of hypoxaemic patients is presented before the prehospital management because it represents the “ideal” management. Some readers may prefer to read section 9 (prehospital care) first because most patients receiveprehospital care before hospital care, but the Guideline Development Group preferred to present the “ideal management” first.

8.1 Assessment and immediate management of breathless patients on arrival in hospital
Breathless patients may arrive in hospital directly (without prior assessment) or in ambulances where they will usually have been assessed by paramedics who may also have initiated emergency treatments including oxygen therapy. As discussed in section 7 of this guideline, assessment, triage and resuscitation of critically ill patients must be undertaken in parallel with the initiation of oxygen therapy and specific treatment must be given for the underlying medical condition. All critically ill patients and all patients at risk of hypercapnic respiratory failure should be triaged as very urgent and should have blood gases taken on arrival in hospital. Furthermore, all seriously ill patients should be assessed by senior clinicians as early as possible. In many cases this may involve liaison with intensive care specialists or with appropriate other specialists who can deal effectively with the patient’s major medical or surgical problems.

- Readers are referred to section 7.1.1 and to disease-specific guidelines for advice concerning the immediate assessment and management of seriously ill patients.
- Readers are referred to section 10 for advice concerning choice of oxygen delivery devices and systems.
- Readers are referred to tables 1–4 and charts 1 and 2 (figs 1 and 2) for a summary of the key elements of oxygen therapy in common medical emergencies.
- Remember to ask for senior advice or specialist advice early in the care of profoundly ill patients.
8.2 Differences in management in hospital compared with a prehospital setting

The immediate management of medical emergencies in hospital settings before blood gas results are available is similar in principle to management in the prehospital setting (section 9). The main priorities are to avoid harmful levels of hypoxaemia for all patients and to avoid harmful levels of hypercapnia for patients who are at risk of this complication. However, the amount of information available to the healthcare professionals increases rapidly in the hospital environment. The hospital management is presented before the prehospital management because it represents the “ideal” management. This may also be achievable in some prehospital settings such as a well equipped primary care centre. However, in many prehospital settings there will usually be less information available concerning a patient’s history and physiology and less equipment available to assess and treat the patient.

Differences between hospital settings and prehospital settings include:

- Pulse oximetry is almost always available in hospital at present. These guidelines also recommend that pulse oximetry must be available in all locations where emergency oxygen is used (section 9.1).
- Blood gas results can be available within minutes of arrival in hospital.
- Additional diagnostic information may be available from history, clinical examination, test results and from the patient’s hospital records.
- Additional equipment and resources are available (eg, ability to ventilate).

Because of the universal availability of oximetry in hospitals, it is rare for the hospital medical team to have to administer oxygen on the basis that a patient “might be hypoxaemic”. However, initial “blind management” is sometimes necessary for patients with shock or with very poor peripheral circulation where a reliable pulse oximetry trace cannot be obtained. Arterial blood gases should be obtained as a matter of urgency in all such cases.

8.3 Which patients need oxygen therapy?

Supplementary oxygen therapy is required for all acutely hypoxaemic patients and for many other patients who are at risk of hypoxaemia, including patients with major trauma and shock. Most acutely breathless patients will require supplementary oxygen therapy, but there are some situations such as acute hyperventilation or diabetic ketoacidosis where an apparently breathless patient will not benefit from oxygen therapy. There are some other clinical situations such as carbon monoxide poisoning where a patient may benefit from oxygen therapy despite a lack of hypoxaemia or breathlessness because carbon monoxide binds more avidly than oxygen to the haemoglobin molecule.

Recommendations

- Oxygen saturation should be measured in all breathless and acutely ill patients (see recommendation 9).
- Oxygen therapy should be given to hypoxaemic patients (see table 1). Patients do not require oxygen therapy if their oxygen saturation is 94% or above (exceptions are carbon monoxide poisoning and pneumothorax; see sections 8.10.7 and 8.11.6). Patients on oxygen with SpO2 >95% may not require oxygen therapy or may require a lower dose (see recommendations 1–3 and table 1).
- All patients with shock, major trauma, sepsis or other critical illness should be managed initially with high concentration oxygen therapy from a reservoir mask. The dose can be adjusted subsequently once the results of blood gas estimations are known and/or the patient is stable (see table 1). [Grade D]

8.4 Which patients require blood gas measurements?

Blood gases should be measured as soon as possible in most emergency situations involving hypoxaemic patients and are essential in patients who may develop type 2 respiratory failure (carbon dioxide retention with risk of respiratory acidosis). Blood gases should also be checked (and the clinical situation should be reviewed) if the oxygen saturation should fall by more than three percentage points, even if the saturation remains within the target range. For example, a fall from 98% to 95% might be due to a significant event such as a pulmonary embolus. In this situation the saturation of 93% will not harm the patient but the patient will remain at serious risk until the pulmonary embolism is diagnosed and treated. If oximetry shows a patient to be hypoxaemic, the initiation of oxygen therapy should not be delayed while awaiting the results of blood gas measurements.

Blood gas measurements are not usually required for patients with no risk factors for hypercapnic respiratory failure and an oxygen saturation of 94% or above breathing air unless the patient requires blood gas estimation for other reasons such as suspected metabolic acidosis or diabetic ketoacidosis. The BTS asthma guideline recommends that arterial blood gas measurements need not be recorded in patients with acute asthma and an oxygen saturation above 92% and no life-threatening features. Arterial blood gas sampling can be technically difficult, especially for poorly perfused patients, and junior staff should ask for assistance from more senior staff in difficult cases.

Following initial clinical assessment and the availability of a pulse oximetry measurement, a decision can be made regarding the need for blood gas estimation within a few minutes of arrival in the hospital environment or if a previously stable patient develops breathlessness within a hospital environment. Oximetry will give no information concerning carbon dioxide or pH levels and a normal pulse oximetry level may provide false reassurance in patients on oxygen therapy who may have unexpected hypercapnia and acidosis. However, careful clinical assessment supplemented by the use of oximetry will allow the setting of an appropriate oxygen saturation target for different groups of patients until blood gas results are available.

If repeated blood gas estimations are required, the timing will depend on the indication. In general, the oxygen saturation (and PaCO2) stabilises at a new higher level within a few minutes of increasing the dose of oxygen but the PaCO2 can take 30–60 min to equilibrate. The rise in blood oxygen level can be monitored with oximetry, so repeat blood gas tests are done mostly to assess critical illness (immediate sampling required) or to monitor pH and Pco2 levels (best done 30–60 min after increasing the dose of oxygen).

Recommendation

13. Blood gases should be checked in the following situations:
- All critically ill patients.
- Unexpected or inappropriate hypoxaemia (SpO2 <94% in patients breathing room air or oxygen) or any patient requiring oxygen to achieve the above
target range. (Allowance should be made for transient dips in saturation to 90% or less in normal subjects during sleep). [Grade D]

- Deteriorating oxygen saturation or increasing breathlessness in a patient with previously stable hypoxaemia (eg severe COPD). [Grade D]

- Any previously stable patient who deteriorates and requires a significantly increased FIO₂ to maintain a constant oxygen saturation. [Grade D]

- Any patient with risk factors for hypercapnic respiratory failure who develops acute breathlessness, deteriorating oxygen saturation, drowsiness or other symptoms of carbon dioxide retention. [Grade D]

- Breathless patients who are thought to be at risk of metabolic conditions such as diabetic ketoacidosis or metabolic acidosis due to renal failure. [Grade D]

- Acutely breathless or critically ill patients with poor peripheral circulation in whom a reliable oximetry signal cannot be obtained. [Grade D]

- Any other evidence from the patient’s medical condition that would indicate that blood gas results would be useful in the patient’s management (eg, an unexpected change in “track and trigger” systems such as a sudden rise of several units in the mEWS score or an unexpected fall in oxygen saturation of 3% or more, even if within the target range). [Grade D]

8.5 Can arterioised earlobe gases be used as a substitute for arterial blood gases?

Readers are referred to section 7.1.3 for advice concerning when to use arterial blood gases and when to use arterioised earlobe blood gases.

8.6 Should oxygen be prescribed at a fixed “dose” or to achieve a target saturation?

In the past, oxygen was prescribed at a fixed FIO₂ or at a fixed flow rate via nasal cannulae or variable performance face masks. However, several audits have shown that many (or most) patients do not receive the prescribed dose of oxygen. Furthermore, a patient’s oxygen requirement may vary over time so the prescribed oxygen dose may be too high or too low even a short time after the prescription was written. For this reason it is recommended that oxygen should be prescribed to a target saturation range rather than prescribing a fixed dose of oxygen or fraction of inspired oxygen. This is analogous to an insulin “sliding scale” where the prescriber specifies a variable dose of insulin to achieve a target blood glucose range rather than prescribing a fixed dose of insulin. This will allow the appropriate healthcare professional—usually a doctor, nurse or physiotherapist—to adjust each patient’s dose of oxygen to achieve the safest oxygen saturation range for each patient.

The prescriber may indicate a starting dose, device or flow rate, but there needs to be an agreed system for adjusting the oxygen dose upwards or downwards according to a patient’s needs (see charts 1 and 2 (figs 1 and 2); sections 11.3.6 and 11.3.7 and charts 3 and 4 (figs 17 and 18)). As a patient improves, he or she is likely to require a lower FIO₂ over a time period that will vary between patients. Most recovering patients will eventually require no supplemental oxygen. On the other hand, a deteriorating patient may need an increased dose of oxygen. This increase can be initiated by nursing staff or physiotherapists, but the requirement for an increased dose of oxygen is an indication for urgent clinical reassessment of the patient (and repeat blood gas measurements in most instances). It is recommended that oxygen should be prescribed to a target saturation range rather than prescribing a fixed dose of oxygen or fraction of inspired oxygen (see recommendations 1, 2, 4 and 5).

8.7 What should be the target oxygen saturation range for patients receiving supplementary oxygen?

8.7.1 Oxygen saturation target range for most patients

As discussed in sections 4–6 of this guideline, there is no evidence of benefit from above normal oxygen saturation in most medical emergencies and there is evidence that excessive doses of oxygen can have adverse effects, even in some patients who are not at risk of hypercapnic respiratory failure. A target oxygen saturation range of 94–98% will achieve normal or near normal oxygen saturation for most patients who are not at risk of hypercapnic respiratory failure. Furthermore, the suggested lower limit of 94% allows a wide margin of error in the oximeter measurement, thus minimising the risk of any patient being allowed to desaturate below 90% due to inaccurate oximetry.

8.7.2. Oxygen requirements for specific groups of patients

- Patients with critical illness requiring high dose oxygen therapy are discussed in section 8.10.
- Patients with medical emergencies which frequently cause breathlessness and hypoxaemia are discussed in section 8.11.
- Patients with COPD and other conditions that may predispose to type 2 respiratory failure are discussed in section 8.12.
- Medical emergencies for which oxygen is commonly given at present but is not actually indicated unless the patient is hypoxaemic are discussed in section 8.13.

8.8 Importance of blood gas measurements in guiding oxygen therapy

As soon as blood gas measurements are available, a patient’s further treatment can be guided by the results of this test. For patients with a normal or low PaCO₂ and no risk factors for hypercapnic respiratory failure, it is safe to aim at an oxygen saturation in the normal range (94–98%). For patients with a raised PaCO₂, a lower oxygen saturation is indicated (88–92%), especially if the patient is acidic. Non-invasive ventilation is recommended for patients with COPD who have hypercapnia and a pH <7.35 ([H⁺] >45 mmol/l) despite 1 h of standard medical treatment including controlled oxygen therapy.

8.9 What should be the initial choice of oxygen delivery system in hospital settings?

The technical and practical aspects of different oxygen delivery systems are discussed in section 10. For major trauma cases and for severely hypoxaemic patients without risk factors for hypercapnic respiratory failure, a non-rebreathing mask (reservoir mask) at 10–15 l/min is the suggested first choice. The delivery system and FIO₂ may be adjusted later to a lower dose of oxygen as a patient improves or towards supported ventilation if the patient deteriorates. The majority of patients with modest hypoxaemia can be treated with nasal cannulae or a simple face mask at a flow rate which is adjusted to maintain the oxygen saturation in the target range for their specific clinical presentation. Chart 2 (fig 2) shows a suggested scheme that allows the oxygen level to be adjusted upwards or downwards in gradual increments depending on a patient’s
clinical progress (see also sections 11.3.6 and 11.3.7). Venturi masks are recommended for low-dose oxygen therapy because they deliver a more reliable oxygen concentration than nasal cannulae or variable flow masks. They can also be combined with a humidifier system when necessary (see section 10.6.3). The mask and/or flow should be rapidly changed if the initial choice does not achieve the target saturation.

8.9.1 Devices used in emergency oxygen therapy in hospitals (see section 10 for further details)
- High concentration oxygen from reservoir mask (10–15 l/min) or bag-valve mask for critical illness or severe hypoxaemia during resuscitation.
- Nasal cannulae (2–6 l/min) or simple face masks (5–10 l/min) for medium-dose oxygen therapy.
- 24% Venturi mask at 2 l/min or 28% Venturi masks at 4 l/min for patients at risk of hypercapnic respiratory failure (change to nasal cannulae at 1–2 l/min when the patient has stabilised).
- Tracheostomy masks for patients with prior tracheostomy (adjust flow to achieve desired saturation).

8.10 Recommended oxygen therapy for major medical emergencies and critical illness (see also table 1)
There are a number of major medical emergencies where patients are very likely to suffer from hypoxaemia. High-dose oxygen therapy from a reservoir mask at 10–15 l/min is recommended in the initial management of all such patients prior to stabilisation in a critical care area or high dependency unit. Following stabilisation, the dose of oxygen can be titrated downwards to maintain a target saturation of 94–98%. It is recommended that patients with COPD or other risk factors for hypercapnia who develop a critical illness should be treated by emergency services in the same manner as other critically ill patients until urgent blood gas results become available because the primary issue is the critical illness. Critically ill patients with hypercapnia, hypoxaemia and acidosis will require immediate assessment by intensive care teams and will usually require intubation and mechanical ventilation.

8.10.1 Cardiac arrest and other conditions requiring cardiopulmonary resuscitation (CPR)
The 2005 guideline for Adult Advanced Life Support issued by Resuscitation Council UK recommends the use of non rebreathing reservoir masks (or 100% oxygen via a self-inflating bag mask system) to deliver the highest possible inspired oxygen level to patients requiring resuscitation. The present guideline endorses these proposals during the period of resuscitation. Subsequent management will depend on the underlying condition and the patient’s degree of recovery. There is theoretical evidence that patients who have survived the initial stages of resuscitation may be managed more safely with 30% oxygen than with 100% oxygen. Some patients will require invasive ventilation following CPR, but others will recover rapidly and an oxygen saturation target of 94–98% is recommended during the convalescent period.

Recommendation (see table 1)
- Use high-dose oxygen from a reservoir mask at 15 l/min or bag-valve mask during resuscitation. [Grade D]

8.10.2 Critically ill patients including major trauma, shock and major sepsis
There is evidence that early intervention to normalise oxygen delivery to the tissues using volume expansion and vasoactive agents is beneficial in the management of critically ill patients with shock or sepsis, but there is no evidence of benefit from attempts to achieve supranormal oxygen delivery. In fact, there is evidence that hyperoxia can cause a paradoxical decrease in whole body oxygen consumption in critically ill patients, and it has been demonstrated recently that hyperoxia can impair oxygen delivery in septic patients.

Most such patients are at risk of multiorgan failure and therefore require intensive care assessment as a matter of urgency. Critical care consensus guidelines set 90% saturation as the minimum level below which oxygen saturation should not be allowed to fall, and the Surviving Sepsis Campaign guideline recommends a target arterial oxygen saturation of 88–95% for patients with sepsis. However, these recommendations are based on directly measured arterial oxygen saturations in critical care settings with intensive levels of nursing and monitoring. The present guideline recommends a slightly higher target saturation range prior to the transfer of these seriously ill patients to critical care facilities.

For most critically ill or severely hypoxaemic patients, initial oxygen therapy should involve the use of a reservoir mask, aiming at an oxygen saturation of 94–98%. If the patient has concomitant COPD or other risk factors for hypercapnic respiratory failure, the initial saturation target should also be 94–98% pending the results of blood gas estimations and assessment by intensive care specialists. If critically ill COPD patients have hypercapnia and acidosis, the correction of hypoxaemia must be balanced against the risks of respiratory acidosis and ventilatory support using non-invasive or invasive ventilation should be considered.

It is also recognised that many patients with long bone fractures may develop hypoxaemia even in the absence of injury to the airway or chest (possibly due to opiate treatment and fat embolism) and they should be monitored with oximetry and given oxygen if necessary. These patients, if not critically ill, should have a target oxygen saturation of 94–98% or 88–92% if they have co-existing COPD or other risk factors for hypercapnic respiratory failure.

Recommendation (see table 1)
- In critical illness, including major trauma and sepsis, initiate treatment with a reservoir mask at 10–15 l/min and aim at a saturation range of 94–98%. [Grade D]

8.10.3 Near-drowning
Survivors of near-drowning may have suffered inhalation of fresh or sea water into the lungs and may become hypoxaemic. Supplemental oxygen should be given to all patients with saturation below 94%, aiming at a target saturation of 94–98%.

Recommendation (see table 1)
- In cases of near-drowning, aim at an oxygen saturation of 94–98%. [Grade D]

8.10.4 Anaphylaxis
Patients with anaphylaxis are likely to suffer from tissue hypoxia due to a combination of upper and/or lower airway obstruction together with hypotension. In addition to specific
treatment of these problems, the Resuscitation Council UK recommends high concentration oxygen (10–15 l/min, presumably by reservoir mask if available) for patients with anaphylaxis. The present guideline would endorse this practice in the immediate management of anaphylaxis followed by a target saturation of 94–98% once the patient’s condition has stabilised.

**Recommendation (see table 1)**

- In anaphylaxis, initiate treatment with a reservoir mask at 10–15 l/min and aim at a saturation range of 94–98%. [Grade D]

### 8.10.5 Major pulmonary haemorrhage or massive haemoptysis

Major pulmonary haemorrhage and massive haemoptysis can occur for a large number of reasons ranging from acute pulmonary vasculitis to erosion of a blood vessel by a lung tumour. In addition to specific treatment of the causative condition, most such patients require supplementary oxygen treatment. A target saturation range of 94–98% is recommended. Treatment should be initiated with high concentration oxygen via a reservoir mask and subsequently adjusted according to Chart 2 (fig 2) to maintain a saturation of 94–98% pending the results of blood gas measurements.

**Recommendation (see table 1)**

- In pulmonary haemorrhage, aim at an oxygen saturation of 94–98%. [Grade D]

### 8.10.6 Major head injury

Patients with major head injury are at risk of hypoxaemia and hypercapnia. They require urgent assessment and maintenance of airway patency, either through positioning, simple adjuncts or early intubation and ventilation to avoid further brain injury due to brain oedema which may be aggravated by hypercapnia. These patients should be referred immediately to appropriately trained specialists, even if this requires an interhospital transfer. Initial treatment should include high concentration oxygen via a reservoir mask pending availability of satisfactory blood gas measurements or until the airway is secured by intubation. Although hypoxaemia is common in patients with head injury, the relative contribution of hypoxaemia to outcome is not yet established. All authors agree that hypoxaemia should be corrected, but a recent review of the literature concluded that there is no evidence of clinical benefit from hyperoxia in brain-injured patients and a subsequent clinical study showed that normobaric hyperoxia did not improve brain metabolism in five patients with acute severe brain injury. There are no UK guidelines for oxygen therapy in the immediate phase after head injury, but US guidelines recommend maintaining an oxygen saturation above 90% for patients with acute brain injury. The present guideline advises giving supplementary oxygen if required to maintain an oxygen saturation in the range of 94–98%.

**Recommendation (see table 1)**

- In cases of major head injury, aim at an oxygen saturation of 94–98%. Initial treatment should involve high concentration oxygen from a reservoir mask at 10–15 l/min pending availability of satisfactory blood gas measurements or until the airway is secured by intubation. [Grade D]

### 8.10.7 Carbon monoxide poisoning

Patients with carbon monoxide poisoning have a normal level of PaO2 but a greatly reduced level of oxygen bound to haemoglobin because this has been displaced by carbon monoxide. Pulse oximetry cannot screen for carbon monoxide exposure as it does not differentiate carboxyhaemoglobin from oxyhaemoglobin and blood gas measurements will show a normal PaO2 in these patients. The blood carboxyhaemoglobin level must be measured to assess the degree of carbon monoxide poisoning. The half-life of carboxyhaemoglobin in a patient breathing room air is approximately 300 min; this decreases to 90 min with high concentration oxygen via a reservoir mask. The most important treatment for a patient with carbon monoxide poisoning is therefore to give high-dose oxygen via a reservoir mask. Comatose patients or those with severe mental impairment should be intubated and ventilated with 100% oxygen. The role of hyperbaric oxygen remains controversial. A 2005 Cochrane review concluded that existing randomised trials did not establish whether the administration of hyperbaric oxygen to patients with carbon monoxide poisoning reduced the incidence of adverse neurological outcomes. However, a randomised trial published in 2007 has suggested that patients with loss of consciousness or high carboxyhaemoglobin levels may have less cognitive sequelae if given hyperbaric oxygen.

**Recommendation (see table 1)**

- In cases of carbon monoxide poisoning, an apparently “normal” oximetry reading may be produced by carboxyhaemoglobin, so aim at an oxygen saturation of 100% and use a reservoir mask at 15 l/min irrespective of the oximeter reading and PaO2. [Grade C]

### 8.11 Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic (see also table 2)

Patients who present with acute medical emergencies who are not critically ill or grossly hypoxic can be treated with medium-dose oxygen therapy from nasal cannulae or a simple face mask with a target saturation range of 94–98%. Some of these patients (eg, patients with pneumonia) may subsequently deteriorate, requiring high concentration oxygen from a reservoir mask or requiring respiratory support such as invasive ventilation. Others may turn out to have an additional diagnosis of COPD or neuromuscular disease with a risk of hypercapnic respiratory failure and they should be managed with a Venturi mask or 2 litres of oxygen via nasal cannulae, aiming at a target saturation of 88–92%. There are no published trials supporting the use of oxygen to relieve breathlessness in non-hypoxaemic patients, and there is evidence from randomised studies that oxygen does not relieve breathlessness compared with air in non-hypoxaemic patients with COPD who are breathless following exertion.

### 8.11.1 Patients with acute onset of hypoxaemia of unknown cause with no pre-existing respiratory disorders or risk factors

It is common for breathless and hypoxaemic patients to have no firm diagnosis at the time of presentation. For most acutely hypoxaemic patients whose medical problem is not yet diagnosed, an oxygen saturation range of 94–98% will avoid the potential hazards associated with hypoxaemia or hyperoxia (see sections 4–6 and table 1). Aiming for an oxygen saturation in the normal range (rather than an abnormally high oxygen
level) will also have the effect of allowing the lowest effective \( \text{FiO}_2 \) to be used, thus avoiding risks such as absorption atelectasis and V/Q mismatch that may be associated with the use of very high fractions of inspired oxygen (see sections 5 and 6). The priority for such patients is to make a specific diagnosis as early as possible and to institute specific treatment for the underlying condition. Early blood gas measurement is mandatory in the management of patients with sudden unexplained hypoxaemia.

**Recommendations (see table 2)**

- For acutely breathless patients not at risk of hypercapnic respiratory failure who have saturations below 85%, treatment should be commenced with a reservoir mask at 10–15 l/min in the first instance. The oxygen dose can be adjusted downwards (using nasal cannulae or a simple face mask) to maintain a target saturation of 94–98% once the patient has stabilised. [Grade D]

- In all other cases without risk factors for hypercapnic respiratory failure, treatment should be commenced with nasal cannulae (or a simple face mask if cannulae are not tolerated or not effective) with the flow rate adjusted to achieve a saturation of 94–98%. [Grade D]

- If medium-dose therapy with nasal cannulae or a simple face mask does not achieve the desired saturation, change to a reservoir mask and seek senior or specialist advice. [Grade D]

**8.11.2 Acute asthma**

The BTS/SIGN guideline for the management of acute asthma recommends that the oxygen saturation should be maintained above 92%.\(^{107}\) The present guideline suggests a target saturation of 94–98% for most disease conditions, including asthma. The lower limit of 94% in this guideline is recommended in order to maintain consistency throughout the guideline. The rationale for this approach is explained in section 6.7 and in recommendation 3. Although there is no danger of tissue hypoxia at any saturation above 90%, a drop of oxygen saturation below 94% may indicate deterioration and should prompt a further assessment. Supplementary oxygen should be started using nasal cannulae at 2–4 l/min or a simple face mask at 5 l/min or 35–40% Venturi mask and adjusted as necessary to maintain a saturation of 94–98%.\(^{210}\) The BTS asthma guideline recommends giving high-flow oxygen to all patients with acute severe asthma. However, this aspect of the guideline was written in the early 1990s, before oximetry was in routine use. A study which was published in 2008 showed that the administration of 100% oxygen to patients with acute severe asthma produced an increased \( \text{PaCO}_2 \) and a decreased peak expiratory flow compared with patients treated with 28% oxygen.\(^{211}\) The authors of that study recommended the use of targeted oxygen therapy rather than giving high concentration oxygen to all patients with acute severe asthma. It remains appropriate to give oxygen to patients with acute severe asthma in the absence of oximetry or blood gas results, but there is no evidence of benefit from giving oxygen to patients who are not hypoxaemic. Oxygen should not be withheld from hypoxaemic patients with severe asthma because of concerns about possible hypercapnia, although there is some evidence that this phenomenon does occur.\(^{211}\) \(^{212}\) Hypercapnia in acute asthma indicates a near-fatal attack and indicates the need for consideration of intensive care admission and ventilation.\(^{117}\)

**Recommendation (see table 2)**

- In acute asthma, aim at an oxygen saturation of 94–98%. [Grade C]

**8.11.3 Pneumonia**

The BTS guideline for pneumonia recommends aiming at an oxygen saturation above 92% and \( \text{PaO}_2 >8 \) kPa (60 mm Hg) in uncomplicated pneumonia with appropriate adjustments for patients with COPD, guided by blood gas measurements.\(^{213}\) The present guideline endorses these principles. For internal consistency, a saturation range of 94–98% is recommended for most adults and it is recommended that patients with COPD complicated by pneumonia should be managed in accordance with the COPD section of the present guideline.

**Recommendation (see table 2)**

- In cases of pneumonia, aim at an oxygen saturation of 94–98%. [Grade D]

**8.11.4 Lung cancer and other cancers with pulmonary involvement**

Most patients with lung cancer who present with acute breathlessness have a specific causative factor such as a pleural effusion, pneumonia, COPD, anaemia or collapse of a lobe or of the left or right lung.\(^{214}\) \(^{215}\) One small double blind trial reported that hypoxaemic patients with advanced cancer (\( \text{SpO}_2 <90\% \)) had reduced dyspnoea breathing oxygen compared with air, but a larger and more recent study failed to show benefit from oxygen compared with air, even when hypoxaemia was present.\(^{130}\) \(^{216}\) A single blind study involving 38 hospice patients with dyspnoea at rest showed a reduction in breathlessness when oxygen or air was given.\(^{217}\) Other studies have shown improvements in breathlessness in patients with cancer given opiates or benzodiazepines but not with oxygen.\(^{131}\) \(^{132}\) \(^{215}\) \(^{216}\) \(^{219}\) A systematic review of oxygen and air flow on the relief of dyspnoea at rest in patients with advanced disease of any cause found low-grade scientific evidence that oxygen and airflow improve dyspnoea in some patients with advanced disease at rest.\(^{134}\) This systematic review could only find evidence involving a total of 83 patients and most were hypoxaemic and already receiving oxygen therapy. Based on the existing evidence, it is likely that cancer patients with significant hypoxaemia may have some relief from breathlessness if given oxygen, but there is no evidence for any benefit in patients who are breathless but not hypoxaemic, and there is evidence that opiates are effective in palliating breathlessness in this group of patients. In addition to specific management of the causative factor, oxygen should be given to maintain a saturation of 94–98% except for patients with co-existing COPD who should be treated in accordance with the COPD section of this guideline. Monitoring of oxygen saturation is not necessary when the patient is in the last few days of life.

**Recommendations (see table 2)**

- In breathlessness due to lung cancer, oxygen therapy may be beneficial and a trial of oxygen therapy is recommended. Aim at an oxygen saturation of 94–98% unless there is co-existing COPD. However, monitoring of oxygen saturation is not necessary when the patient is in the last few days of life. [Grade D]
8.11.5 Deterioration of fibrotic lung conditions and other conditions involving parenchymal lung disease or alveolitis

It is recognised that patients with fibrosing lung conditions such as idiopathic pulmonary fibrosis may have acute deteriorations or exacerbations, often during intercurrent chest infections. Other patients may present acutely with breathlessness due to extrinsic allergic alveolitis, sarcoidosis or other types of parenchymal lung disorders. These patients often have a high degree of V/Q mismatch and a requirement for high oxygen concentrations to achieve satisfactory blood gases and they are not at risk of hypercapnia. It is recommended that treatment is started with 60% oxygen from a Venturi mask or 6 l/min via nasal cannulae if the patient can tolerate a high nasal flow rate. The oxygen level should be adjusted upwards or downwards to maintain an oxygen saturation in the range of 94–98%, but this level may not be achievable or only achievable with a reservoir mask. Patients with end-stage pulmonary fibrosis are rarely suitable for invasive or non-invasive ventilation because of the progressive nature of the condition.

Recommendation (see table 2)

- In acute deterioration of pulmonary fibrosis or other parenchymal lung diseases, aim at an oxygen saturation of 94–98% or the highest possible if these targets cannot be achieved. [Grade D]

8.11.6 Pneumothorax

As with pleural effusions, patients with a large pneumothorax may be breathless and hypoxaemic and may require supplementary oxygen for symptom relief pending definitive treatment by aspiration or drainage. However, high concentration inhaled oxygen can also increase the rate of reabsorption of air from a pneumothorax up to fourfold. For this reason, the BTS guideline on the management of pneumothorax recommends the use of high concentration oxygen (reservoir mask) in all non-COPD patients who require hospital admission for observation due to a moderate-sized pneumothorax that does not require drainage. Once a pneumothorax is drained or aspirated successfully, the patient should not require oxygen therapy unless there is additional pathology such as pneumonia, asthma or COPD requiring specific treatment.

Recommendations (see table 2)

- In most cases of pneumothorax, aim at an oxygen saturation of 94–98% if the patient is at risk of hypercapnic respiratory failure. [Grade D]
- In patients having hospital observation without drainage, the use of high concentration oxygen (15 l/min flow rate via reservoir mask) is recommended. [Grade C]

8.11.7 Pleural effusion

If a pleural effusion is causing significant breathlessness, the most effective treatment is to drain the effusion (but not too quickly in view of the risk of re-expansion pulmonary oedema). Hypoxaemic patients with pleural effusions are likely to benefit from supplementary oxygen therapy. The BTS guidelines for management of pleural effusions do not give any specific advice concerning oxygen therapy, but it seems reasonable to give supplementary oxygen to hypoxaemic patients to maintain a saturation of 94–98%.

Recommendations (see table 2)

- In pleural effusion, aim at an oxygen saturation of 94–98% (or 88–92% if the patient is at risk of hypercapnic respiratory failure). [Grade D]

8.11.8 Pulmonary embolism

Most patients with suspected pulmonary embolism have normal oxygen saturation and the main focus of treatment is to reach a specific diagnosis and to commence anticoagulant treatment. These patients do not require oxygen therapy unless there is hypoxaemia. In these cases, the lowest dose of oxygen that will achieve a target saturation of 94–98% is recommended. However, patients with massive or multiple pulmonary embolism may be profoundly hypoxaemic and should initially be given high concentration oxygen via a reservoir mask to achieve an oxygen saturation of 94–98% pending definitive treatment such as thrombolysis. It has been suggested that the blood oxygen saturation may underestimate the severity of pulmonary artery obstruction in acute pulmonary embolism if shock is present.

Recommendation (see table 2)

- In pulmonary embolism, aim at an oxygen saturation of 94–98% or 88–92% if the patient is at risk of hypercapnic respiratory failure. [Grade D]

8.11.9 Acute heart failure

Most patients with acute heart failure are breathless, usually due to pulmonary oedema or low cardiac output, especially if cardiogenic shock is present. The pathophysiology of oxygen transport in cardiogenic shock has been discussed in detail by Cremer and colleagues. It has been shown in an animal model that the ventilatory failure of cardiogenic shock may be due to an impairment of the contractile process of the respiratory muscles.

In addition to specific treatment for heart failure, patients should be given supplementary oxygen to maintain a saturation of 94–98%. This is consistent with the European Society of Cardiology Task Force and European Society of Intensive Care recommendation that patients with acute heart failure should receive oxygen to maintain SpO2 of 92–96%. It is reasonable to initiate treatment with 40% or 60% oxygen for hypoxaemic patients with heart failure, followed by upward or downward adjustment to maintain saturation in the desired range. Patients with marked hypoxaemia (saturation <85%) should be treated with a reservoir mask initially and patients with co-existing COPD will require a lower target saturation of 88–92% pending the availability of blood gas results.

In hospital settings, patients with acute pulmonary oedema may benefit from continuous positive airway pressure and from non-invasive ventilatory support.

Recommendations (see table 2)

- In acute heart failure, aim at an oxygen saturation of 94–98% or 88–92% if the patient is at risk of hypercapnic respiratory failure. [Grade D]
- Consider treatment with continuous positive airway pressure if there is hypoxaemia and treatment with non-invasive ventilation (BiPAP) if there is co-existent hypercapnia. [Grade C]
8.11.10 Postoperative breathlessness or hypoxaemia on general surgical wards

These guidelines do not cover immediate postoperative care in post-anaeathetic recovery units, high dependency units or intensive care units (ICUs). Some recent trials have shown a reduced incidence of wound infection when high-dose oxygen was given perioperatively to patients having bowel surgery but not general surgery.79-81 This planned use of oxygen postoperatively is also outside the scope of this guideline.

There is some controversy about the use of “routine” supplemental oxygen postoperatively and no good evidence supporting such a policy.59 153 228-230 The SIGN guideline on postoperative care recommends supplemental oxygen therapy for certain high-risk groups such as those with coronary artery disease, obesity, thoracic and upper abdominal surgery, but acknowledges lack of evidence to support these suggestions and does not specify an oxygen dose or target saturation for such patients.229 This SIGN guideline recommends maintaining an oxygen saturation above 92% for postoperative patients, which fits well with the suggested target saturation in the present guideline of 94–98% for most patients who require supplemental oxygen therapy.

Patients on general surgical wards can develop sudden breathlessness or hypoxaemia due to a variety of postoperative complications such as pneumonia, pulmonary embolism, opiate analgesia and atelectasis. The use of oxygen for specific postoperative complications such as pneumonia should follow the guidance for each condition (for most patients the target will be 94–98%). Special care must be taken in cases of COPD and other risk factors for hypercapnic respiratory failure. Management of these cases can be enhanced by early specialist referral or the input of expert assistance from ICU Outreach Teams. These cases should be identified as being at risk during preoperative assessment and a target saturation of 88–92% is suggested pending the availability of blood gas results.

Recommendations (see table 2)

- For postoperative surgical patients, aim at a saturation of 94–98% or 88–92% if at risk of hypercapnic respiratory failure. [Grade D]
- For postoperative surgical patients with COPD or other risk factors for hypercapnic respiratory failure, aim at a saturation of 88–92% pending results of blood gas analysis. If the PaCO2 is normal, adjust target range to 94–98% and repeat blood gas measurements after 30–60 min (see table 3 and chart 1 (fig 1)).

8.11.11 Breathlessness due to severe anaemia

If breathlessness is due to severe anaemia, the specific treatment is blood transfusion. Studies by Canadian researchers in the late 1990s have shown that haemoglobin levels of 70 g/l (7 g/dl) were as safe as higher levels and may produce fewer complications in the critically ill.33 However, this study was conducted using non-leucocyte-depleted blood and it is possible that some of the infective complications in the group who were given more transfusions might have been avoided by the use of leucocyte-depleted blood. The optimal transfusion target for critically ill patients therefore remains the subject of ongoing discussion among experts in critical care medicine (section 5.6.2). Giving oxygen to increase an already normal oxygen saturation will have very little effect on the oxygen-carrying power of the blood, but it is reasonable to administer supplemental oxygen to maintain a saturation of 94–98% (if the saturation is below these levels breathing air of if breathlessness is a very prominent symptom).

Recommendations (see table 2)

- In anaemia, aim at an oxygen saturation of 94–98% or 88–92% if the patient is at risk of hypercapnic respiratory failure. [Grade D]
- Give packed red cells if the haemoglobin level falls below 70–80 g/l (7–8 g/dl) in most cases or 100 g/l (10 g/dl) if the patient has unstable or symptomatic ischaemic heart disease. [Grade B]

8.11.12 Sickle cell crisis

Patients with sickle cell disease frequently present with an acute painful crisis and less frequently with an “acute chest syndrome” comprising breathlessness, chest pain and fever with pulmonary infiltrates on the chest radiograph. The exact causes and mechanisms are not well understood, but oxygen should be given to all hypoxaemic patients with sickle cell crisis to avoid further intravascular sickling. There are no randomised studies of oxygen therapy in acute chest syndrome and no randomised studies of acute painful crisis in adults, but two small randomised trials showed no clinical benefit in non-hypoxaemic children with acute painful crisis.231 232 Patients with sickle cell disease may have a reduced oxygen saturation even when clinically stable. Homi and colleagues reported a mean saturation of only 92.5% (95% CI 92.0% to 93.0%) in a group of children and young adults (age 9–18 years) with stable sickle cell disease compared with an average saturation of 97.1% (95% CI 96.2% to 97.3%) in a local control group.233 The British Committee for Standards in Haematology have recommended that oxygen should be given if the oxygen saturation falls below what is normal for the individual patient or a default target of 95% if the usual saturation is unknown.234 This is consistent with the advice in the present guideline to aim at a normal or near-normal oxygen saturation for non-hypoxaemic patients with a target saturation of 94–98%. Readers are referred to the guideline on sickle cell disease for disease-specific management of this condition.234

Recommendation (see table 2)

- In sickle cell crisis and acute chest syndrome, aim for an oxygen saturation of 94–98% or aim at the saturation level that is usual for the individual patient. [Grade B]

8.12 Recommended oxygen therapy for patients who may be vulnerable to medium or high doses of oxygen (see also table 3)

COPD is the best known condition that can predispose to hypercapnic (type 2) respiratory failure with acidosis, especially if the blood oxygen level is increased above 10 kPa (75 mm Hg).14 235 However, there are a number of other conditions which can render patients vulnerable to hypercapnic respiratory failure. The emphasis for such patients is to avoid clinically harmful levels of hypoxaemia or hypercapnia by giving carefully titrated oxygen therapy or, if necessary, by supporting the patient with the use of non-invasive or invasive mechanical ventilation.

Non-COPD patients at risk of hypercapnic respiratory failure include the following:

- Cystic fibrosis.
- Non-CF bronchiectasis (often in association with COPD or severe asthma).
- Severe kyphoscoliosis or severe ankylosing spondylitis.
Severe lung scarring from old tuberculosis (especially with thoracoplasty).

- Morbid obesity (body mass index >40 kg/m²).

- Musculoskeletal disorders with respiratory muscle weakness, especially if on home ventilation.

- Overdose of opiates, benzodiazepines or other respiratory depressant drugs.

8.12.1 COPD exacerbations

There is an extensive literature documenting the effects of high-dose oxygen therapy in acute COPD. These reports show that the administration of supplemental oxygen to patients with exacerbated COPD often causes a rise in PaCO₂ with subsequent respiratory acidosis for reasons summarised in sections 5.3, 5.4 and 6.3.1. The literature is summarised in detail in the review by Murphy et al. Some patients with COPD are prone to repeated episodes of hypercapnic respiratory failure and others may not ever suffer from this complication. Even among patients with COPD with chronic hypercapnia, not all will develop an increased carbon dioxide level (and acidosis) during acute exacerbations. Apart from patients with recurrent hypercapnic respiratory failure, it is not possible to predict if individual patients with COPD will develop hypercapnia during an acute exacerbation, so all patients with moderate or severe COPD should be considered to be at risk of this complication until the results of blood gas measurements are available. It is therefore essential that patients who are at risk of having COPD should be diagnosed accurately, and this can only be done by measurement of FEV₁.

Patients with acute severe exacerbations of COPD may be too breathless to undertake spirometry on arrival in hospital, but many patients are able to perform spirometry on arrival in hospital and all patients should have the test performed before discharge from hospital to confirm the diagnosis of COPD and to assess the severity of the condition. There is very little literature describing the effects of oxygen therapy in the other conditions listed above, but they are recognised to be at risk of hypercapnic respiratory failure and should be treated in a manner analogous to patients with COPD.

It has been shown that patients with COPD with a pH reading <7.35 ([H⁺] >45 mmol/l) despite controlled oxygen therapy are more likely to die and more likely to meet criteria for intubation and ventilation. One of these reports also showed that patients with a high PaO₂ on arrival in hospital (≥10.0 kPa or 75 mm Hg) were more likely to meet criteria for ventilation and the severity of acidosis was related to high PaO₂ values. Based on these results, Plant and colleagues recommended an upper limit of about 92% saturation for patients with exacerbations of COPD to prevent the PaO₂ rising above 10 kPa. This report was supported by the recent work of Joosten et al which showed that a PaO₂ of >74.5 mm Hg (10 kPa) in acute COPD was associated with an increased likelihood of admission to a high dependency unit, increased mortality and a longer stay in hospital. Consequently, the guideline group has recommended a maximum saturation of 92% while awaiting blood gas results in acute exacerbations of COPD and other conditions that may predispose to type 2 respiratory failure. Although the rise in PaCO₂ (and fall in pH) is greatest in patients who are given sufficient oxygen therapy to elevate the PaO₂ above 10 kPa, it is important to note that hypercapnia can occur in acute COPD even if the oxygen saturation is <88%.

The best management strategy for persistently acidic COPD patients is a trial of non-invasive ventilation with supplementary oxygen therapy. Some patients with previous hypercapnic respiratory failure will have alert cards or an entry in their electronic record to alert the emergency team to the optimal dose of oxygen required during the patient’s previous hospital admissions (see section 9.7). In the absence of such information, it is suggested that a target of 88–92% should be set initially for patients with a history of previous non-invasive or invasive ventilation and, if necessary, modified later based on blood gas results. These patients should be categorised as very urgent by ambulance teams and emergency services, requiring immediate blood gas measurement and senior assessment on arrival at the hospital emergency department.

Unfortunately, many clinical studies have shown that patients with COPD are frequently given very high doses of oxygen, either because of misdiagnosis or because the risks of hyperoxia in patients with COPD have been overlooked. Many patients with COPD are unaware of the diagnosis or are mislabelled as having asthma (see section 9.5). The consensus from the literature is that patients with acute exacerbations of COPD should be treated with Venturi masks to minimise the risks of hypercapnic respiratory failure and to achieve a high gas flow from the mask in patients with a high inspiratory flow rate. It is not yet known if it is better to start with a 28% Venturi mask or a 24% Venturi mask. Management with a 28% Venturi mask appears to be safe. The current guideline recommends starting with a 28% Venturi mask in cases of COPD with no known history of hypercapnic respiratory failure, with downward adjustment to a 24% mask (in hospital) if the saturation rises above 92%. In cases of prior hypercapnic failure who do not have an oxygen alert card, it is recommended that prehospital treatment should be commenced using a 28% Venturi mask at 4 l/min or a 24% Venturi mask in hospitals with a target saturation of 88–92%. Observational studies in the 1960s suggested that a PaO₂ of 50 mm Hg or 6.7 kPa (saturation about 84%) will prevent death from hypoxaemia in acute COPD exacerbations. If the saturation should fall below 88% despite treatment with a 24% or 28% Venturi mask, the patient should be treated with nasal cannulae or a simple face mask with the flow adjusted to maintain a saturation of 88–92% pending the availability of blood gas results. This small subgroup of patients is at very high risk of death and should be treated as a high priority on arrival in emergency departments, requiring immediate senior assessment and arterial blood gas measurements.

- Measurement of FEV₁ may confirm (or exclude) a diagnosis of airflow obstruction and the FEV₁ level is a useful indicator of disease severity in COPD. [Evidence level III]

- Patients with exacerbations of COPD are at risk of hypercapnic (type 2) respiratory failure with respiratory acidosis. [Evidence level IIa]

- The risk of respiratory acidosis in patients with hypercapnic respiratory failure is increased if the arterial oxygen tension is above 10.0 kPa due to previous excessive oxygen use. [Evidence level IIa]

- These patients with chronic lung disease are usually “acclimatised” to living with an oxygen saturation which may be in the high 80s or low 90s and there is not likely to be any benefit from increasing the saturation above these levels during acute illness. [Evidence level III]
If the diagnosis is unknown, patients over 50 years of age who are long-term smokers with a history of chronic breathlessness on minor exertion such as walking on level ground and no other known cause of breathlessness should be treated as if having COPD for the purposes of this guideline. Patients with COPD may also use terms such as chronic bronchitis and emphysema to describe their condition but may sometimes mistakenly use “asthma”. FEV₁ should be measured on arrival in hospital if possible and should be measured at least once before discharge from hospital in all cases of suspected COPD. [Grade D]

Patients with a significant likelihood of severe COPD or other illness that may cause hypercapnic respiratory failure should be triaged as very urgent on arrival in hospital emergency departments and blood gases should be measured on arrival in hospital. [Grade D]

Prior to availability of blood gas measurements, use a 28% Venturi mask at 4 l/min or 24% Venturi mask at 2 l/min and aim for an oxygen saturation of 88–92% for patients with risk factors for hypercapnia but no prior history of type 2 respiratory failure. [Grade D]

For patients with known previous hypercapnic respiratory failure but no oxygen alert card, aim at a saturation of 88–92% until the results of blood gas measurements are available (see recommendation 5).

If the saturation remains below 88% in prehospital care despite a 28% Venturi mask, change to nasal cannulae at 2–6 l/min or a simple face mask at 5 l/min with target saturation of 88–92% and alert the A&E department that the patient is to be treated as a high priority. [Grade D]

Patients with a respiratory rate >30 breaths/min should have the flow rate set to 50% above the minimum flow rate specified for the Venturi mask and/or packaging. Increasing the oxygen flow rate into a Venturi mask does not increase the concentration of oxygen which is delivered (see recommendation 32).

Aim at a prespecified target saturation range (if available) in patients with a history of previous respiratory acidosis. In many cases the ideal target saturation will be specified on the patient’s alert card. If no information is available, aim at a saturation level of 88–92% pending blood gas results. [Grade D]

Patients with previous hypercapnic respiratory failure should have a personalised oxygen alert card and this information should be available to primary care staff, ambulance staff and hospital staff (see recommendations 23–25).

If following blood gas measurements the pH and PaCO₂ are normal, aim for an oxygen saturation of 94–98% unless there is a history of previous hypercapnic respiratory failure requiring non-invasive ventilation or intermittent positive pressure ventilation. [Grade D]

Recheck blood gases after 50–60 min (or if there is evidence of clinical deterioration) for all patients with COPD or other risk factors for hypercapnic respiratory failure even if the initial PaCO₂ measurement was normal. [Grade D]

If the PaCO₂ is raised but pH is >7.55 ([H⁺] < 45 nmol/l), the patient has probably got long-standing hypercapnia; maintain target range of 88–92% for these patients. Blood gas measurements should be repeated at 50–60 min to check for rising PaCO₂ or falling pH. [Grade D]

If the patient is hypercapnic (PaCO₂ >6 kPa or 45 mm Hg) and acidic (pH <7.35 or [H⁺] >45 nmol/l), consider non-invasive ventilation, especially if the acidosis has persisted for more than 30 min despite appropriate therapy. [Grade A]

Once patients have stabilised, consider changing from Venturi mask to nasal cannulae at 1–2 l/min (see recommendation 31).

### 8.12.2 Exacerbation of cystic fibrosis

Patients with breathlessness due to cystic fibrosis should be managed in a Cystic Fibrosis Centre unless this is not possible for geographical reasons. If not possible, all cases should be discussed with the Cystic Fibrosis Centre or managed according to a protocol that has been agreed with the regional centre. Patients with advanced cystic fibrosis may suffer from exacerbations which are similar to exacerbations of advanced COPD with associated hypoxaemia and hypercapnia. The principles of management are similar to those in acute exacerbations of COPD, including a need to maintain adequate oxygen saturation and avoiding excessive hypercapnia and acidosis. As in COPD, non-invasive ventilation may be of value in severe cases. Non-invasive ventilation in cystic fibrosis may also be helpful to reduce symptoms (e.g., work of breathing and dyspnoea) and assist in airway clearance.

It is recommended that patients with acute exacerbations of cystic fibrosis should be managed on similar lines to patients with acute exacerbations of COPD with a target oxygen saturation of 88–92% for most patients, but recognition that individual patients may need to be managed differently on the basis of previous and current blood gas measurements. One study has shown that patients with a respiratory rate above 30 breaths/min often have an inspiratory flow rate above the minimum flow rate specified on the mask packaging. However, there is no direct experimental evidence of the clinical effectiveness of increased flow rates from Venturi devices. It is possible that patients with very high inspiratory flow rates might benefit from a 28% Venturi mask with the flow rate set at 6–8 l/min to minimise the risk of the inspiratory flow rate exceeding the gas flow rate (see table 10 in section 10). Patients with cystic fibrosis who have had previous episodes of hypercapnic respiratory failure should be issued with an oxygen alert card with recommendations based on previous blood gas measurements (see recommendations 23–25).

### Recommendation (see table 3)

- Initial treatment of cystic fibrosis exacerbations should be similar to the initial treatment of COPD exacerbations (see section 8.12.1). [Grade D]

### 8.12.3 Chronic musculoskeletal and neurological disorders

Hypoxaemia due to musculoskeletal and neurological disorders is usually associated with acute illness (such as a chest infection) superimposed on a chronic neuromuscular condition. However, muscle weakness can be acute or subacute (e.g., Guillain-Barré syndrome, see section 8.13.7). For most patients with inadequate ventilation due to neuromuscular weakness, non-invasive or invasive ventilatory support is more useful than supplementary oxygen and these patients are at risk of hypercapnic respiratory failure which may be aggravated by high doses of oxygen. For this reason it is recommended that spirometry should be monitored carefully and blood gases should be obtained as early as possible in all such cases. Pending the availability of blood gas results, a saturation target of 88–92% will avoid the risks of severe hypoxaemia or severe hypercapnia.
In the initial management of musculoskeletal and neurological disorders with acute respiratory failure, aim at an oxygen saturation of 88–92%. Many such patients will be suitable for non-invasive ventilation. [Grade D]

8.12.4 Obesity-hypoventilation syndrome
Patients with the obesity-hypoventilation syndrome often develop chronic hypercapnic respiratory failure and they may decompensate acutely to produce hypercapnic respiratory failure with acidosis. For purposes of oxygen therapy, these patients should be treated in a similar manner to patients with hypercapnic respiratory failure due to an acute exacerbation of COPD (but they clearly do not require bronchodilator and steroid therapy). The initial target saturation will usually be 88–92% but, as with COPD, a lower target range may be appropriate for individual patients based on blood gas measurements during a previous exacerbation or due to acute acidosis. Assessment of patients with increasing shortness of breath or worsening oxygen saturation must include blood gases. As in COPD, patients with respiratory acidosis may benefit from non-invasive ventilation.

Recommendations (see table 3)

- In the initial management of the obesity-hypoventilation syndrome with acute exacerbation, aim at an oxygen saturation of 88–92%. [Grade D]
- Non-invasive ventilation should be considered for all of the above groups of patients if the pH is <7.35 or [H+] >45 nmol/l. [Grade C]

8.13 Common medical emergencies for which oxygen therapy is indicated only if hypoxaemia is present (see also table 4)
There are a number of conditions such as myocardial infarction, angina and stroke for which oxygen was traditionally given to all patients in an attempt to increase oxygen delivery to the heart or brain. However, the administration of supplemental oxygen to normoxaemic patients has very little effect on blood gas measurements during a previous exacerbation or due to acute acidosis. There is evidence from randomised studies that oxygen does not relieve breathlessness compared with air in non-hypoaxemic COPD patients who are breathless following exertion.

8.13.1 Acute myocardial infarction, suspected myocardial infarction and acute coronary syndromes
Some patients with acute myocardial infarction have heart failure and should be treated accordingly (see section 8.11.9). Most patients with suspected or confirmed myocardial infarction are not hypoaxemic and most are not breathless. In the case of non-hypoaxemic patients, it is not known if supplementary oxygen may be beneficial by increasing the amount of oxygen delivered to the hypoaxemic area of myocardium or whether it may actually cause vasoconstriction with increased systemic vascular resistance and reduced myocardial oxygen supply with worsened systolic myocardial performance. A recent study of patients having coronary arteriography found that breathing 100% oxygen reduced coronary blood flow velocity by 20% and increased coronary resistance by 23%. There is also a theoretical possibility that high oxygen levels might exacerbate reperfusion injury to the heart. Despite a multitude of large studies of intervention in myocardial infarction, there has been only one randomised study of oxygen therapy (in 1976) and this study did not identify any benefit from such therapy but found some evidence of potential harm. This trial reported a significantly greater rise in myocardial enzyme in the oxygen group, suggesting a greater infarct size. There was a threefold increase in mortality on oxygen therapy that did not reach statistical significance (3 deaths in 77 patients treated with air versus 9 deaths in 80 patients given oxygen at 6 l/min via a simple face mask for 24 h). A systematic review and a historical review of oxygen therapy in acute myocardial ischaemia have both concluded that there was no evidence to support this practice in non-hypoaxemic patients and some evidence of possible harm.

One study from 1969 showed that hypoxia did not affect the availability of oxygen for myocardial metabolism in normal subjects until the oxygen saturation fell to about 50%, but evidence of myocardial ischaemia was seen at saturations of 70–85% in subjects with coronary artery disease. In these circumstances it is advised that patients with myocardial infarction or chest pain suspicious of myocardial infarction should be given supplementary oxygen if required to maintain a saturation of 94–96%.

The study by Lal and colleagues in the 1960s showed that hypoxia was present in a high proportion of patients diagnosed with myocardial infarction and could usually be reversed by medium-dose oxygen, but sometimes required treatment with a reservoir mask to achieve a PaO2 oxygen tension >60 mm Hg (8 kPa). The study by Wilson and Channer in 1997 showed that desaturation below 90% was common in patients with myocardial infarction within the first 24 h of admission to a coronary care unit, but these authors may not have been aware that nocturnal desaturation to this level is very common in healthy individuals. Wilson and Channer did not demonstrate any correlation between hypoxaemic events and adverse cardiac events. They did, however, show that monitoring by oximetry was inadequate in UK coronary care units in the mid 1990s.

There are no UK guidelines for oxygen therapy in acute myocardial infarction. The 1998 European Society for Cardiology/European Resuscitation Council Task Force recommended the use of 3–5 l/min oxygen via face mask to all patients with chest pain of presumed cardiac origin, but no evidence was presented to support this advice. However, most of the papers that have raised concerns about the effects of oxygen on myocardial blood flow have been published since that date (see preceding paragraph). The European Society of Cardiology published subsequent guidance on the management of ST elevation myocardial infarction in 2008. This revised guidance recommended the use of oxygen at 2–4 l/min by mask or nasal cannulae for patients with heart attacks associated with breathlessness or heart failure. The 2007 SIGN guideline for acute coronary syndromes states that there is no evidence that routine administration of oxygen to all patients with acute coronary syndromes improves clinical outcome or reduces infarction size. The SIGN guideline gives a grade D recommendation that oxygen should be administered to patients with hypoxaemia, pulmonary oedema or continuing myocardial ischaemia.
The European Resuscitation Council Guidelines for the management of acute coronary syndromes in 2005 recommended the use of supplementary oxygen at 4–8 l/min (device not specified) for patients with arterial oxygen saturation <90% and/or pulmonary congestion. The guideline acknowledged the lack of evidence of benefit for non-hypoxaemic patients but recommended supplementary oxygen in case of unrecognised hypoxaemia. This situation might apply in the prehospital setting but not in the hospital setting. The limited available evidence therefore supports the suggestion that clinicians should aim at normal or near-normal oxygen saturation in patients with myocardial infarction, acute coronary syndrome and chest pain suspicious of coronary artery disease. A target saturation range of 94–98% will meet all of these goals, and further research of this topic should be prioritised because this is such a common medical problem and there is so little existing evidence. Most 999 calls to ambulance services because of chest pain are currently treated with high concentration oxygen in accordance with the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) guidance.

However, most such patients have a final diagnosis of undifferentiated chest pain rather than acute coronary artery syndrome and most patients with undifferentiated chest pain are normoxaemic. The clinical management of a very large number of patients will therefore be changed following the introduction of this guideline.

Recommendation (see table 4)

- In myocardial infarction and acute coronary syndromes, aim at an oxygen saturation of 94–98% or 88–92% if the patient is at risk of hypercapnic respiratory failure. [Grade D]

8.13.2 Stroke

In the past it was customary to give supplementary oxygen to all patients with stroke to try to improve cerebral oxygenation. However, there has been only one randomised trial of oxygen therapy in stroke. This trial found no difference in 1-year survival for the entire cohort of patients with stroke and no difference in survival for patients with more severe strokes. However, for patients with minor or moderate strokes, 1-year mortality was 18% in the group given oxygen and 9% in the group given air (OR 0.45; 95% CI 0.25 to 0.90, p = 0.023). Based largely on the results of this trial, the Royal College of Physicians stroke guideline recommends that oxygen saturation should be maintained in the normal range in patients with stroke. It is recommended that patients with stroke should receive supplementary oxygen only if this treatment is required to achieve an oxygen saturation of 94–98% (88–92% for patients with co-existing risk of COPD or other risk of respiratory acidosis).

There has also been some discussion concerning the optimal body position for the management of patients with stroke and potential hypoxaemia. A systematic review concluded that there was limited evidence that sitting in a chair had a beneficial effect and lying positions had a deleterious effect on oxygen saturation in patients with acute stroke with respiratory co-morbidities, but patients with acute stroke without respiratory co-morbidities can adopt any body position. The authors of this review recommended that people with acute stroke and respiratory co-morbidities should be positioned as upright as possible.

Recommendation (see table 4)

- In stroke, aim at an oxygen saturation of 94–98% or 88–92% if the patient is at risk of hypercapnic respiratory failure. [Grade B]

8.13.3 Obstetric emergencies and labour

The use of oxygen has been recommended during many obstetric emergencies and, in particular, for collapse related to haemorrhage, pulmonary embolism, eclampsia or amniotic fluid embolism. Severe pre-eclampsia and eclampsia may occasionally present with pulmonary oedema and this can occur in the antenatal or postnatal periods. Medical problems such as pneumonia or acute exacerbations of asthma are not uncommon during pregnancy. Peripartum cardiomyopathy is rare but may present with heart failure in the postnatal period. Major trauma is increasingly common, particularly related to road traffic accidents.

The use of oxygen during pregnancy should follow the same general principles as the use of oxygen for other patients. Pregnant women suffering major trauma or severe hypoxaemia should be started on high concentration oxygen via a non-rebreathing reservoir mask and those with milder hypoxaemia can use nasal cannulae or a simple face mask or Venturi mask to achieve an oxygen saturation of 94–98% in most cases. If an undelivered woman is hypoxaemic, she should be managed with left lateral tilt applied. This will improve cardiac output and may also facilitate breathing for mechanical reasons.

Oxygen is commonly given as part of the treatment for many obstetric emergencies. However, it is recommended that, when oxygen is administered during pregnancy or labour, clinicians should aim to achieve normoxaemia (saturation 94–98%). There is no randomised trial evidence to suggest that maternal ‘‘hyperoxaemia’’ is beneficial to mother or fetus.

Oxygen is often given when acute fetal compromise is suspected in labour in the hope of increasing oxygen delivery to the fetus. A Cochrane review found no trials addressing the use of oxygen for fetal compromise. However, two trials of prophylactic oxygen in labour found a significant increase in the incidence of cord blood acidosis ([H+] >63 mmol/l) in the oxygenation group (RR 3.5 (95% CI 1.34 to 9.19)).

It is recommended that pregnant women with evidence of hypoxaemia should have their blood oxygen saturation maintained in the normal range (94–98%) using supplemental oxygen as necessary to achieve this effect. This applies before or during labour as well as in the postnatal period. The causes of maternal hypoxaemia may include trauma, pre-existing or de novo medical conditions as well as pregnancy-specific complications. In all of these situations the aim should be normoxaemia (saturation 94–98%).

Recommendations

14. Women who suffer from major trauma, sepsis or acute illness during pregnancy should receive the same oxygen therapy as any other seriously ill patients, with a target oxygen saturation of 94–98%. The same target range should be applied to women with hypoxaemia due to acute complications of pregnancy (eg, collapse related to amniotic fluid embolus, eclampsia or antepartum or postpartum haemorrhage). [Grade D]

15. Women with underlying hypoxaemic conditions (eg, heart failure) should be given supplemental
8.13.4 Anxiety and hyperventilation or dysfunctional breathing
Many patients who present to hospital with breathlessness are found to have no cardiopulmonary problems and many such patients have a specific diagnosis of hyperventilation, dysfunctional breathing, upper airway dysfunction or panic attacks, sometimes in addition to asthma or some other underlying respiratory disorder. Many patients will have an abnormally high oxygen saturation of 99% or 100% and clearly do not require supplemental oxygen therapy. Many other non-hypoxaemic patients will present to hospital with acute breathlessness of unknown cause, and the majority of patients with an elevated respiratory rate are likely to have an organic illness. In some cases simple investigations will reveal a specific diagnosis such as pneumothorax or pneumonia or pulmonary embolism, but many cases remain undiagnosed. A policy of giving supplementary oxygen if the saturation falls below 94% will avoid exposing patients with undiagnosed medical illnesses to the risk of hypoxaemia while avoiding the unnecessary use of oxygen in patients with behavioural or dysfunctional breathlessness.

Studies in normal volunteers have demonstrated that compensatory desaturation may occur shortly after voluntary hyperventilation. The mean PaO\textsubscript{2} of 10 male volunteers increased from 13.7 kPa (105 mm Hg) to 18.6 kPa (140 mm Hg) during hyperventilation but fell to a nadir of 7.8 kPa (58 mm Hg) about 7 min after cessation of hyperventilation and did not normalise until after a total of 17 min of observation. It is not known whether or not this occurs after pathological hyperventilation, but this phenomenon could cause considerable confusion if it should occur in an emergency department.

A traditional treatment for hyperventilation was to ask the subject to rebreathe from a paper bag to allow the carbon dioxide level in the blood to normalise. However, it has been shown that this practice can cause hypoxaemia with potentially fatal consequences. The average fall in oxygen tension during rebreathing was 26 mm Hg (3.5 kPa) and the maximum fall was 42 mm Hg (5.6 kPa). This guideline does not recommend rebreathing from a paper bag in cases of hyperventilation unless the patient has been shown to have hypoxemia and a low carbon dioxide level, and any such treatment should be monitored with continuous oximetry and discontinued if the patient should desaturate.

Recommendations (see table 4)
- Organic illness must be excluded before making a diagnosis of hyperventilation. [Grade C]
- Patients with a definite diagnosis of hyperventilation should have their oxygen saturation monitored. Those with normal or high SpO\textsubscript{2} do not require oxygen therapy. [Grade B]
- Rebreathing from a paper bag can be dangerous and is NOT recommended as a treatment for hyperventilation. [Grade C]

8.13.5 Poisoning with substances other than carbon monoxide
Many poisons and drugs can cause respiratory or cardiac depression or direct toxic effects on the lungs. The treatment of individual toxic agents is beyond the scope of this guideline. Specific antidotes such as naloxone should be given if available and oxygen saturation should be monitored closely. Supplementary oxygen should be given to achieve a target saturation of 94–98% pending the results of blood gas analysis (88–92% if at risk of hypercapnic respiratory failure). All potentially serious cases of poisoning should be monitored in a level 2 or level 3 environment (high dependency unit or intensive care unit).

Three specific types of lung injury deserve special mention. Oxygen is known to be hazardous to patients with paraquat poisoning and oxygen potentiates bleomycin lung injury. Because of these risks, oxygen should be given to patients with these conditions only if the oxygen saturation falls below 90%. Some authors have suggested the use of hypoxic ventilation with 14% oxygen as a specific treatment for paraquat poisoning.

Bleomycin lung injury can be potentiated by high-dose oxygen therapy, even if given several years after the initial lung injury. It is therefore recommended that high doses of oxygen should be avoided in patients with possible bleomycin-induced lung injury and a lower oxygen saturation target range should be accepted (eg, 88–92%).

There is evidence from animal experiments that oxygen may potentiate lung injury from aspiration of acids. The effect in humans is not known so patients with acid inhalation should have the usual adult target saturation range of 94–98%, but it would appear prudent to aim in the lower half of the target range for these patients and clinical trials in humans are clearly required.

Recommendations (see table 4)
- In most poisonings, aim at an oxygen saturation of 94–98%. [Grade D]
- In poisoning by paraquat and bleomycin, aim at a saturation of 88–92%. [Grade D]

8.13.6 Metabolic, endocrine and renal disorders
Many metabolic and renal disorders can cause metabolic acidosis which increases respiratory drive as the body tries to correct the acidosis by increased excretion of carbon dioxide via the lungs. Although these patients have tachypnoea, they do not usually complain of breathlessness and most have a high oxygen saturation (unless there is a co-existing pulmonary or cardiac problem). Supplementary oxygen is not required for such patients unless the oxygen saturation is reduced. In such cases, oxygen should be given to maintain a saturation of 94–98%.

Recommendation (see table 4)
- In most metabolic and renal disorders, aim at an oxygen saturation of 94–98%. [Grade D]
8.13.7 Acute and subacute neuromuscular disorders producing respiratory muscle weakness
Patients with acute or subacute conditions affecting the respiratory muscles are at risk of sudden onset of respiratory failure with hypoxaemia and hypercapnia and may require non-invasive or invasive ventilatory support. This applies especially to patients with Guillain-Barré syndrome for whom spirometry should be monitored carefully as this should detect the onset of severe respiratory failure prior to the development of hypoxaemia. If the oxygen level falls below the target saturation, urgent blood gas measurements should be undertaken and the patient is likely to need ventilatory support.

SECTION 9: EMERGENCY USE OF OXYGEN IN AMBULANCES, COMMUNITY AND PREHOSPITAL SETTINGS
This section applies to a range of clinical settings to include emergency oxygen use in patients’ homes, GP practices or health centres and during emergency ambulance journeys to hospital. Management in some prehospital settings such as a Primary Care Centre or in a paramedic ambulance may be almost identical to hospital management. Readers are referred to section 10 for advice concerning choice of oxygen delivery devices and systems.

Readers are referred to tables 1–4 and charts 1 and 2 (figs 1 and 2) for a summary of the key elements of oxygen therapy in common medical emergencies. A brief summary of this section can be downloaded from www.brit-thoracic.org.uk.

Ongoing care at home of chronically hypoxaemic patients is not covered by this guideline. There is little literature on which to base any recommendations when such patients have an acute exacerbation of their condition, but patient safety should be the priority. The NICE guidelines on COPD recommend that patients receiving long-term oxygen and those with an arterial PO2 of <7 kPa should be considered for treatment in hospital during exacerbations (recommendation 135 in NICE guideline). The BTS Emergency Oxygen Guideline Group would add that chronically hypoxaemic patients with a clinical exacerbation associated with a 3% or greater fall in oxygen saturation on their usual oxygen therapy should be assessed in hospital with blood gas estimations. Arterial PO2 of <7 kPa equates to SpO2 below approximately 85%.

9.1 Pulse oximetry and availability of oxygen
It is essential to provide optimal oxygen therapy at the earliest possible opportunity while the acutely breathless patient is being assessed and treated in the community and during transport to hospital. For most such patients the main concern is to give sufficient oxygen to support their needs. Hypoxaemia can lead to cardiac arrhythmias, renal damage and, ultimately, cerebral damage. However, excessive oxygen therapy can also be dangerous for some patients, especially those with advanced COPD. Target saturation should be used; pulse oximetry is necessary to achieve this. Section 10.4.2 provides advice concerning the choice of oxygen cylinders in primary care practices.

Emergency ambulances and emergency/fast response type vehicles and ambulance service motorbikes and cycles should be equipped with oxygen and oximeters germane to the mode of transport. Thus, fast response cars/motorbikes and cycles will require handheld finger oximeter-type devices and staff initiating oxygen in the home will need a portable or finger oximeter. Community First Responder (CFR) schemes are encouraged to seek the opinion of the ambulance service to which they are affiliated to discuss the purchase and use of pulse oximeters. Likewise Voluntary Aid Societies (VAS) medical directors are encouraged to discuss the purchase and use of pulse oximeters.

Recommendations
18. Pulse oximetry must be available in all locations where emergency oxygen is being used (see also the limitations of using pulse oximetry section 7.1.2). [Grade D]
19. Emergency oxygen should be available in primary care medical centres, preferably using oxygen cylinders with integral high-flow regulators. Alternatively, oxygen cylinders fitted with high-flow regulators (delivering over 6 l/min) must be used. [Grade D]
20. All documents which record oximetry measurements should state whether the patient is breathing air or a specified dose of supplemental oxygen. [Grade C]

9.2 Clinical assessment by initial responder(s) (GP, nurse or ambulance team)
It is suggested that the first healthcare professional(s) to encounter an acutely breathless patient should perform an initial “ABC” assessment (airway, breathing, circulation), followed by obtaining a quick history from the patient and/or family or friends. Immediate assessment should include a recording of pulse rate and respiratory rate and pulse oximetry should be recorded.

- Clinical assessment of a breathless patient starts with “ABC” (airway, breathing, circulation) (see recommendation 7).
- A brief history should be taken from the patient or other informant.
- Initial assessment should include pulse and respiratory rate in all cases (see recommendation 7).
- Pulse oximetry should always be measured in patients with breathlessness or suspected hypoxaemia (see recommendation 9).
- Disease-specific measurements should also be recorded (eg, peak expiratory flow in asthma, blood pressure in cardiac disease).

9.3 Immediate management of hypoxaemic patients
Having ascertained that the airway is clear, the emergency responders should commence oxygen treatment if the oxygen saturation is below the target. The initial oxygen therapy should follow the general principles given in tables 1–4 and charts 1 and 2 (figs 1 and 2). There is some evidence that bronchodilator therapy, however given, can cause increased V/Q mismatch and reduced blood oxygen levels in acutely ill patients shortly after treatment (see section 10.8.1).

Recommendations
- The initial oxygen therapy to be used in the various clinical situations is given in tables 1–4.
- If there is a clear history of asthma or heart failure or other treatable illness, appropriate treatment should be instituted in accordance with guidelines or standard management plans for each disease. [Grade D]
21. The oxygen saturation should be monitored continuously until the patient is stable or arrives at hospital for a full assessment. The oxygen concen-
9.4 Patients with known COPD
A proportion of breathless patients will have COPD (chronic bronchitis and emphysema). Unfortunately, a recent Cochrane review of oxygen therapy for COPD in the prehospital setting found no relevant studies.282 Audits of emergency admissions in UK hospitals have shown that about 25% of breathless medical patients who require hospital admission have COPD as a main diagnosis. Many of these patients will require carefully controlled oxygen therapy because they are at risk of carbon dioxide retention or respiratory acidosis. In a large UK study,283 47% of patients with exacerbated COPD had PaCO₂ >6.0 kPa (45 mm Hg), 20% had respiratory acidosis (pH <7.35 or [H+] >45 nmol/l) and 4.6% had severe acidosis (pH <7.25 or [H+] >56 nmol/l). Acidosis was more common if the blood oxygen was >10 kPa (75 mm Hg). Plant and colleagues34 recommended that patients with acute COPD should be maintained within a PaO₂ range of 7.3–10 kPa (55–75 mm Hg) to avoid the dangers of hypoaxaemia and acidosis.

Recommendation (see table 3)
- Patients with COPD should initially be given oxygen via a Venturi 28% mask at a flow rate of 4 l/min or a 24% Venturi mask at a flow rate of 2 l/min. Some patients may benefit from higher flow rates via the Venturi mask (see recommendation 32). The target oxygen saturation should be 88–92% in most cases or an individualised saturation range based on the patient’s blood gas measurements during previous exacerbations. [Grade C]

9.5 Patients who should be assumed to have COPD
One of the challenges faced by the initial clinical response staff is that the diagnosis may be unclear and the patient’s medical records or detailed history may not be available. It has been shown that ambulance teams may be aware of a diagnosis of COPD in only 58% of cases.283 The guidelines group consider that an initial diagnosis of COPD should be assumed if there is no clear history of asthma and the patient is >50 years of age and a long-term smoker or ex-smoker with a history of longstanding breathlessness on minor exertion. The diagnosis should be reassessed on arrival at hospital where more information will probably become available, and the FEV₁ should be measured unless the patient is too breathless to undertake spirometry.

Recommendation
- If the diagnosis is unknown, patients >50 years of age who are long-term smokers with a history of chronic breathlessness on minor exertion such as walking on level ground and no other known cause of breathlessness should be treated as if having COPD for the purposes of this guideline.

9.6 Other patients at risk of hypercapnic respiratory failure with respiratory acidosis
- Any patient with severe kyphoscoliosis or severe ankylosing spondylitis.
- Severe lung scarring from old tuberculosis (especially with thoracoplasty).
- Morbid obesity (body mass index >40 kg/m²).
- Patients with neuromuscular disorders (especially if muscle weakness has led to wheelchair use).
- Any patient on home mechanical ventilation.
- Use of home mechanical ventilation.
- Overdose of opiates, benzodiazepines or other drugs causing respiratory depression.

9.7 Oxygen alert cards and 24% or 28% Venturi masks in patients with COPD (and others at risk of respiratory acidosis) who have had an episode of hypercapnic respiratory failure
The administration of high oxygen concentrations in acute COPD and other conditions (see section 8.12) leads to worsening of hypercapnic respiratory failure and respiratory acidosis.34 Patients with COPD and a PaO₂ >10 kPa (75 mm Hg) and a PaCO₂ >6.0 kPa (45 mm Hg) may be assumed to have had excessive oxygen therapy. If a patient is found to have respiratory acidosis due to excessive oxygen therapy, the oxygen therapy should not be discontinued immediately because the oxygen level will fall significantly over 1–2 min by virtue of the alveolar gas equation (see section 5.2.1) whereas the carbon dioxide level will take much longer to correct itself (see section 6.3.2). In this situation the oxygen treatment should be stepped down to 28% or 24% oxygen from a Venturi mask depending on oxygen saturation and blood gas results. A saturation target of 88–92% is recommended for acidic patients in type 2 respiratory failure and non-invasive ventilation is required if the acidosis does not resolve quickly.25, 34 This avoidable problem has occurred historically during the transfer to hospital, prior to measurement of arterial blood gases or before a definitive diagnosis is known. Furthermore, ambulance teams are often not informed at present of a diagnosis of COPD and may not be aware of the presence of other high-risk conditions such as kyphoscoliosis or respiratory failure due to neuromuscular conditions. These patients can be issued with an oxygen alert card and a 24% or 28% Venturi mask based on previous blood gas results. The recommended oxygen saturation will be based on the clinical scenario for each individual patient but will usually be 88–92%, occasionally 85–88% or 85–90% based on previous blood gas results. Patients should be instructed to show this card to the ambulance crew and emergency department staff in order to avoid the use of high oxygen concentrations. This scheme can be successful.284 The ambulance service can also be informed about which patients are issued with oxygen alert cards.285 The current Joint Royal Colleges Ambulance Liaison Committee (JRCALC) guideline for the use of oxygen in COPD are being revised to accommodate these changes.284 An example of an oxygen alert card is shown in fig 8.

Recommendations
23. Patients with COPD (and other at-risk conditions) who have had an episode of hypercapnic respiratory failure should be issued with an oxygen alert card
and with a 24% or 28% Venturi mask. They should be instructed to show the card to the ambulance crew and emergency department staff in the event of an exacerbation. [Grade C]

24. The content of the alert card should be specified by the physician in charge of the patient’s care, based on previous blood gas results. [Grade D]

25. The primary care team and ambulance service should also be informed by the responsible clinician that the patient has had an episode of hypercapnic respiratory failure and carries an oxygen alert card. The home address and ideal oxygen dose or target saturation ranges of these patients can be flagged in the ambulance control systems and disseminated to ambulance crews when required. [Grade D]

26. Out-of-hours services providing emergency primary care services should be informed by a responsible clinician that the patient has had an episode of hypercapnic respiratory failure and carries an oxygen alert card. Use of oxygen in these patients will be guided by the instructions on the alert card. [Grade D]

27. During ambulance journeys oxygen-driven nebulisers should be used for patients with asthma and may be used for patients with COPD in the absence of an air-driven compressor system. If oxygen is used for patients with known COPD, its use should be limited to 6 min. This will deliver most of the nebulised drug dose but limit the risk of hypercapnic respiratory failure (section 10.8.2). [Grade D]

28. If a patient is suspected to have hypercapnia or respiratory acidosis due to excessive oxygen therapy, the oxygen therapy should not be discontinued but should be stepped down to 28% or 24% oxygen from a Venturi mask depending on oxygen saturation and subsequent blood gas results. [Grade C]

9.8 Choice of devices in prehospital care
The range of oxygen delivery devices is very wide as discussed in section 10. However, most patients can be managed with one of five types of oxygen delivery device.

### Table 10

<table>
<thead>
<tr>
<th>Oxygen cylinder sizes</th>
<th>Size</th>
<th>C</th>
<th>CD</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>HX</th>
<th>J</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (cm)</td>
<td></td>
<td>36</td>
<td>49</td>
<td>46</td>
<td>79</td>
<td>86</td>
<td>124</td>
<td>94</td>
<td>145</td>
</tr>
<tr>
<td>Capacity (l)</td>
<td></td>
<td>170</td>
<td>460</td>
<td>340</td>
<td>680</td>
<td>1360</td>
<td>3400</td>
<td>2300</td>
<td>6800</td>
</tr>
</tbody>
</table>

29a. It is recommended that the following delivery devices should be available in prehospital settings where oxygen is administered (see section 10): [Grade D]
- high concentration reservoir mask (non-rebreath mask) for high-dose oxygen therapy;
- nasal cannulae (preferably) or a simple face mask for medium-dose oxygen therapy;
- 28% Venturi mask for patients with definite or likely COPD (patients who have an oxygen alert card may have their own 24% or 28% Venturi mask);
- tracheostomy masks for patients with tracheostomy or previous laryngectomy.

### SECTION 10: PRACTICAL ASPECTS OF OXYGEN THERAPY
Oxygen delivery systems can be considered as two components:
- the method of storage and provision of oxygen (eg, cylinders);
- the method of delivery to the patient (eg, Venturi mask).

The options available for both will depend on the environment in which it is being used and the needs of the patient.

10.1 Oxygen storage and provision

10.1.1 Cylinders (compressed gas)
Cylinders contain compressed gas held under a very high pressure. They come in an array of sizes and hence capacity, ranging from small portable cylinders for individual patient use to large cylinders suitable for hospital use (table 10). These can be used for bedside administration where piped oxygen is not available or can be the supply for a piped system.

With recent changes in technology, high pressure cylinders are now available (ie, filled to 200 bar rather than 137 bar which can contain 54% more gas for the same size cylinder). It is important for all users of oxygen to be aware that most oxygen cylinders are colour-coded (black cylinder with white shoulder). Small lightweight cylinders are also available for ambulatory use (eg, some weigh 5.2 kg when full). All systems containing compressed gases in the UK are subject to the Pressure Systems Safety Regulations 2000 (SI 2000 No 128). These regulations are intended to prevent the risk of injury from pressurised systems.

- Trusts must ensure that they have a policy in place which ensures the safety of patients, staff and contractors in the provision, storage, use and maintenance of compressed gas systems as required by the Health and Safety at Work etc Act 1974.
- Clinicians using oxygen cylinders should check the labelling of the cylinder to ensure that it is an oxygen cylinder and checks should be made to ensure that the cylinder is not empty or near-empty.

10.1.2 Liquid oxygen
Liquid oxygen is contained in pressure tanks and is obtained from atmospheric oxygen by fractional distillation. It has to be evaporated into a gas before use. Large tanks are often used by...
hospitals and small tanks can be used domestically. Portable liquid oxygen is also available in small portable containers which can be filled from the larger tanks.

10.1.3 Oxygen concentrators
Oxygen concentrators are largely used in the domiciliary setting for the provision of long-term oxygen therapy and are therefore not used in the acute setting so will not be covered further.

10.2 Patient delivery methods/interfaces

10.2.1 High concentration reservoir mask (non-rebreathing mask) (fig 9)
This type of mask delivers oxygen at concentrations between 60% and 90% when used at a flow rate of 10–15 l/min. The concentration is not accurate and will depend on the flow of oxygen and the patient’s breathing pattern. These masks are most suitable for trauma and emergency use where carbon dioxide retention is unlikely (table 1).

10.2.2 Simple face mask (fig 10)
This type of mask delivers oxygen concentrations between 40% and 60%. It is sometimes referred to as an MC Mask, Medium Concentration Mask, Mary Catterall Mask or as a “Hudson Mask”, but the latter description is discouraged because the Hudson Company make many types of mask (including high concentration reservoir masks). The guideline group favours the term “simple face mask”. The oxygen supplied to the patient will be of variable concentration depending on the flow of oxygen and the patient’s breathing pattern. The concentration can be changed by increasing or decreasing the oxygen flows between 5 and 10 l/min. However, different brands of simple face mask can deliver a different oxygen concentration at a given flow rate. Flows of <5 l/min can cause increased resistance to breathing, and there is a possibility of a build-up of carbon dioxide within the mask and rebreathing may occur.

10.2.3 Venturi mask (fig 11)
A Venturi mask will give an accurate concentration of oxygen to the patient regardless of oxygen flow rate (the minimum suggested flow rate is written on each Venturi device and the available options are shown in table 11). The oxygen concentration remains constant because of the Venturi principle. The gas flow into the mask is diluted with air which is entrained via the cage on the Venturi adaptor. The amount of air sucked into the cage is related to the flow of oxygen into the Venturi system. The higher the flow the more air is sucked in. The proportions remain the same and therefore the Venturi mask delivers the same concentration of oxygen as the flow rate is increased.

Venturi masks are available in the following concentrations: 24%, 28%, 35%, 40% and 60%. They are suitable for all patients needing a known concentration of oxygen, but 24% and 28% Venturi masks are particularly suited to those at risk of carbon dioxide retention (eg, patients with COPD). A further benefit of Venturi masks is that the flow rate of gas from the mask will usually exceed the inspiratory flow rate of the patient. One study has shown that patients with a respiratory rate >30 breaths/min often have an inspiratory flow rate above
the minimum flow rate specified on the mask packaging. Therefore, for patients with a high respiratory rate, it is suggested that the flow rate for Venturi masks should be set above the minimum flow rate listed on the packaging (increasing the oxygen flow rate into a Venturi mask does not increase the concentration of oxygen which is delivered). The accuracy of oxygen delivery from a Venturi mask is greatly reduced if the mask is not accurately placed on the patient’s face.

- Patients with a respiratory rate >30 breaths/min often have a flow rate which is above the minimum delivered by the Venturi system as specified by the flow rate recommended for the mask. [Evidence III]

Venturi masks deliver a constant percentage of oxygen but the effect on the patient will depend on the condition being treated and on the breathing pattern and baseline oxygen saturation of the patient. As might be expected from the oxygen dissociation curve, patients with an oxygen saturation that is already in the normal range will have a very small rise in oxygen saturation (although the arterial oxygen tension is likely to rise substantially). However, patients with very low oxygen saturation will have a marked rise if given even a small dose of oxygen. This is because the oxygen dissociation curve is actually a “rapid escalator” rather than a “slippery slope”. This is illustrated in fig 12 which uses actual oxygen saturations from King et al and Warrel et al together with calculated saturations from Bone et al and DeGaute et al and Schiff and Massaro.

10.2.4 Nasal cannulae (fig 13)

Nasal cannulae can be used to deliver low- and medium-dose oxygen concentrations. However, there is wide variation in patients’ breathing patterns so the same flow rate of nasal oxygen may have widely different effects on the blood oxygen and carbon dioxide levels of different patients. Nasal cannulae at 1-4 l/min can have effects on oxygen saturation approximately equivalent to those seen with 24-40% oxygen from Venturi masks. The oxygen dose continues to rise up to flows above 6 l/min but some patients may experience discomfort and nasal dryness at flows above 4 l/min, especially if maintained for several hours. Although one might expect mouth breathing to reduce the efficiency of nasal cannulae, the majority of studies have shown that mouth breathing results in either the same inspired oxygen concentration or a higher concentration, especially when the respiratory rate is increased. This is important because patients with acute breathlessness are likely to breathe quickly and via the mouth rather than the nose. As there is marked individual variation in breathing pattern, the flow rate must be adjusted based on oximetry measurements and, where necessary, blood gas measurements. A crossover comparison of nasal cannulae versus a Venturi mask (both adjusted to give satisfactory initial oxygen saturation) showed that the oxygen saturation of patients with exacerbated COPD fell below 90% for 5.4 h/day during treatment with a Venturi mask compared with only 3.7 h/day during treatment with nasal cannulae.

The upper range of oxygen delivery from nasal cannulae is a little lower than the output of a simple face mask, but the lower range goes a lot lower than a simple face mask which should not be used below a flow rate of 5 l/min (about 40% oxygen). The performance and variation of nasal cannulae for medium concentration oxygen therapy is broadly similar to that of the simple face mask, both in laboratory experiments and in clinical practice. One study suggested that the saturation was lower with nasal cannulae than with simple face masks in a subgroup of men following abdominal surgery. Further studies are required to see if this was a chance finding or

---

**Figure 11** (A) Venturi mask. (B) Range of concentrations available. (C) Operation of Venturi valve. For 24% Venturi mask the typical oxygen flow of 2 l/min gives a total gas flow of 51 l/min. For 28% Venturi mask, 4 l/min oxygen flow gives a total gas flow of 44 l/min (table 11).

---

**Table 11** Total gas flow rate (l/min) from Venturi masks at different oxygen flow rates

<table>
<thead>
<tr>
<th>Oxygen flow (l/min)</th>
<th>24% oxygen</th>
<th>28% oxygen</th>
<th>35% oxygen</th>
<th>40% oxygen</th>
<th>60% oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>84</td>
<td>82</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>67</td>
<td>50</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>56</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>89</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>67</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>102</td>
<td>44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
a genuine clinical difference between the devices. Three patient preference studies comparing nasal cannulae with simple face masks in postoperative care found that patient preference was strongly in favour of nasal cannulae with up to 88% of patients preferring cannulae to masks. Another advantage of cannulae over simple face masks is that they are less likely to be removed accidentally and they allow the patient to speak and eat. There are no comparisons of these devices in acute care, but there is no reason to believe that the results would be any different for patients requiring medium-dose oxygen therapy.

Advantages of nasal cannulae compared with simple face masks for medium-dose oxygen therapy (Evidence level III):

- Comfort (but a minority of patients dislike the flow of oxygen into the nose, especially above 4 l/min).
- Adjustable flow gives wide oxygen dose range (flow rate of 1–6 l/min gives FIO2 from approximately 24% to approximately 50%).
- Patient preference.
- No claustrophobic sensation.
- Not taken off to eat or speak and less likely to fall off.
- Less affected by movement of face.
- Less inspiratory resistance than simple face masks.
- No risk of rebreathing of carbon dioxide.
- Cheaper.

Disadvantages of nasal cannulae:

- May cause nasal irritation or soreness.
- Will not work if nose is severely congested or blocked.

10.2.5 Tracheostomy mask (fig 14)

These devices are designed to allow oxygen to be given via a tracheostomy tube or to patients with previous laryngectomy (ie, “neck breathing patients”). The oxygen flow rate should be adjusted to achieve saturation in accordance with tables 1–4 and chart 1 (fig 1). Oxygen given in this way for prolonged periods needs constant humidification and patients may need suction to remove mucus from the airway.
10.2.6 Continuous positive airways pressure and non-invasive ventilation

These treatment options are beyond the scope of the present guideline. Readers are referred to the BTS guideline concerning the use of non-invasive ventilation in patients with exacerbations of COPD.32

10.3 Oxygen carriage and delivery during patient transport in ambulances

Transport of oxygen cylinders in vehicles comes under the Transport of Dangerous Substances Act or the Carriage Regulations only if 1000 litres or more (measured by the water capacity of the cylinder) is carried at any one time. Ambulances are therefore exempt from this. Normal health and safety requirements will still apply.301 302

10.3.1 Health and Safety Executive guidance for safe use of oxygen cylinders301 302

- All cylinders must be secured appropriately so they cannot move in transit (includes portable cylinders).
- No smoking in the vicinity of cylinders.
- Cylinders must be checked regularly for obvious signs of leakage.
- Cylinders must be kept out of direct sunlight.
- Green warning triangle “compressed gas” should be displayed on the vehicle.
- Cylinders should never be lifted by the neck.
- They should only be changed by suitably trained personnel.
- Apart from portable cylinders, all cylinders should be moved using a cylinder trolley.

10.3.2 Oxygen use by UK ambulance services

Currently within the UK the Ambulance Service—whether NHS or private—has a range of vehicles and oxygen delivery systems at their disposal. There is an increasing use of cycle response units which tend to use the lightweight AZ or C sized cylinder with a capacity of 170 litres. Motorcycle response units are generally equipped with the same AZ or C sized cylinders. Fast response units based on cars tend to be equipped with at least two of the lightweight CD sized cylinders which hold 460 litres. The CD cylinder is also the size favoured by mountain, cave and mines rescue teams.

Front-line ambulances are usually equipped with piped oxygen fittings (Schrader type) and supplied from two HX sized (2300 litres) cylinders, as well as carrying at least two CD sized cylinders to power a portable oxygen-powered resuscitator. The piped supply has several outlet points placed in strategic positions to which are attached standard Schrader flow meters (0–15 l/min). This enables oxygen to be given throughout the patient’s journey. The ambulance is also equipped with a portable supply which can be used at the site of an accident, taken into a patient’s home or can be used when transferring a patient. They carry a range of patient interfaces for delivering the oxygen under the different circumstances encountered.

Portable resuscitators are always capable of supplying free-flow oxygen therapy as well as their resuscitator facility. Again, there are a variety of portable oxygen-powered resuscitators and it is beyond the scope of these guidelines to describe each one available for use in prehospital care. It is strongly suggested that those practitioners who need to work closely with the Ambulance Service should become familiar with the equipment used by their local Ambulance Service provider. With the possible exception of the cycle response units, all types of Ambulance Service response will have portable resuscitators, bag-valve-mask devices and portable suction as a minimum. Front-line emergency department ambulances will also have vehicle-powered suction available.

It is also very common now for patient transport service ambulances to be equipped with an oxygen supply, normally an HX cylinder (2500 litres) delivering the oxygen via a flow meter attached directly to the cylinder. Such vehicles also tend to carry basic hand-held suction devices. The masks available are generally high concentration reservoir masks and are provided specifically for emergency use for patients who might become ill on the vehicle. Vehicles that are equipped with an oxygen supply should also carry oximeters to ensure appropriate use of oxygen (see section 9.8 for advice on which oxygen delivery devices should be carried in ambulances).

10.4 Oxygen carriage in other vehicles and in primary care settings and patients’ homes

10.4.1 Oxygen carriage in private cars (Health and Safety Executive Guidance)301 302

When travelling by car, patients have the freedom to carry their own portable oxygen cylinder. Some general practitioners in rural areas also carry oxygen in their cars. However, it is advised that certain safety precautions should be followed:

- It is good practice for the car to display a green warning triangle for “compressed gas”.
- The cylinder should be secure within the car and cannot move during transport or in the event of an accident.

10.4.2 Medical centres and primary care practices

The majority of medical centres and practices should have a supply of oxygen for emergency use. Generally, cylinders with integral high-flow regulators should be ordered. Otherwise, the cylinder must be fitted with a high-flow regulator capable of delivering a flow of >6 l/min in order to deliver medium and high-dose oxygen therapy. A recommended list of oxygen delivery devices for use in prehospital care is given in section 9.8.

- Emergency oxygen should be available in primary care medical centres, preferably using oxygen cylinders with integral high-flow regulators. Alternatively, oxygen cylinders fitted with high-flow regulators (delivering >6 l/min) must be used (see recommendation 19).

Figure 14  Tracheostomy mask.
10.4.3 Patients’ homes
In patients’ homes oxygen is either provided for long-term therapy where an oxygen concentrator is provided (with or without a lightweight cylinder for ambulatory needs) or for short-term/short-burst therapy. Long-term oxygen therapy is covered in other guidelines. This existing home oxygen supply may be used by a patient or general practitioner in an emergency situation before the arrival of an ambulance.

The patient/carer should be made aware of the following Health and Safety recommendations:

- All cylinders should be stored on a cylinder trolley or suitably secured so they cannot be knocked over.
- There should be no trailing oxygen tubing.
- A green warning triangle for “compressed gas” should be displayed by the front door (warns emergency services in the event of a fire).
- The minimum number of cylinders should be stored in the house.
- There should be no smoking in the vicinity of oxygen cylinders.
- Cylinders must be checked regularly for obvious signs of leakage.
- Cylinders must be kept out of direct sunlight.
- Oxygen must not be used near a naked flame.

10.5 Oxygen delivery systems in hospitals
Most hospitals have piped oxygen systems as described previously, although some wards can still be found where piped oxygen is not available and large compressed gas cylinders are used to supply the oxygen. Acute hospitals can spend up to £100 000 per annum on liquid oxygen, so any device that uses lower oxygen flow rates could have significant economic savings for hospitals (eg, nasal cannulae instead of a simple face mask for medium-dose oxygen).

10.5.1 Postoperative care on general surgical wards
Medium concentration masks and nasal cannulae are usually sufficient (target saturation 94–98%) except for patients with known significant COPD who should receive oxygen from a 24% or 28% Venturi mask or 1–2 l/min from nasal cannulae aiming at a saturation range of 88–92%.

10.5.2 Emergency departments
Medium or high concentration oxygen is normally used (via nasal cannulae, simple face mask or reservoir mask), but particular attention should be given to patients who have type 2 respiratory failure when a 24% or 28% Venturi mask or nasal cannulae at a flow rate of 1–2 l/min would be appropriate.

10.5.3 General wards and respiratory wards
The method of oxygen delivery will depend on the following circumstances:

- Expected duration of treatment.
- Type of respiratory illness.
- Pattern of breathing (high or low respiratory rate and drive).
- Need for humidification.
- Risk of carbon dioxide retention.
- Presence of confusion and its effect on potential compliance.

Nasal cannulae, simple face masks, reservoir masks and Venturi masks should be used where appropriate (see tables 1–4 and charts 1 and 2 (figs 1 and 2)). Nasal cannulae at flow rates of 0.5–1.0 l/min are sometimes used as a substitute for Venturi masks in acute or post-acute patients with COPD on respiratory wards (adjusting flow as necessary to achieve the desired arterial blood gas tensions). This practice requires the use of paediatric flow meters to ensure consistent and finely calibrated oxygen delivery and is not recommended outside specialist units.

10.5.4 Devices used in emergency oxygen therapy
Based on the advantages of each delivery system discussed above, the following recommendations are made for delivery of oxygen in medical emergencies. It is likely that additional equipment will be maintained in specialist units, but specialist treatment is outside the scope of the present guideline.

Recommendations (see tables 1–4)

- Most hospital patients can be managed with the same delivery device as in recommendation 29a, but a 24% Venturi mask should also be available.
  - The high concentration reservoir mask at 10–15 l/min is the preferred means for delivering high-dose oxygen to critically ill patients. [Grade D]
  - Nasal cannulae should be used rather than simple face masks in most situations requiring medium-dose oxygen therapy. Nasal cannulae are preferred by patients for reasons of comfort and they are less likely to be removed during meals (see section 10.2.4). There is also a cost saving. [Grade C]
  - The flow rate from nasal cannulae for medium-dose oxygen therapy should be adjusted between 2 and 6 l/min to achieve the desired target saturation. [Grade C]
  - Venturi masks are recommended for patients requiring precise control of FIO2. Venturi masks can deliver a constant FIO2 of 24%, 28%, 35%, 40% and 60% oxygen with a greater gas flow than a simple face mask. In those at risk of developing hypercapnic respiratory failure with oxygen therapy, the use of Venturi masks may reduce this risk. Furthermore, there is less likelihood of dilution of the oxygen stream by room air if the patient’s inspiratory flow rate exceeds the flow rate delivered by the face mask. [Grade D]

30. For many patients Venturi masks can be substituted with nasal cannulae at low flow rates (1–2 l/min) to achieve the same target range once patients have stabilised. [Grade D]

31. The flow rate from simple face masks should be adjusted between 5 and 10 l/min to achieve the desired target saturation. Flow rates below 5 l/min may cause carbon dioxide rebreathing and increased resistance to inspiration. [Grade C]

32. Patients with COPD with a respiratory rate of >30 breaths/min should have the flow rate set to 50% above the minimum flow rate specified for the Venturi mask and/or packaging (increasing the oxygen flow rate into a Venturi mask increases the total gas flow from the mask but does not increase the concentration of oxygen which is delivered). [Grade C]

10.5.5 Flow meters
All oxygen delivery systems must have a method of taking the high pressure/flow of gas and reducing it so it can be administered to the patient at a specific flow depending on the individual’s needs and mask being used.
Piped oxygen points have Schrader flow meters and cylinders have pressure and flow regulators. Most oxygen flow meters use a floating ball to indicate the flow rate. The centre of the ball should be aligned with the appropriate flow rate marking. The example shown in fig 15 indicates the correct setting to deliver 2 l/min.

10.5.6 Oxygen tubing and oxygen wall outlets

Oxygen tubing is needed to connect flow meters and regulators to the patient delivery device. It is important to ensure that all tubing is connected correctly at both ends. The National Patient Safety Agency has reported frequent adverse events related to oxygen use, including four reports of instances where an oxygen mask was connected in error to a compressed air outlet instead of an oxygen outlet. Compressed air outlets are often used to drive nebulisers on in hospitals because they are quieter than electrical compressors. However, the flow meter looks very similar to an oxygen flow meter and is often mounted beside an oxygen flow meter so it is very important to ensure that air flow meters are clearly labelled. There is a similar risk with other piped gas outlets such as those delivering nitrous oxide in some hospitals. Air flow meters are never required in an emergency and should be removed from wall sockets or covered by a designated “hood” when not in use. The guideline authors are also aware of some cases where twin oxygen outlets were in use and the wrong one had been turned on or off. For example, one patient tried to turn off the oxygen flow after finishing a nebulised treatment but accidentally turned off the oxygen flow to a neighbouring patient with serious consequences. It is recommended that patients should not be allowed to adjust oxygen flow, especially if there are dual outlets.

Recommendation
33. Trusts should take measures to eliminate the risk of oxygen tubing being connected to the incorrect wall oxygen outlet or to outlets that deliver compressed air or other gases instead of oxygen. Air flow meters should be removed from the wall sockets or covered with a designated air outlet cover when not in use.

10.6 Use of humidified oxygen

10.6.1 Rationale for use of humidified oxygen

The upper airway normally warms, moistens and filters inspired gases. When these functions are impaired by a pathological process or when they are bypassed by an artificial airway, it is common practice to provide humidification. The main reason for using humidification, especially with high-flow oxygen, is that it may reduce the sensation of dryness in the upper airways that oxygen can cause. However, in the non-intubated population there appears to be little scientific evidence of any benefit from humidified oxygen except that single doses of nebulised isotonic saline have been shown to assist sputum clearance and reduce breathlessness in patients with COPD. There is also evidence that humidification, when combined with physiotherapy, can increase sputum clearance in bronchiectasis. Randomised controlled trials of the effects of humidified high-flow oxygen on patient comfort are required.

Recommendations
34. Humidification is not required for the delivery of low-flow oxygen or for the short-term use of high-flow oxygen. It is not therefore required in prehospital care. Pending the results of clinical trials, it is reasonable to use humidified oxygen for patients who require high-flow oxygen systems for more than 24 h or who report upper airway discomfort due to dryness. [Grade B]

35. In the emergency situation, humidified oxygen use can be confined to patients with tracheostomy or an artificial airway although these patients can be managed without humidification for short periods of time (eg, ambulance journeys). [Grade D]

36. Humidification may also be of benefit to patients with viscous secretions causing difficulty with expectoration. This benefit can be achieved using nebulised normal saline. [Grade C]
10.6.2 Use of bubble humidification systems

Humidified oxygen is widely administered in hospitals across the UK and this is presumed to alleviate nasal and oral discomfort in the non-intubated patient. Humidification of supplemental oxygen is commonly delivered by bubbling oxygen through either cold or warm sterile water before it reaches the patient. However, the effect on patient comfort is negligible.Bubble humidifiers may, however, represent an infection hazard and should not be used.

- There is no evidence of a clinically significant benefit from “bubble bottle” systems but there is an infection risk. [Evidence level III]

Recommendation

37. Bubble bottles should not be used because there is no evidence of a clinically significant benefit but there is a risk of infection. [Grade C]

10.6.3 Large volume nebulisation-based humidifiers

If humidification is required, it should ideally deliver the inspired gas at a of 32–36°C. Cold water humidifiers are simple and inexpensive but less efficient than a warm water system (about 50% relative humidity at ambient temperatures). The warm water option is more effective, targeting a relative humidity of 100%, but both systems are thought to be a potential infection control risk. Warm water humidifiers are expensive and mostly confined to intensive care units and high dependency units and thus outside the scope of this guideline.

Newer humidifying systems are really “giant nebulisers” with a 1-litre reservoir of saline or sterile water and an adjustable Venturi device (fig 16). These systems are attached directly to the oxygen flow meter and connected to an aerosol mask via flex tube. They allow delivery of precise oxygen concentrations of 28%, 35%, 40% and 60% oxygen via their Venturi device. This requires a specific oxygen flow rate as well as adjusting the Venturi nozzle on the device. It is possible to deliver 24% oxygen using a special adaptor. These large volume humidifiers have a high humidification output. The main indication for use is to assist with expectoration of viscous sputum. There are no published randomised studies involving these devices, but it has been shown that single doses of nebulised saline can assist sputum production and relieve breathlessness in patients with COPD.

- Patients requiring high flow rates or longer term oxygen might benefit from a large volume oxygen humidifier device, especially if sputum retention is a clinical problem. [Evidence level III]
- In the absence of an artificial airway the decision to humidify supplemental oxygen needs to be made on an individual basis but this practice is not evidence-based. [Evidence level IV]

10.7 Use of oxygen in patients with tracheostomy or laryngectomy

The number of patients with a tracheostomy being cared for in a ward setting is increasing as critical care personnel use this as a method of facilitating weaning from mechanical ventilation. In the absence of a pressurised circuit, oxygen is predominantly delivered via tracheostomy mask. This is a variable performance device and delivers concentrations up to 60–70%. If the patient deteriorates and requires an increased oxygen concentration exceeding the concentration that a variable performance interface can deliver (60–70%), it will be necessary to seek an alternative delivery system, usually a T-piece device fitted directly to the tracheostomy tube.

With a mask system the interface will be connected to a humidification system via elephant tubing. As inserting a tracheostomy tube bypasses the patient’s natural mechanisms to warm and moisturise inspired gases, it is essential to humidify any supplemental oxygen being delivered to the tracheostomised patient. This will help maintain a patent tracheostomy tube, reducing the build-up of secretions within the inner tube or the tracheostomy itself and minimising any subjective discomfort that the patient may experience.

Recommendation

38. When oxygen is required by patients with prior tracheostomy or laryngectomy, a tracheostomy mask (varying the flow as necessary) should achieve the desired oxygen saturation (tables 1–4). An alternative delivery device, usually a two-piece device fitted directly to the tracheostomy tube, may be necessary if the patient deteriorates. [Grade D]
10.8 Delivering oxygen to patients who require nebulised bronchodilator therapy

10.8.1 Nebulised bronchodilator therapy in asthma

In patients with acute severe asthma oxygen should be used as the driving gas for the nebulised bronchodilators whenever possible at a gas flow rate of 6–8 l/min because these patients are at risk of hypoxaemia. If the available cylinders in general practice do not produce this flow rate, an air-driven nebuliser (with electrical compressor) should be used with supplemental oxygen by nasal cannulae at 2–6 l/min to maintain an appropriate oxygen saturation level. There is some evidence that bronchodilator therapy (whether delivered by nebuliser or by metered dose inhaler) may cause pulmonary vasodilatation leading to increased V/Q mismatch and reduced blood oxygen levels in acutely ill patients and in patients with stable COPD and asthma.309–311 The lowest oxygen saturation occurs not during bronchodilator therapy but about 25 min later.312 One group reported a rise in oxygen saturation during bronchodilator therapy.312

► There is some evidence that bronchodilator therapy, however given, can cause increased V/Q mismatch and reduced blood oxygen levels in acutely ill patients shortly after treatment. [Evidence level III]

10.8.2 Nebulised bronchodilator therapy for patients with COPD and other risk factors for hypercapnic respiratory failure

When an oxygen-driven nebuliser is given to patients with COPD there is a risk of hypercapnia and acidosis due to the high FiO2 which is delivered. In acute exacerbations of COPD the carbon dioxide level can rise substantially within 15 min of commencing high-dose oxygen therapy.102 When nebulised bronchodilators are given to hypercapnic patients, they should ideally be given using an electrical compressor and, if necessary, supplemental oxygen should be given concurrently by using nasal cannulae at 1–4 l/min to maintain an oxygen saturation of 88–92%. If an electrical compressor is not available, compressed air can be used to drive the nebuliser but care should be taken to ensure that the nebuliser is not attached an oxygen outlet (see section 10.5.6). Once the nebulised treatment is completed, controlled oxygen therapy with a fixed concentration (Venturi) device should be reinstituted.

Compressed air is not routinely available during ambulance journeys. In this situation oxygen-driven nebulisers may be used but should be limited to 6 min for patients with known COPD because the nebuliser mask delivers a high dose of oxygen (about 60%). Most of the effective dose from a nebuliser chamber is delivered within 6 min and it is known that high-dose oxygen can cause significant hypercapnia in acute COPD within 15 min.102 Limiting oxygen-driven nebulisers to 6 min will limit the risk of hypercapnic respiratory failure while delivering most of the nebulised drug dose. It must be recognised that patients with COPD may develop hypercapnia and respiratory acidosis if they are left on high-flow oxygen via a nebuliser mask system long after the nebulisation process has finished.

► High-dose oxygen therapy can cause hypercapnia within 15 min in acute COPD. [Evidence level III]

Recommendations

39. For patients with asthma, nebulisers should be driven by piped oxygen or from an oxygen cylinder fitted with a high-flow regulator capable of delivering a flow rate of >6 l/min. The patient should be changed back to his/her usual mask when nebuliser therapy is complete. If the cylinder does not produce this flow rate, an air-driven nebuliser (with electrical compressor) should be used with supplemental oxygen by nasal cannulae at 2–6 l/min to maintain an appropriate oxygen saturation level. [Grade D]

40. When nebulised bronchodilators are given to patients with hypercapnic acidosis, they should be driven by compressed air and, if necessary, supplemental oxygen should be given concurrently by nasal cannulae at 2–4 l/min to maintain an oxygen saturation of 88–92%. The same precautions should be applied to patients who are at risk of hypercapnic respiratory failure prior to the availability of blood gas results. Once the nebulised treatment is completed for patients at risk of hypercapnia, controlled oxygen therapy with a fixed concentration (Venturi) device should be reinstituted. [Grade D]

► During ambulance journeys, oxygen-driven nebulisers may be used in the absence of an air-driven compressor system. If oxygen is used, its use should be limited to 6 min for patients with known COPD. This will deliver most of the nebulised drug dose but limit the risk of hypercapnic respiratory failure (see recommendation 27).

SECTION 11: PRESCRIPTION, ADMINISTRATION AND MONITORING OF OXYGEN THERAPY

11.1 Safe prescription and administration of oxygen

11.1.1 Legal status of medical oxygen: does it need a prescription?

Medical oxygen is a drug. However, the legal status of oxygen in the UK is that of a medicinal product on the General Sales List (Medicines and Healthcare Products Regulatory Agency, personal communication). This means that the sale or dispensation of oxygen does not technically require a prescription because it is not a “prescription only medicine”. This status was conferred for practical reasons to facilitate the use of oxygen in the domiciliary setting where the distribution system no longer involves pharmacies. However, the use of oxygen by paramedics, nurses, doctors, physiotherapists and others in emergency situations is similar to the use of all other medicinal products by these people. Clinical governance requires that the intentions of the clinician who initiates oxygen therapy should be communicated clearly to the person who actually administers oxygen to the patient and an accurate record must be kept of exactly what has been given to the patient. In this respect, oxygen is in the same category as paracetamol, aspirin, ibuprofen, antihistamines, anti-emetics and many other medicines that do not require a prescription if purchased by a patient for his/her own use but do require accurate documentation if administered by a health professional to a patient. In healthcare settings, all of these medicines are conventionally recorded on a “prescription chart” or “drug kardex” alongside drugs in the “prescription only” category such as antibiotics.

A hospital “prescription chart” is a document in which doctors and other prescribing clinicians make a list of all drugs and medicinal products required by a patient and where nurses and other clinicians make a record of all drugs that have been administered to the patient. These documents are also used by hospital pharmacies to dispense medicines but, for technical reasons, these hospital documents (or the equivalent documents in primary care settings or the Patient Report Form (PRF) or ePRF used by the ambulance services) do not have the same
legal status as a prescription that is given to a patient to take to a community pharmacist for the purposes of dispensing a medicine. The “prescription” of oxygen in acute healthcare settings is therefore not technically a prescription for two reasons: (1) oxygen is not a prescription only medicine; and (2) a hospital drug chart is not truly a prescription. The second issue applies to all medicines used in healthcare settings, not just to oxygen. However, the words “prescription” or “prescription chart” are widely used to describe the documents which record the use of medicines in UK hospitals and other healthcare settings. For this reason, the present guideline will use the term “prescribe” and “prescription chart” for all orders for oxygen use.

The important issue is that there must be a clear written record of all medicinal products, including oxygen, which are given to a patient by healthcare professionals. Ideally, this document should be prepared at the time when oxygen therapy is commenced. In emergencies, however, clinicians will treat the patient first and subsequently make written records of all treatments given, including oxygen therapy.

11.1.2 Reasons to prescribe oxygen therapy (see sections 5 and 6)
Oxygen is prescribed for hypoxaemic patients to increase oxygen tension and decrease the work of breathing necessary to maintain a given PaO\(_2\). The concentration of oxygen required depends on the condition being treated; an inappropriate concentration may have serious or even lethal effects. Appropriate target saturation ranges for common medical emergencies are given in section 8 of this guideline and in tables 1–4. Each hospital should have an agreed patient group directive for oxygen prescribing to allow staff to adjust oxygen delivery devices and to give oxygen in emergency situations prior to the availability of a prescription.

11.1.3 Implementing an oxygen prescription policy
Oxygen prescriptions should include starting dose and initial mode of delivery and whether the oxygen therapy should be continuous or as-required. The most important aspect of the prescription is to give a target range. The clinicians who administer oxygen (usually nurses, midwives or physiotherapists) should be trained and empowered to adjust the oxygen dose upwards and downwards as necessary to maintain the patient in the target saturation range. This will require all hospitals to have an agreed oxygen administration programme with universal access to educational materials about oxygen administration. The clinicians who monitor the oxygen saturation (often health care assistants) should be trained to inform those who have been trained to administer oxygen if the oxygen saturations fall above or below the target saturations. Those doing the monitoring should also understand the importance for the patient of keeping in the target range. Implementing this policy will require all hospitals to have agreed patient group directives and training programmes for all clinical staff and regular training programmes in the safe use of oxygen and audit of outcomes.

11.1.4 Administration and monitoring of oxygen therapy
The appropriate device should be used to provide the prescribed oxygen and the effects should be monitored using pulse oximetry, monitoring of respiration rate and close observation of the patient. Arterial or capillary blood gas analysis should be repeated if clinical progress is not satisfactory and in all cases of hypercapnia and acidosis.

11.1.5 Education of health professionals
The clinician or healthcare professional administering the oxygen therapy should be aware of the hazards of hypoxaemia and hyperoxaemia and the signs and symptoms of inadequate or excessive oxygen delivery.

11.1.6 How to prescribe oxygen effectively
In the past, oxygen was often not prescribed at all or prescribed on a standard hospital drug chart as “oxygen”. It was unusual for the prescription to include full details of what device to use, what flow rate(s) to administer and whether the prescription was for a fixed dose of oxygen or to aim at a specific oxygen saturation target.\(^2\)\(^-\)\(^8\)

It has been shown that a purpose-designed oxygen prescription sheet can improve oxygen prescribing in the short term,\(^9\) but experience has shown that free-standing oxygen prescription charts are often forgotten and unused.

Recent audit studies by members of the guideline group (not yet published) have shown improved standards of prescribing with the use of a preprinted section for oxygen use in all hospital drug charts. This system was further enhanced by setting a desired saturation range for each patient. Suggested target saturations for common medical conditions are given in sections 8 and 9 of this guideline. It is important that healthcare professionals where oxygen is administered are familiar with the optimal saturation ranges for common conditions (summary guideline for hospitals; web appendix 2), and it is also important that those delivering the oxygen are familiar with the equipment in use and the best types of device to deliver low, medium and high-dose oxygen therapy. Chart 3 in fig 17 shows a working example of a preprinted oxygen section for a hospital prescription chart, and charts 1 and 2 (figs 1 and 2) give advice to prescribers and advice to those delivering oxygen on wards.

The safe use of oxygen includes careful consideration of the appropriate delivery device (mask, cannulae, etc) together with an appropriate source of oxygen and an appropriate oxygen flow rate.

- For hypoxaemic patients, oxygen therapy should continue during other treatments such as nebulised therapy (see recommendations 27, 39 and 40).

Recommendations for safe prescribing and safe administration of oxygen

41 Every healthcare facility should have a standard oxygen prescription document or, preferably, a designated oxygen section on all drug prescribing cards. (Grade C)
- Oxygen saturation should be measured in all breathless patients and supplemental oxygen should be given to all breathless hypoxaemic patients and to all critically ill patients. Oxygen saturation should be measured under as optimal conditions as possible e.g. nail varnish should be removed (see recommendation 9).
- Clinicians should assess the clinical status of the patient prior to prescribing oxygen and the patient’s condition should be reassessed frequently during oxygen use (see recommendations 7–9).

42 A prescription for oxygen should always be written, except in life-threatening emergencies when it must be started immediately. (Grade D)

43 Doctors and other prescribers should prescribe oxygen using a target saturation range (sections 5,
Oxygen  The method and rate of oxygen delivery should be altered by nurses or other healthcare professionals in order to achieve the target saturation range as per hospital guideline. For most conditions, oxygen should be prescribed to achieve a target saturation of 94–98% (or 88–92% for those at risk of hypercapnic respiratory failure). The nurse should sign this prescription chart on every drug round. The delivery device and flow rate should be recorded alongside the oxygen saturation on the bedside observation chart or Early Warning Score chart.

*Saturation is indicated in almost all cases except for palliative terminal care.

**Drug OXYGEN**

<table>
<thead>
<tr>
<th>Circle target oxygen saturation</th>
<th>Date administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>88–92% 94–98% Other_____</td>
<td></td>
</tr>
<tr>
<td>Starting device/flow rate</td>
<td></td>
</tr>
<tr>
<td>PRN/continuous (refer to O₂ guideline)</td>
<td>06</td>
</tr>
<tr>
<td>Tick here if saturation not indicated *</td>
<td>09</td>
</tr>
<tr>
<td>Date and signature</td>
<td>14</td>
</tr>
<tr>
<td>Print name</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>22</td>
</tr>
</tbody>
</table>

**Figure 17**  Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change from continuous to “as required” (PRN) as a patient improves).
weaning and discontinuation should be instituted (see recommendations 73–76). [Grade D]

49 Most patients are prescribed continuous oxygen. However, some patients may be prescribed oxygen as required (PRN). In this scenario, if patients are on air at the time of the drug round, nurses should still sign the drug chart but the observation chart should be filled in using the code A for air (see chart 4, fig 18). [Grade D]

11.2 Starting oxygen therapy
Safe prescribing and safe administration of oxygen are closely linked. In emergencies oxygen therapy should be started immediately and prescribed as soon as possible. In all other situations oxygen should be prescribed in accordance with the standards described in section 11.1 before administration is commenced. The healthcare professional who administers the oxygen therapy (usually a nurse or physiotherapist) should be fully trained and should follow local or national protocols as described in section 11.1.

Recommendations
- The administering healthcare professional should note the oxygen saturation before commencing oxygen therapy (see recommendation 9).

50 The healthcare professional should commence oxygen therapy using an appropriate delivery system and flow rate as specified in sections 8, 9 and 10 of this guideline. The target oxygen saturation and whether the patient is having continuous oxygen, PRN oxygen or no oxygen therapy should be added on the respiratory section of the observation chart. [Grade D]

51 Whenever possible, patients should be given an oxygen information sheet (example in web appendix 5 of this guideline). [Grade D]

11.3 Monitoring oxygen therapy
11.3.1 Pulse oximeters
Pulse oximetry should be available to all healthcare staff managing patients receiving oxygen therapy and they should be trained in their use (see section 7 for technical and practical information regarding oximeter use). Clinicians should be aware that pulse oximetry gives no information about the P\textsubscript{aCO\textsubscript{2}} or pH and most pulse oximeters are unreliable when a patient’s Sp\textsubscript{O\textsubscript{2}} falls below about 85%. Pulse oximetry is dependent on pulsatile flow, and it may not be possible to achieve a satisfactory oximeter reading in patients with cold hands, especially those with severe Raynaud’s phenomenon due to collagen vascular diseases (which may also cause hypoxic lung disease). The readings may also be affected by shock, skin pigmentation, nail

<table>
<thead>
<tr>
<th>Respiratory rate, oxygen saturation and oxygen therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical review required if saturation is outside target range. Observation frequency________</td>
</tr>
<tr>
<td>Continuous oxygen / PRN / Not on oxygen therapy</td>
</tr>
<tr>
<td>Date</td>
</tr>
<tr>
<td>Time</td>
</tr>
<tr>
<td>Respiratory rate</td>
</tr>
<tr>
<td>Oxygen saturation %</td>
</tr>
<tr>
<td>Oxygen device or air</td>
</tr>
<tr>
<td>Oxygen flow rate l/min</td>
</tr>
<tr>
<td>Your initials*</td>
</tr>
</tbody>
</table>

*All changes to oxygen delivery systems must be initialed by a registered nurse or equivalent.

If the patient is medically stable and in the target range on two consecutive rounds, report to a registered nurse to consider weaning off oxygen.

<table>
<thead>
<tr>
<th>*Codes for recording oxygen delivery on observation chart</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Air (not requiring oxygen, or weaning or on ‘PRN’ oxygen)</td>
</tr>
<tr>
<td>N Nasal cannulæ</td>
</tr>
<tr>
<td>SM Simple mask</td>
</tr>
<tr>
<td>V24 Venturi 24%</td>
</tr>
<tr>
<td>V28 Venturi 28%</td>
</tr>
<tr>
<td>V35 Venturi 35%</td>
</tr>
<tr>
<td>V40 Venturi 40%</td>
</tr>
<tr>
<td>V60 Venturi 60%</td>
</tr>
</tbody>
</table>

Figure 18 Chart 4: Working example of respiratory section of observation chart for hospital use.
varnish, etc (see section 7). It is essential to record the oxygen delivery system alongside the oximetry result.

- All measurements of oxygen saturation should be recorded in the observation chart along with the code for the oxygen delivery system that is being used. If the patient is breathing air at the time of the observation, this should also be recorded in the chart (see recommendation 9 and chart 4 (fig 18)).

11.3.2 Arterial or arteriolised capillary blood gases

- Arterial or arteriolised capillary blood gases should be measured and the inspired oxygen concentration noted on arrival at hospital (or at the time when oxygen therapy becomes necessary) for most patients requiring emergency oxygen therapy (see recommendations 11–13).

- Blood gas measurements should be repeated in all critically ill patients and in many other cases according to the response to treatment (see recommendations 11–13).

11.3.3 Physiological monitoring: “track and trigger” systems

- Early Warning Scoring systems (EWS or mEWS) are useful for monitoring patients. [Evidence Level III]

- Tachypnoea is a sensitive indicator of deteriorating respiratory function. [Evidence Level III]

- All acutely ill patients should have physiological monitoring using Early Warning Scores or a similar physiological assessment system in addition to pulse oximetry (see recommendation 8).

11.3.4 Monitoring during the first hour of oxygen therapy

Recommendations

52 All patients should have their oxygen saturation observed for at least five minutes after starting oxygen therapy. [Grade D]

53 If the oxygen saturation should fall below the target saturation and the patient is unstable, medical advice should be sought. [Grade D]

54 If the oxygen saturation is above the target saturation range and the patient is stable, the delivery system and oxygen flow rate should be reduced accordingly. [Grade D]

55 Patients who have a target saturation of 88–92% should have their blood gases measured within 30–60 min. This is to ensure that the carbon dioxide level is not rising. This recommendation also applies to those who are at risk of developing hypercapnic respiratory failure but who have a normal PaCO2 on the initial blood gas measurement. [Grade D]

56 Stable patients whose oxygen saturation is within their target saturation range of 94–98% do not need repeat blood gas measurements within 30–60 min if there is no risk of hypercapnia and acidosis and may not need any further blood gas measurements. [Grade D]

11.3.5 Subsequent monitoring

The exact requirements for monitoring will depend on the clinical condition of each patient. Saturations are usually measured after 1 h of oxygen therapy and then 4-hourly. Stable patients should be monitored four times a day. However, critically ill patients will require continuous monitoring of oxygen saturation and other physiological measurements.

Recommendations

57 Stable patients on oxygen treatment should have SpO2 and physiological variables (eg, mEWS) measured four times a day. [Grade D]

58 In those who are unstable, oxygen saturation should be monitored continuously and the patient should ideally be managed in a high dependency area. [Grade D]

59 If the patient is clinically stable and the oxygen saturation is within the target range, treatment should be continued (or eventually lowered) depending on the clinical situation. [Grade D]

60 Any sudden fall in oxygen saturation should lead to clinical evaluation of the patient and, in most cases, measurement of blood gases. [Grade D]

61 Oxygen therapy should be increased if the saturation is below the desired range and decreased if the saturation is above the desired range (and eventually discontinued as the patient recovers). [Grade D]

62 The saturation should be monitored continuously for at least 5 min after any increase or decrease in oxygen dose to ensure that the patient achieves the desired saturation range. [Grade D]

63 The new saturation (and the new delivery system) should be recorded on the patient’s observation chart after 5 min of treatment at the new oxygen dose. Each change should be recorded by the clinician trained to administer oxygen by signing the observation chart (only changes should be signed for). [Grade D]

64 Repeat blood gas measurements are not required for stable patients who require a reduced dose of oxygen (or cessation of oxygen therapy) to maintain the desired target saturation. [Grade D]

65 Patients with no risk of hypercapnia do not always need repeat blood gas measurements after an increase in oxygen dose. However, the patient requires clinical review to determine why the oxygen saturation has fallen. [Grade D]

66 Patients at risk of hypercapnia (usually those with a target range of 88–92%; see table 3) require repeat blood gas estimation 30–60 min after an increase in oxygen therapy. [Grade D]

67 For patients with no risk of hypercapnia, monitoring by pulse oximeter is sufficient (repeated blood gases not required) provided the saturation remains in the desired range, usually 94–98%. [Grade D]

11.3.6 When to increase oxygen therapy

In most instances, failure to achieve the desired oxygen saturation is due to the severity of the patient’s illness but it is worth checking that the oxygen delivery device and the oxygen flow rate are correct. If the oxygen is being delivered from a cylinder, clinicians should check the labelling of the cylinder to ensure that it is an oxygen cylinder and checks should be made to ensure that the cylinder is not empty or near-empty.

Recommendations

68 If a patient’s oxygen saturation is lower than the prescribed target range, first check all aspects of
the oxygen delivery system for faults or errors. [Grade D]

69 If a patient’s oxygen saturation is consistently lower than the prescribed target range, there should usually be a medical review and the oxygen therapy should be increased according to an agreed written protocol. [Grade D]

70 The patient should be observed for 5 min after oxygen therapy has been increased. [Grade D]

71 If the oxygen saturation fails to rise following 5–10 min of increased oxygen therapy or if there is clinical concern following medical review, then blood gas measurements should be repeated. [Grade D]

72 If the target saturation is in the 88–92% range, blood gas measurements should be repeated at 30–60 min after any increase in oxygen therapy to ensure that the carbon dioxide level is not rising. [Grade D]

11.3.7 When to lower oxygen therapy
Most conditions which require supplemental oxygen therapy will improve with treatment and it will then be possible to reduce the amount of oxygen administered to the patient. Improvement will usually be confirmed by observing an improving oxygen saturation and a reduction in the physiological score on the mEWS observation chart as discussed in section 7.

Recommendations

73 Lower the oxygen dose if the target saturation is higher than the prescribed range. [Grade D]

74 Lower the oxygen dose if the patient is clinically stable and the oxygen saturation has been in the upper zone of the target range for some time (usually 4–8 h). [Grade D]

75 Saturations should be observed for 5 min following a change of oxygen therapy or rechecked after 5 min on the lower dose of oxygen. [Grade D]

76 If the target saturation is maintained, the new delivery system and flow should be continued. Repeat blood gas measurements are not required. If the patient is stable the process can be repeated and the patient can eventually be weaned off oxygen (see section 12). [Grade D]

SECTION 12: WEANING AND DISCONTINUATION OF OXYGEN THERAPY
In most acute illnesses, oxygen therapy will be reduced gradually as the patient recovers and oxygen therapy can be discontinued once the patient can maintain a saturation of 94–98% while breathing air (or the patient’s baseline oxygen saturation level if known). However, some patients may be continued on oxygen therapy to palliate breathlessness, often on a PRN basis (as required, not continuous). Some patients may have episodic hypoxaemia during recovery from acute illness (eg, patients with COPD with intermittent mucus plugging) and some convalescent patients may be comfortable at rest with a normal oxygen saturation but may desaturate and become breathless when they start to mobilise. There is no evidence that oxygen, either before or after exercise, is of benefit to non-hypoxaemic patients either by relieving breathlessness or by shortening length of stay in hospital. More research in this area is needed.

Some patients with chronic lung diseases will already have been established on long-term oxygen therapy and should be tapered slowly to their usual maintenance dose of oxygen.

A small number of patients who have suffered major respiratory or cardiac injury may require a prescription for home oxygen to permit safe discharge from hospital. However, many patients with COPD exacerbations may have a low PaO₂ on discharge from hospital but a reasonable PaO₂ at a subsequent clinic visit, so decisions about long-term oxygen should not be made on the basis of blood gas measurements made during acute exacerbations of COPD (see Royal College of Physicians clinical guideline for domiciliary oxygen services).

12.1 How to discontinue oxygen therapy for stable patients
Recommendations

► Reduce oxygen therapy gradually for stable patients (see section 11.3.7).

77 Most stable convalescent patients will eventually be stepped down to 2 l/min via nasal cannulae prior to cessation of oxygen therapy. Patients at risk of hypercapnic respiratory failure may be stepped down to 1 l/min via nasal cannulae or a 24% Venturi mask at 2 l/min as the lowest oxygen dose prior to cessation of oxygen therapy. [Grade D]

78 Oxygen therapy should be stopped once a patient is clinically stable on low-dose oxygen and the oxygen saturation is within the desired range on two consecutive observations. Oxygen should also be stopped if the patient is on a written protocol of timed oxygen (eg, postoperatively). [Grade D]

79 Oxygen saturation on room air should be monitored for 5 min after stopping oxygen therapy. If it remains in the desired range it should be rechecked at 1 h. [Grade D]

80 If the oxygen saturation and physiological “track and trigger” score (eg, mEWS) is satisfactory at 1 h, the patient has safely discontinued oxygen therapy but saturation and physiology should continue to be monitored on a regular basis according to the patient’s underlying clinical condition. [Grade D]

81 If the saturation falls on stopping oxygen therapy, recommence the lowest dose that maintained the patient in the target range and monitor for 5 min. If this restores the saturation into the target range, continue oxygen therapy at this level and attempt discontinuation of oxygen therapy again at a later date provided the patient remains clinically stable. [Grade D]

82 If a patient requires oxygen therapy to be restarted at a higher dose than before to maintain the same target saturation range, the patient should have a clinical review to establish the cause for this deterioration. [Grade D]

83 Some patients may have episodic hypoxaemia (eg, after minor exertion) after they have safely discontinued continuous oxygen therapy. If these patients require intermittent oxygen therapy, they should have a prescription for oxygen as required (PRN) but PRN oxygen should not be routinely prescribed for those who have stopped continuous oxygen therapy. [Grade D]
84 Cross oxygen off the drug chart when oxygen discontinued (and sign to confirm discontinuation). [Grade C]

SECTION 13: OUTCOMES AND AUDIT

13.1 Audit
Successful audits of oxygen prescription and use have been carried out at the pilot hospitals in Salford and Southend and the use of oxygen prescription linked to “track and trigger” or mEWS scoring systems has also been audited in conjunction with the outreach teams.

One year after publication of this guideline the Emergency Oxygen Guideline Committee will organise a UK-wide audit to establish how many hospital, PCT providers and ambulance services have introduced the guideline. Audit of oxygen use within individual trusts will also be strongly encouraged.

13.2 Audit of compliance with guidelines
It is recommended that all users of oxygen will audit their own practice against the suggested optimal practice suggested in this guideline. This applies especially to high-frequency users such as ambulance services, emergency departments and medical wards.

“On the job audit”
Regular reviews of the drug card and observation chart on medical rounds at the pilot sites have been very important in the successful introduction of this policy. This has provided instant feedback for doctors, nurses and health care assistants and has produced successful change.

Whole hospital and ward audits
An audit tool has been developed at the pilot sites (web appendix 7). This has been successfully used hospital-wide and on individual wards. It is suggested that audits are done soon after the introduction of the policy.

Other audit questions could include the following:
- Does the trust have an oxygen prescribing policy based on this guideline?
- Is this policy known to all staff and available at all times on the trust intranet?
- Was oxygen prescribed for every patient who was using oxygen at the time of the audit?
- Did every patient have a target oxygen saturation specified (and was this target appropriate)?
- Was oxygen given in accordance with the present guideline?
- Was FEV₁ measured in patients with a diagnosis of COPD (either acutely or prior to discharge and subsequently during follow-up)?

SECTION 14: DISSEMINATION AND IMPLEMENTATION OF THE GUIDELINE

14.1 Dissemination
Dissemination of this guideline will be encouraged and supported strongly by the societies involved in the production of the guideline. It is hoped that each specialist Society or College will alert members to the key recommendations in this guideline. Copies will be sent to the chief executives, medical directors and head nurses of all hospital and primary care trusts and ambulance trusts and voluntary and private ambulance providers in the UK and also to the directors of education at nursing schools, medical schools and at Education for Health (National Respiratory Training Centre).

14.2 Local guidelines
It is recognised that many trusts tend to modify national guidelines for local use. Short “user friendly” versions of the guideline website for acute hospitals, ambulance services and general practice are shown in appendices 2 and 4 on the BTS website (www.brit-thoracic.org.uk).

Educational materials will be made available on the BTS website to include guideline summaries and flow charts in addition to teaching slides. It is hoped that the shortened version of this guideline (or a customised local version) will be made available on the website of every NHS trust.

14.3 Local oxygen policy
It is usual for a new policy to be presented to the local policy committee. A specimen example of a local policy is available in web appendix 3 to help with the production of this policy in individual trusts.

14.4 New prescription chart
The introduction of the guideline will require a new “oxygen section” in the prescription chart in all hospitals. A specimen example is available in chart 3 (fig 17). From experience at the two pilot sites, it is recommended that oxygen should be at the start of the prescription chart because so many patients are prescribed oxygen. The oxygen prescription may be missed if it is placed in another part of the drug chart.

14.5 Staff education
Medical staff education will be required before the introduction of the guideline and regularly thereafter. Teaching slides are available on the BTS website. It is thought that these would be suitable for FY1, FY2 and specialty training lectures and other educational material. They are also suitable for undergraduate medical education. Nursing staff and nursing students will also require education as will physiotherapists, pharmacists, midwives and other clinicians who use oxygen. Lecture studies have also been produced for this purpose and are available on the BTS website. It is thought that these would be more successful than relying on training days. We believe that this would take too long to train enough staff adequately. Slides are available for ambulance staff and primary care staff on the BTS website.

14.6 Local champions
The guideline committee has tried to identify local champions in hospitals, PCT providers and ambulance services who will help to introduce these guidelines. The local champions are listed in web appendix 13 on the BTS website. It is hoped that the champions will help organise the introduction of a local guideline and oxygen policy, a new prescription chart and help organise staff education.

Clinical governance leads will also need to become committed to the implementation of the emergency oxygen guideline and audit of this process.

14.7. Benefits of nationwide implementation
One major benefit of nationwide implementation will be that, when staff transfer between organisations, they will be familiar with the oxygen prescription and administration system.
SECTION 15: AREAS REQUIRING FURTHER RESEARCH
Because of the life and death nature of many conditions for which emergency oxygen therapy is used, it seems that clinicians have been wary of conducting controlled trials of oxygen therapy for most of the commoner indications. It is worrying that the few existing trials of oxygen therapy given to non-hypoxaemic patients in common conditions such as heart attacks, strokes and difficult labour have failed to show benefit, and there have been suggestions of possible harm in these trials despite the near universal use of oxygen for such conditions in the past.

Further research is required in many areas including:
- Use of oxygen in myocardial infarction.
- Use of oxygen in unstable coronary syndromes.
- Use of oxygen in chest pain of presumed cardiac origin.
- Use of oxygen in obstetric emergencies.
- Benefits of alert cards and personalised oxygen masks for patients with prior hypercapnic respiratory failure.
- Possible benefits of alert cards for all patients with COPD.
- Clinical outcomes of patients exposed to hyperoxia.
- Studies to determine if different types of oxygen mask can affect clinical outcomes.
- Comparisons of nasal cannulae and simple face masks, especially after abdominal surgery.
- Studies to determine if implementation of this guideline improves patient outcomes.
- Prospective studies to establish the ideal target saturation range in patients with exacerbation COPD; for example, should the target range be 88–92% or slightly lower or slightly higher for optimal outcome?
- Prospective studies of the effect of oxygen in non-hypoxaemic patients with major trauma and head injury.
- Audit studies of survival outcomes in patients given oxygen therapy.
- Oxygen levels and outcomes in a wide range of conditions.
- Use of oxygen PRN or as required for relief or breathlessness in non-hypoxaemic patients with acute illness.
- Effects of humidified high-flow oxygen on patient comfort.
- Effects of increased flow rates from Venturi masks on patient comfort and oxygen saturation.
- Use of nasal cannulae to deliver low-dose oxygen therapy (e.g., nasal cannulae at 0.5–1.0 l/min compared with 24% and 28% face masks).
- Clinical trials of efficacy and patient tolerance using nasal cannulae at higher flow rates such as 6–10 l/min.
- Effect of cigarette smoking on blood levels of oxygen and carbon dioxide in acute illness.
- Randomised trial of “precautionary use” of oxygen in critical illness compared with a conservative policy of monitoring carefully and giving oxygen only if the saturation falls below the target range.
- Studies to compare the outcome of oxygen therapy in critical illness, comparing the North American target saturation of >90% with the higher target saturations in this guideline (94–98%).

SECTION 16: MEMBERSHIP OF WORKING PARTY AND AUTHORSHIP
16.1 Membership of Working Party

16.2 Authorship of sections of the guideline
The outline of the guideline was developed and refined by the entire group at various meetings and email discussions as described in section 2 and each section was edited by all group members, but the work of preparing the main draft for each section was divided as follows:

16.2.1 Main text of guideline
1. Introduction: R O’Driscoll, A Davison
2. Methodology: R O’Driscoll, A Davison
3. Normal values and definitions: R O’Driscoll, A Davison, M Elliott, I Howard
4. General blood gas physiology: I Howard, R O’Driscoll, A Davison
5. Advanced blood gas physiology: I Howard, R O’Driscoll, M Elliott
6. Hypoxia, hyperoxia, etc: I Howard, R O’Driscoll, A Davison, R Kishen
7. Clinical/laboratory assessment: R O’Driscoll, M Elliott
8. Hospital settings: R O’Driscoll
9. Prehospital settings: A Davison, D Whitmore, F Moore, M Levy
11. Prescription of oxygen: A Davison, S Perrott, R O’Driscoll
12. Weaning and discontinuation: A Davison, R O’Driscoll
13. Outcomes and audit: R O’Driscoll, A Davison
14. Dissemination/implementation: A Davison, R O’Driscoll
15. Areas requiring further research: R O’Driscoll, A Davison

16.2.2 Web appendices (available on BTS website: www.brit-thoracic.org.uk)
1. Summary of recommendations: whole group
2. Summary of Guideline for hospital use: A Davison/R O’Driscoll
3. Example of local oxygen policy: N Linaker, L Ward, R Smith, R O’Driscoll, A Davison
4. Summary for prehospital settings: A Davison, R O’Driscoll, D Whitmore, M Levy


Life-saving oxygen treatments

BTS guideline

APPENDICES

List of appendices available on the British Thoracic Society website (www.brit-thoracic.org.uk)

Table 1 Critical illnesses requiring high levels of supplemental oxygen.

Table 2 Serious illnesses requiring moderate levels of supplemental oxygen if the patient is hypoxaemic.

Table 3 Patients requiring controlled or low-dose oxygen therapy.

Table 4 Conditions for which oxygen is not required unless the patient is hypoxaemic.

Chart 1 Oxygen prescription for acutely hypoxaemic patients in hospital.

Chart 2 Flow chart for oxygen administration on general wards in hospitals.

Chart 3 Working example of the respiratory section of an observation chart for hospitalwards.

Chart 4 Working example of oxygen section for a hospital prescription chart.

Chart 5 Working example of the respiratory section of an observation chart for hospital use.

(All of the above are available within the guideline but indexed here for the benefit of online users.)
Appendix 1 Summary of recommendations concerning administration and monitoring of oxygen therapy.
Appendix 2 Summary of guideline for hospital use.
Appendix 3 Example of local oxygen policy.
Appendix 4 Summary of guideline and flow charts for emergency oxygen use in ambulances, community and prehospital settings (including example of oxygen alert card).
Appendix 5 Patient information sheet.
Appendix 6 Summary of prescription, administration, monitoring, weaning and discontinuation of oxygen therapy.
Appendix 7 Lecture on emergency oxygen use for doctors.
Appendix 8 Teaching aids on emergency oxygen use for nurses, midwives, pharmacists, physiotherapists and other practitioners who use oxygen.
Appendix 9 Key points for primary care trust managers, practice-based commissioning groups and general practice managers.
Appendix 10 Key points for ambulance service managers.
Appendix 11 List of NHS Trusts with oxygen champions.
Appendix 12 List of NHS Trusts with oxygen champions.
Appendix 13 Details of search methodology.

Abbreviations and symbols used in this guideline

Abbreviations
ABG arterial blood gas
BTS British Thoracic Society
Cao2 oxygen content of blood
CO cardiac output (expressed in l/min)
CO2 carbon dioxide
COPD chronic obstructive pulmonary disease
CPAP continuous positive airway pressure
dO2 oxygen delivery from the lungs to the tissues (ml/min)
ELBG earlobe blood gases
EPR electronic patient record
EWS (mEWS) Early Warning Score System or modified EWS
FiO2 fraction of inspired oxygen (eg, 21% oxygen = FiO2 0.21)
[H+] hydrogen ion concentration (normal range 35–45 mmol/l (pH 7.35–7.45); lower levels are alkalotic, higher levels are acidic)
Hb haemoglobin (carries oxygen in the blood stream)
HPV hypoxic pulmonary vasoconstriction
ICU intensive care unit
IPPV intermittent positive pressure ventilation
kPa kilo Pascal (unit of measurement for pressures) 1 kPa = 7.5 mm Hg
MC mask medium concentration mask (also known as simple face mask)
mm Hg millimetres of mercury (unit of measurement for pressures)
NICE National Institute for Health and Clinical Excellence
NIPPV non-invasive positive pressure ventilation
NIV non-invasive ventilation
O2 oxygen
PCO2 carbon dioxide tension (partial pressure) in blood or alveolus
Paco2 arterial carbon dioxide tension (partial pressure): normal range is 4.6–6.1 kPa (34–46 mm Hg)
PACO2 alveolar carbon dioxide tension
Pao2 arterial oxygen tension (normal ranges shown in table 7)
Pao2 alveolar oxygen tension
pH unit of measurement for acidity of blood (normal range 7.35–7.45 ([H+] 35–45 mmol/l): lower levels are acidotic, higher levels are alkalotic
PIO2 inspired oxygen tension
PRN (on prescriptions) as required, as the need arises (from Latin pro re nata)
ROS reactive oxygen species
SD standard deviation from the mean
SIGN Scottish Intercollegiate Guideline Network
Sao2 arterial oxygen saturation
Spo2 arterial oxygen saturation measured by pulse oximetry
V˙O2 rate of oxygen consumption by the body (normal 250 ml/min)
V/Q ratio of ventilation to perfusion in the lungs
V/Q mismatch discrepancy between ventilation and blood flow in localised areas of the lung, causing decrease in oxygen level and rise in CO2 level

Symbols
> greater than or above (eg, PacO2 >6.0 kPa)
< less than or below (eg, PacO2 <8.0 kPa)
≥ greater than or equal to (eg, age ≥70 years)
≤ less than or equal to (eg, pH ≤7.3)
index

Note: References in bold are to tables and figures.

ABC assessment vi17, vi28, vi45
absorption atelectasis vi16, vi24, vi37
acid aspiration vi7, vi25–6, vi44
acidosis vi16, vi18
assessment vi32
definition vi15
risks of vi26–7
see also metabolic acidosis; respiratory acidosis
acute chest syndrome in sickle cell disease vi39
acute coronary syndromes vi7, vi42–3
acute heart failure vi5, vi38
acute illness vi4
administration of oxygen therapy vi1, vi4
acute illness vi4
adult anaemia vi21, vi39
anaemia
and assessment of hypoxaemia vi29
haemoglobin saturation vi19, vi20
pulse oximetry in vi30
supplemental oxygen therapy vi5, vi39
anapnoea vi4
anaphylaxis vi4, vi35–6
ankylosing spondylitis vi39, vi46
antiemetic effects of oxygen therapy vi24
anaemia vi26
anxiety vi7, vi44
aortic body vi18
arterial blood gas sampling vi2, vi31, vi33
in hypercapnia/acidosis vi32
in monitoring of therapy vi59
arterial blood gas sampling vi2, vi31, vi33
in hypercapnia/acidosis vi32
in monitoring of therapy vi59
assessment
in acute illness vi28–9
in ambulance/community/prehospital settings vi45
in hospital settings vi32
of hypoxaemia vi2, vi31–2
of hypoxaemia vi2, vi28–31
asthma
acute vi5, vi33, vi37
misdiagnosis vi40, vi41
nebulised bronchodilator therapy vi4, vi55
in pregnancy vi43
prehospital treatment vi47
aust vi61
benzodiazepine overdose vi40, vi46
bicarbonate vi15, vi16, vi19
bleomycin lung injury vi7, vi25–6, vi44
blood
carbon dioxide physiology vi16
electrolyte levels in hypercapnia vi26
lactate levels vi27
normal pH range vi15
oxygen physiology vi15–16
pH measurement vi31, vi32
blood gas physiology
advanced concepts vi17–21
general concepts vi15–17
blood gas sampling vi2, vi31
in hypercapnia/acidosis vi32
importance of vi34
indications for vi33–4
in monitoring of therapy vi59
repeated vi33
blood transfusion in anaemia vi21, vi39
body positioning vi2
and oxygen tension vi13
in stroke vi43
and V/Q matching vi28
Bohr effect vi17, vi18
bone fractures vi35
breath-hold time, effects of breathing oxygen vi20
breathlessness
acute onset with unknown cause vi36–7
assessment and immediate management on arrival at hospital vi32
clinical assessment vi28–9
postoperative vi5, vi23, vi39
without hypoxaemia vi1, vi10, vi27, vi36
bronchiectasis, non-cystic fibrosis vi39
bronchodilator therapy, nebulised vi4, vi55
bubble humidifiers vi54
cancer with pulmonary involvement vi37
carbon dioxide
normal homeostasis vi19
physiology vi16, vi19–20
carbon dioxide dissociation curve vi19
carbon dioxide tension (PcO2) in carbon dioxide dissociation curve vi19
and haemoglobin saturation vi17
measurement vi31, vi32
venous sampling vi32
carbon dioxide tension, arterial (PaCO2) vi16
effect on ventilation vi19
in guidance of oxygen therapy vi34
measurement vi31, vi32
normal range vi14, vi16
regulation vi13–20, vi19
relationship with total carbon dioxide content vi19, vi19
carbon monoxide poisoning vi14, vi16, vi17, vi19
pulse oximetry in vi30
recommendations vi36
supplemental oxygen therapy vi4, vi23, vi33
carbonic acid vi15
carbon monoxide vi23, vi30, vi30–1, vi36
cardiac arrest vi4, vi32, vi35
cardiac arrhythmias in hypercapnia vi26
cardiac output (Q) vi17, vi21
cardiogenic shock vi20, vi21, vi38
cardiomyopathy, periapartum vi43
cardiopulmonary resuscitation vi4, vi23, vi35
cardiovascular system
effects of hypercapnia vi26
effects of hyperoxia/hyperoxygenation vi22, vi25
effects of hypoxia vi22
carotid body vi16, vi18
cars, private, oxygen carriage in vi51
cerebral oedema at high altitude vi13
cerebrovascular system
effects of hypercapnia vi26
effects of hyperoxia/hyperoxygenation vi25
chest pain vi43
chronic bronchitis vi41
chronic obstructive pulmonary disease see COPD
cluster headaches vi23
coma in hypercapnia vi31, vi32
community, emergency oxygen use in vi45–7
Community First Responder (CFR) schemes vi45
compensatory desaturation vi44
confusion
in hypercapnia vi32
in hypoxaemia vi29
continuous positive airway pressure (CPAP) vi5, vi6, vi38, vi51
convulsions in hypercapnia vi49, vi50
COPD
assumption of diagnosis vi46
diagnosis vi41
exacerbation vi6, vi29, vi40–1
hypercapnia in vi16, vi20
and hypercapnic respiratory failure vi2, vi24, vi32, vi39, vi40
hypoxaemia in vi22
nebulised bronchodilator therapy vi55
NICE guidelines vi45
oxygen saturation in vi14
oxygen saturation response to treatment vi49, vi50
in prehospital settings vi46
target oxygen saturation vi1, vi40, vi41
coronary artery disease vi7, vi42–3
CPR vi4, vi23, vi35
cyanide poisoning vi14–15
cyanosis vi29
cylinders, oxygen vi47
Health and Safety Executive guidance for safe use vi51
transport in vehicles vi51
cystic fibrosis vi6, vi39, vi41
cytopathic dysoxia vi15
dead space, increased vi19, vi20
delivery systems vi3–4, vi47–55
in ambulances vi47, vi51
in hospital settings vi35, vi52–3, vi53
initial choice vi34–5
in medical and primary care centres vi51
in patients’ homes vi52
in prehospital settings vi47
diabetic ketoacidosis vi15, vi33, vi34
2,3-diphosphoglycerate vi18
discontinuation of therapy vi1, vi60–1
drowning vi4, vi35
drowsiness
in hypercapnia vi31, vi32
in respiratory acidosis vi31
drug charts vi1, vi6, vi32
initial choice vi34–5
in medical and primary care centres vi51
in patients’ homes vi52
in prehospital settings vi47
diabetic ketoacidosis vi15, vi33, vi34
2,3-diphosphoglycerate vi18
discontinuation of therapy vi1, vi60–1
drowning vi4, vi35
drowsiness
in hypercapnia vi31, vi32
in respiratory acidosis vi31
drug charts vi1, vi55–6, vi57–8, vi57, vi61
drug overdose vi7, vi16, vi40, vi44, vi46
dysfunctional breathing vi7, vi44
earlobe
blood gas sampling from vi31
pulse oximetry vi30
Early Warning Scoring systems vi2, vi23, vi28, vi29, vi34, vi59, vi60, vi61
eclampsia vi43
education of health professionals vi56, vi61
Eisenmenger’s syndrome vi19
elderly patients
oxygen saturation normal values vi13, vi13
oxygen tension normal values vi13, vi13
emphysema vi14, vi41
end-tidal carbon dioxide monitoring vi32
diabetes mellitus vi7, vi44
electrolyte disorders vi17, vi8, vi32
evidence hierarchy vi10, vi10
extrapulmonary shunt vi15
fast response units, oxygen carriage vi51
fat embolism vi35
fetal compromise vi43
FEV1
in COPD vi40
effects of breathing pure oxygen vi24
measurement vi29
flow meters vi52–3, vi53
flushing
in hypercapnia vi31, vi32
in respiratory acidosis vi31
forced expiratory volume in 1 s see FEV1
gangrene vi14
Guideline
abbreviated versions vi11
areas covered/not covered vi11
audit of compliance with vi61
benefits of nationwide implementation vi61
dissemination vi61
intended users and scope vi10–11
key questions vi11–12
limitations vi11
local champions vi61
local modification vi61
need for and purpose vi10
piloting vi12
planned review and updating vi12
production methodology vi11–12
staff education regarding vi61
Guillain-Barre syndrome vi45
haematocrit vi18
haemoglobin vi15, vi16, vi17
optimal levels vi21
oxygen carrying capacity regulation vi17, vi18
haemoptysis, massive vi6, vi6
Haldane effect vi19, vi24
head injury, major vi4, vi36
headache
crash vi23
due to hypercapnia vi26, vi32
Health and Safety Executive, guidance for safe use vi51
health professionals, education of vi56, vi61
hepatitis, hypoxic vi22
high-dose oxygen therapy vi4, vi26, vi35–6
histotoxic hypoxia vi14–15
hospitals vi3
assessment of breathless patient on arrival vi32
comparison with prehospital setting vi33
management of hypoxaemia in vi32–45
oxygen delivery systems vi35, vi52–3, vi53
“Hudson mask” see simple face mask
humidified oxygen vi3–4, vi53–4, vi54
hydrogen peroxide vi25
hyperbaric oxygen vi11
in carbon monoxide poisoning vi36
in wound healing vi23
hypoxaemia vi16, vi18
in acute asthma vi37
assessment vi2, vi31–2
definition vi15
mechanisms vi20
pathophysiology vi20
risks of vi26
in supplemental oxygen therapy vi24–5
hypercapnic (type 2) respiratory failure
blood gas measurement in vi33, vi34
and COPD vi2, vi24, vi32, vi39, vi40
definition vi15
and obesity-hypoventilation syndrome vi42
and oxygen alert cards vi3, vi46–7
and respiratory acidosis vi40
risk factors vi28, vi39–40, vi46
hyperoxaemia vi15, vi19
effects and risks of vi16, vi22, vi24–6
potential benefits in non-hypoxaemic patients vi23–4
hyperoxaemia vi15, vi27
effects and risks of vi22, vi35
pathophysiology vi19
hyperventilation vi17, vi20, vi32, vi33, vi44
hypocapnia vi20
hypotension vi2, vi30, vi31, vi35
hypoventilation
alveolar vi20
global vi19
and hypocapnia vi20
obesity-hypoventilation syndrome vi42
pathological vi20
physiological vi20
hypoxaemia vi10
acute vi23
acute onset with unknown cause vi5, vi36–7
assessment vi2, vi28–31
causes vi16
definition vi14
effects and risks of vi13–14, vi21–3, vi45
episodic vi60
management in ambulance/community/prehospital settings vi45–7
management in hospital settings vi32–45
and oxygen dissociation curve vi18
postoperative vi5, vi23, vi39
rebound vi29
ventilatory response to vi18, vi18
hypoxaemic hypoxia vi14, vi18–19
hypoxia
anaemic vi14, vi18, vi19, vi20, vi30
definitions vi14–15
effects and risks of vi13, vi15, vi21–3, vi22
hypoxaemic vi14, vi18–19
hypoxic vi14, vi18–19
pathophysiology vi18–19
hypoxic bronchodilation vi18
hypoxic drive vi16, vi24
hypoxic hepatitis vi22
hypoxic hypoxia vi14, vi18–19
hypoxic pulmonary vasoconstriction (HPV) vi16, vi17, vi18, vi19, vi24, vi25
idiopathic pulmonary fibrosis vi5, vi38
ineffective ventilation, and hypercapnia vi20
intermittent positive pressure ventilation (IPPV) vi2, vi5, vi6, vi7, vi28, vi41
intrapulmonary shunt vi19
intubation vi32
kidneys
disorders vi7, vi44
effects of hypoxia and hyperoxia vi22
in hypoxaemia vi26
oxygen delivery vi18
kyphoscoliosis vi39, vi46
labour vi3, vi7, vi42–4
lactate, blood levels vi27
lactic acidosis vi15
laryngectomy vi54
liquid oxygen vi47–8
low-dose oxygen therapy vi6, vi39–42
lung cancer vi5, vi37
lung scarring vi40, vi46
Mary Catterall (MC) mask see simple face mask
mechanical ventilation vi46
see also specific types
medical centres vi3, vi51
medium concentration (MC) mask see simple face mask
metabolic acidosis vi15, vi33, vi34
metabolic disorders vi7, vi44
metabolic system, effects of hypoxia and hyperoxia vi22
methaemoglobinemia vi30
mEWS vi2, vi23, vi28, vi29, vi34, vi59, vi60, vi61
moderate-dose oxygen therapy vi5, vi36–9
modified Early Warning Scoring systems vi2, vi23, vi28, vi29, vi34, vi59, vi60, vi61
monitoring oxygen therapy vi11, vi56, vi58–60, vi58
motion sickness vi24
motorcycle response units, oxygen carriage vi51
mountain sickness vi13
musculoskeletal disorders vi6, vi7, vi41–2, vi45, vi46
myocardial infarction vi7, vi11, vi16, vi25, vi42–3
myocardial ischaemia vi22, vi26, vi42
 naloxone vi7, vi44
nasal cannulae vi3, vi34, vi35, vi47, vi49–50
nausea and vomiting vi24
near-drowning vi4, vi35
nebulisation-based humidifiers vi54, vi54
nebulisers vi3, vi4, vi47, vi55
neurological system, effects of hypoxia and hyperoxia vi22
neuromuscular disorders vi6, vi7, vi41–2, vi45, vi46
non-invasive ventilation (NIV) vi5, vi6, vi7, vi8, vi28, vi32, vi34, vi35, vi38, vi40, vi41, vi42, vi46, vi51
non-rebreathing (reservoir) mask vi3, vi34, vi47, vi48, vi48
noradrenaline in hypcapnia vi26
normal values and definitions vi12–15
North West Oxygen Guideline vi10
obesity, morbid vi6, vi40, vi42, vi46
obesity-hypoventilation syndrome vi42
observation chart vi1, vi58, vi59
obstetric emergencies vi2–3, vi17
opioid overdose vi7, vi40, vi42, vi44, vi46
outcomes vi61
oxygen alert cards vi3, vi6
oxygen cascade vi27
oxygen content of arterial blood (CaO2) vi17
oxygen delivery (Dox) vi17
calculation vi21
optimisation strategies vi20–1
regulation vi18
renal vi18
oxygen dissociation curve vi17, vi18, vi26, vi49
oxygen therapy vi15–16
oxygen saturation, arterial (SaO2)
in acute illness vi13–14, vi23
assessment see pulse oximetry at altitude vi13
in chronic disease vi13–14
definition vi15
during airline flights vi22
in elderly patients vi13, vi13
falling levels vi1, vi23, vi33, vi34, vi59
and hypoxaemia vi14
monitoring vi3, vi23
normal ranges at sea level vi13, vi13, vi15 and oxygen content of arterial blood vi17
relationship with oxygen tension vi17, vi17, vi21
target see target oxygen saturation
upper limit vi23
variations during sleep vi14
oxygen saturation, pulse oximetry (Spo2) vi15
oxygen tension, alveolar (PaO2) vi17–18, vi17
oxygen tension, arterial (PaO2) vi17–18
in the alveolar-capillary unit vi17
definition vi15
in elderly patients vi13, vi13
ideal target vi27
normal ranges at sea level vi13, vi13
optimisation vi21
relationship with oxygen saturation vi17, vi17, vi21
oxyhaemoglobin saturation vi14, vi15

Index

panic attack vi7, vi44
paracetamol poisoning vi7, vi25–6, vi44
parenchymal lung disease vi38
partial pressure of carbon dioxide see carbon dioxide tension, arterial (PaCO₂)
partial pressure of oxygen see oxygen tension, arterial (PaO₂)
patient transport services, oxygen carriage and delivery vi51
patients’ homes, oxygen supplies vi52
peripartum cardiomyopathy vi43
physiological deterioration, delay in recognition vi25
plutynoae and orthodeoxia vi28
pleural effusion vi5
pneumonia vi5, vi36, vi37
and hypoxaemia vi29
in pregnancy vi43
pneumothorax vi5, vi22, vi38
poisoning vi7, vi14–15, vi25–6, vi44
see also carbon monoxide poisoning
polycthemia vi19, vi22, vi38
postoperative supplemental oxygen therapy vi5, vi23, vi39, vi52
pre-eclampsia vi43
pregnancy vi2–3, vi7, vi14, vi36–9, vi37, vi38
prehospital settings, emergency oxygen use in vi45–7
preoxygenation vi20
prescription of oxygen vi1, vi4, vi5, vi34, vi46
prevalence of emergency oxygen use vi10
safe, recommendations for vi56–7
safety, policy implementation vi56
need for vi55–6
lack of vi3, vi46
fixed dose vs. target saturation vi34
lack of vi3, vi46
need for vi55–6
policy implementation vi56
prescription charts vi1, vi55–6, vi57–8, vi61
reasons for vi56
safe, recommendations for vi56–7
prevalence of emergency oxygen use vi10
primary care centres vi3, vi51
pulmonary circulation vi17–18, vi17
effects of hypercapnia vi26
pulmonary embolism vi5, vi29, vi33, vi38, vi43
pulmonary fibrosis vi5, vi38
pulmonary haemorrhage, major vi4, vi36
pulmonary hypertension at altitude vi13
pulmonary oedema vi17, vi21, vi38
high altitude vi13
in myocardial infarction vi42
in pregnancy vi43
pulse oximetry vi1, vi2
in ambulance/community/prehospital settings vi45
artefacts vi30
with arteriolarised blood gas sampling vi31
availability vi3, vi33, vi45
in monitoring of therapy vi56–9
recommendations vi31
value and limitations vi29–31
pulse rate in hypoxaemia vi20

Raynaud’s phenomenon vi58
reactive oxygen species (ROS) vi16, vi25
rebreathing vi20, vi44, vi48
recommendations, grading of vi10, vi10
reperfusion injury vi42
research required vi62
reservoir mask vi3, vi34, vi35, vi47, vi48, vi48
respiratory acidosis
acute on chronic vi15
assessment vi32
compensated vi15
definition vi15
and hypercapnic respiratory failure vi40
risk factors for vi46
risks of vi26–7
respiratory exchange ratio (RER) vi18–19

hypoxaemia vi29
respiratory system, effects of hypoxia and hyperoxia vi22
restraint systems vi28
resuscitation vi17
resuscitators, portable vi51

sarcoidosis vi38
sepsis
major vi4, vi33, vi35
in pregnancy vi43
septic shock vi21
serious illness requiring moderate-dose oxygen therapy vi5, vi36–9
shock
arterial blood gas sampling in vi31
cardiogenic vi20, vi21, vi38
septic vi21
supplemental oxygen therapy vi4, vi33, vi35
sickle cell crisis vi5, vi30, vi39
simple face mask vi3, vi34, vi35, vi48, vi48
comparison with nasal cannulae vi49–50
skin pigmentation and pulse oximetry vi30
sleep, oxygen saturation variations during vi14
smoking and carboxyhaemoglobin vi30, vi30–1
spirometry
in COPD vi40
in Guillain-Barre syndrome vi45
stagnant hypoxia vi14, vi19, vi20, vi22
storage of oxygen vi47–8, vi47
stoke vi17, vi25, vi43
superoxide vi25
supplemental oxygen therapy
administration vi1, vi9, vi56–7, vi57
in ambulance/community/prehospital settings vi45–7
availability vi45
commencing vi58
continuous/as required vi58, vi60
decreasing vi60
definition vi27
discontinuation/weaning from vi1, vi60–1
excessive vi46–7
in hospital settings vi32–45
increasing vi59–60
indicators for vi10, vi33
monitoring vi1, vi56, vi58–60, vi58
in non-hypoxaemic patients vi23–4, vi27–8
physiology vi20
potential adverse effects and risks of vi16, vi22, vi24–6
rationale vi27
sudden cessation vi25
uncontrolled vi26
see also specific disorders
Surviving Sepsis Campaign guideline vi35

tachycardia
in hypercapnia vi26
in hypoxaemia vi29
tachypnoea vi29, vi44, vi59
target oxygen saturation vi1, vi8
in acute illness vi1–2, vi27–8
concept of ranges vi16–17
in COPD vi1, vi40, vi41
ideal vi17
monitoring and maintenance vi1, vi56, vi58–60, vi58
and oxygen prescription vi34
rationale for ranges vi21–3
recommended ranges vi1, vi15–16, vi23, vi27, vi34, vi36–7
thoracoplasty vi40, vi46
tissue hypoxia vi14, vi15, vi19
tissue oxygenation optimisation strategies vi20–1
tracheostomy vi54
tracheostomy mask vi3, vi4, vi35, vi47, vi50, vi51, vi54

Raynaud’s phenomenon vi58
reactive oxygen species (ROS) vi16, vi25
rebreathing vi20, vi44, vi48
recommendations, grading of vi10, vi10
reperfusion injury vi42
research required vi62
reservoir mask vi3, vi34, vi35, vi47, vi48, vi48
respiratory acidosis
acute on chronic vi15
assessment vi32
compensated vi15
definition vi15
and hypercapnic respiratory failure vi40
risk factors for vi46
risks of vi26–7
respiratory exchange ratio (RER) vi18–19

hypoxaemia vi29
respiratory system, effects of hypoxia and hyperoxia vi22
restraint systems vi28
resuscitation vi17
resuscitators, portable vi51

sarcoidosis vi38
sepsis
major vi4, vi33, vi35
in pregnancy vi43
septic shock vi21
serious illness requiring moderate-dose oxygen therapy vi5, vi36–9
shock
arterial blood gas sampling in vi31
cardiogenic vi20, vi21, vi38
septic vi21
supplemental oxygen therapy vi4, vi33, vi35
sickle cell crisis vi5, vi30, vi39
simple face mask vi3, vi34, vi35, vi48, vi48
comparison with nasal cannulae vi49–50
skin pigmentation and pulse oximetry vi30
sleep, oxygen saturation variations during vi14
smoking and carboxyhaemoglobin vi30, vi30–1
spirometry
in COPD vi40
in Guillain-Barre syndrome vi45
stagnant hypoxia vi14, vi19, vi20, vi22
storage of oxygen vi47–8, vi47
stoke vi17, vi25, vi43
superoxide vi25
supplemental oxygen therapy
administration vi1, vi9, vi56–7, vi57
in ambulance/community/prehospital settings vi45–7
availability vi45
commencing vi58
continuous/as required vi58, vi60
decreasing vi60
definition vi27
discontinuation/weaning from vi1, vi60–1
excessive vi46–7
in hospital settings vi32–45
increasing vi59–60
indicators for vi10, vi33
monitoring vi1, vi56, vi58–60, vi58
in non-hypoxaemic patients vi23–4, vi27–8
physiology vi20
potential adverse effects and risks of vi16, vi22, vi24–6
rationale vi27
sudden cessation vi25
uncontrolled vi26
see also specific disorders
Surviving Sepsis Campaign guideline vi35

tachycardia
in hypercapnia vi26
in hypoxaemia vi29
tachypnoea vi29, vi44, vi59
target oxygen saturation vi1, vi8
in acute illness vi1–2, vi27–8
concept of ranges vi16–17
in COPD vi1, vi40, vi41
ideal vi17
monitoring and maintenance vi1, vi56, vi58–60, vi58
and oxygen prescription vi34
rationale for ranges vi21–3
recommended ranges vi1, vi15–16, vi23, vi27, vi34, vi36–7
thoracoplasty vi40, vi46
tissue hypoxia vi14, vi15, vi19
tissue oxygenation optimisation strategies vi20–1
tracheostomy vi54
tracheostomy mask vi3, vi4, vi35, vi47, vi50, vi51, vi54
track and trigger systems vi1, vi2, vi23, vi28, vi29, vi34, vi59, vi60, vi61
transcutaneous carbon dioxide assessment vi32
transcutaneous oxygen assessment vi31
trauma vi4, vi33, vi35
in pregnancy vi43
tremor in hypercapnia vi32
tuberculosis vi40, vi46
tubing vi53
twin oxygen outlets vi3, vi53
type 1 respiratory failure vi14

ventilation, in hypoxaemia vi29
ventilation/perfusion (V/Q) matching vi17–18
and body positioning vi28
and carbon dioxide vi19
maximisation vi28

ventilation/perfusion (V/Q) mismatch vi19, vi37
in COPD vi20
and hypercapnic respiratory failure vi24
ventilatory drive and hypercapnic respiratory failure vi24
Venturi mask vi3, vi35, vi48–9, vi49, vi50
in COPD vi40, vi41, vi46
in hospital settings vi52
issuing to patients vi3, vi46–7
in prehospital settings vi47
vital signs vi1
Voluntary Aid Societies (VAS) vi45

wall outlets vi3, vi53
weaning from therapy vi1, vi60–1
wound healing, effects of oxygen therapy vi23, vi39